0001224608falsetrue00012246082024-02-062024-02-060001224608us-gaap:CommonStockMember2024-02-062024-02-060001224608cno:RightsToPurchaseSeriesEJuniorParticipatingPreferredStockMember2024-02-062024-02-060001224608cno:A5125SubordinatedDebenturesDue2060Member2024-02-062024-02-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 6, 2024
CNO Financial Group, Inc.
(Exact Name of Registrant as Specified in Charter)
| | | | | | | | |
Delaware | 001-31792 | 75-3108137 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
11825 North Pennsylvania Street
Carmel, Indiana 46032
(Address of Principal Executive Offices) (Zip Code)
(317) 817-6100
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
Title of each class | | Trading Symbol | | Name of each exchange on which registered |
Common Stock, par value $0.01 per share | | CNO | | New York Stock Exchange |
Rights to purchase Series E Junior Participating Preferred Stock | | | | New York Stock Exchange |
5.125% Subordinated Debentures due 2060 | | CNOpA | | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| | | | | |
Item 2.02. | Results of Operations and Financial Condition. |
On February 6, 2024, CNO Financial Group, Inc. ("CNO" or the "Company") issued: (i) a press release announcing its financial results for the quarter ended December 31, 2023, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference; (ii) the Quarterly Financial Supplement for December 31, 2023, a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference; and (iii) additional financial information related to its financial and operating results for the quarter ended December 31, 2023, a copy of which is attached hereto as Exhibit 99.3 and is incorporated herein by reference.
The information contained under Item 2.02 in this Current Report on Form 8-K (including Exhibits 99.1, 99.2 and 99.3) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information contained in this Current Report on Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
| | | | | |
Item 9.01(d). | Financial Statements and Exhibits. |
The following materials are furnished as exhibits to this Current Report on Form 8-K:
| | | | | |
99.1 | |
99.2 | |
99.3 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | |
| CNO Financial Group, Inc. |
| |
Date: February 6, 2024 | |
| By: | /s/ Michellen Wildin | |
| | Michellen Wildin | |
| | Senior Vice President and Chief Accounting Officer | |
| | |
Exhibit 99.1
News
For Immediate Release
CNO Financial Group Reports Fourth Quarter and Full Year 2023 Results
Strong fourth quarter earnings, sustained full-year sales momentum and agent force growth
Carmel, Ind., February 6, 2024 - CNO Financial Group, Inc. (NYSE: CNO) today announced its financial results for the fourth quarter and full year ended December 31, 2023. Net income in 4Q23 was $36.3 million, or $0.32 per diluted share, compared to $38.0 million, or $0.33 per diluted share, in 4Q22. Net income for year ended December 31, 2023 was $276.5 million, or $2.40 per diluted share, compared to $630.6 million, or $5.36 per diluted share, in 2022. Net income in 2023 and 2022 reflected non-economic market impacts which increased (decreased) earnings by $(18.8) million and $334.9 million, respectively.
Net operating income (1) for the quarter ended December 31, 2023 was $133.9 million, or $1.18 per diluted share, compared to $82.9 million, or $0.71 per diluted share, in 4Q22. Net operating income (1) for the year ended December 31, 2023 was $356.1 million, or $3.09 per diluted share, compared to $360.4 million, or $3.06 per diluted share, in 2022.
In 4Q23, significant items positively impacted both net income and net operating income (1) by $26.4 million, or $0.23 per diluted share. For the year, both net income and net operating income (1) were favorably impacted by significant items of $43.3 million, or $0.37 per diluted share, in 2023 and $17.9 million, or $0.15 per diluted share, in 2022.
"CNO delivered strong earnings growth in the quarter and exceptional full-year operating performance," said Gary C. Bhojwani, chief executive officer. "Our diverse, integrated distribution generated four consecutive quarters of sales momentum, increased agent counts and record growth across multiple product categories. This high level of operating performance underscores the health and strength of our business model and will contribute to sustained profitable growth."
"Our capital position and free cash flow generation remained strong, enhanced by our new Bermuda reinsurance structure. We delivered solid earnings results in the year, driven by stable insurance product margins and improved investment portfolio yield. During 2023, we returned more than $230 million to shareholders."
"CNO enters 2024 with considerable sales momentum and a growing agent force amid favorable macro trends. We continue to prioritize strong capital management and profitable growth, which are the cornerstone of our commitment to deliver enduring value to our customers, associates, agents and shareholders."
Full Year 2023 Highlights (as compared to the corresponding period in the prior year where applicable)
•Total new annualized premiums ("NAP") (4) up 9%; total Health insurance NAP up 11%
• Consumer Division field NAP up 16%
•Worksite Division NAP up 29%
• Established CNO Bermuda Re and executed initial reinsurance transaction
• Returned $233.2 million to shareholders
• Return on equity ("ROE") of 14.0%; operating ROE, as adjusted, (6) of 9.8%
Fourth Quarter 2023 Highlights (as compared to the corresponding period in the prior year where applicable)
•Total Health insurance NAP (4) up 5%; total Life insurance NAP up 8%
• Consumer Division NAP up 4% and producing agent count up 9%
•Worksite Division NAP up 20% and producing agent count up 27%
• Returned $96.7 million to shareholders
• Book value per share was $20.26; book value per diluted share, excluding accumulated other comprehensive loss, (2) was $33.94
Adoption of New Accounting Standard
As previously disclosed, we adopted ASU 2018-12 related to targeted improvements to the accounting for long-duration insurance contracts effective January 1, 2023. We selected the modified retrospective transition method except for market risk benefits where we were required to use the full retrospective approach. All prior periods presented herein have been recast in accordance with the new standard. As a result of the adoption of the new guidance, shareholders' equity as of December 31, 2022 increased $368.0 million and was comprised of: (i) an increase to retained earnings of $232.2 million; and (ii) a decrease to accumulated other comprehensive loss of $135.8 million. Net income and net operating income (1) increased (decreased ) $(5.4) million and $17.1 million in the fourth quarter of 2022, respectively. Concurrent with the adoption of the new guidance, we also updated the method of determining non-operating earnings for our fixed indexed annuities to better isolate the volatile non-economic accounting impacts of that line of business.
FINANCIAL SUMMARY
Quarter End
(Amounts in millions, except per share data)
(Unaudited)
Net operating income, a non-GAAP(a) financial measure, is used consistently by CNO’s management to evaluate the operating performance of the Company and is a measure commonly used in the life insurance industry. It differs from net income primarily because it excludes certain non-operating items such as net realized investment gains (losses) from sales and change in the allowance for credit losses, changes in fair values of embedded derivatives and market risk benefits and the liability for a deferred compensation plan, and certain significant and unusual items included in net income. Management believes an analysis of net operating income is important in understanding the profitability and operating trends of the Company’s business. Net income is the most directly comparable GAAP measure.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Per diluted share | | | | | | | |
| Quarter ended | | Quarter ended |
| December 31, | | December 31, |
| 2023 | | | 2022 | | % change | | 2023 | | | 2022 | | % change |
| | | | | | | | | | | | | |
Income from insurance products (b) | $ | 1.19 | | | | $ | 0.73 | | | 63 | | | $ | 135.8 | | | | $ | 85.4 | | | 59 | |
Fee income | 0.16 | | | | 0.08 | | | 100 | | | 17.8 | | | | 9.2 | | | 93 | |
Investment income not allocated to product lines (c) | 0.34 | | | | 0.22 | | | 55 | | | 38.3 | | | | 25.2 | | | 52 | |
Expenses not allocated to product lines | (0.18) | | | | (0.11) | | | 64 | | | (19.8) | | | | (12.8) | | | 55 | |
Operating earnings before taxes | 1.51 | | | | 0.92 | | | | | 172.1 | | | | 107.0 | | | |
Income tax expense on operating income | (0.33) | | | | (0.21) | | | 57 | | | (38.2) | | | | (24.1) | | | 59 | |
Net operating income (1) | 1.18 | | | | 0.71 | | | 66 | | | 133.9 | | | | 82.9 | | | 62 | |
Net realized investment gains (losses) from sales and change in allowance for credit losses | 0.01 | | | | (0.23) | | | | | 1.4 | | | | (27.2) | | | |
Net change in market value of investments recognized in earnings | 0.08 | | | | (0.08) | | | | | 8.8 | | | | (9.0) | | | |
Changes in fair value of embedded derivative liabilities and market risk benefits | (1.10) | | | | (0.14) | | | | | (124.6) | | | | (16.4) | | | |
| | | | | | | | | | | | | |
Other | (0.10) | | | | (0.05) | | | | | (11.6) | | | | (5.9) | | | |
Non-operating loss before taxes | (1.11) | | | | (0.50) | | | | | (126.0) | | | | (58.5) | | | |
Income tax benefit on non-operating loss | 0.25 | | | | 0.12 | | | | | 28.4 | | | | 13.6 | | | |
| | | | | | | | | | | | | |
Net non-operating loss | (0.86) | | | | (0.38) | | | | | (97.6) | | | | (44.9) | | | |
Net income | $ | 0.32 | | | | $ | 0.33 | | | | | $ | 36.3 | | | | $ | 38.0 | | | |
| | | | | | | | | | | | | |
Weighted average diluted shares outstanding | 113.7 | | | | 116.7 | | | | | | | | | | |
FINANCIAL SUMMARY
Year End
(Amounts in millions, except per share data)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Per diluted share | | | | | | | |
| Year ended | | Year ended |
| December 31, | | December 31, |
| 2023 | | | 2022 | | % change | | 2023 | | | 2022 | | % change |
| | | | | | | | | | | | | |
Income from insurance products (b) | $ | 3.13 | | | | $ | 2.89 | | | 8 | | | $ | 360.0 | | | | $ | 339.9 | | | 6 | |
Fee income | 0.27 | | | | 0.20 | | | 35 | | | 31.0 | | | | 23.7 | | | 31 | |
Investment income not allocated to product lines (c) | 1.04 | | | | 1.22 | | | (15) | | | 120.2 | | | | 143.9 | | | (16) | |
Expenses not allocated to product lines | (0.45) | | | | (0.35) | | | 29 | | | (51.7) | | | | (40.8) | | | 27 | |
Operating earnings before taxes | 3.99 | | | | 3.96 | | | | | 459.5 | | | | 466.7 | | | |
Income tax expense on operating income | (0.90) | | | | (0.90) | | | — | | | (103.4) | | | | (106.3) | | | (3) | |
Net operating income (1) | 3.09 | | | | 3.06 | | | 1 | | | 356.1 | | | | 360.4 | | | (1) | |
Net realized investment losses from sales and change in allowance for credit losses | (0.54) | | | | (0.53) | | | | | (62.7) | | | | (62.2) | | | |
Net change in market value of investments recognized in earnings | (0.06) | | | | (0.62) | | | | | (6.3) | | | | (73.2) | | | |
Changes in fair value of embedded derivative liabilities and market risk benefits | (0.26) | | | | 3.74 | | | | | (29.9) | | | | 440.2 | | | |
| | | | | | | | | | | | | |
Other | (0.03) | | | | 0.38 | | | | | (3.8) | | | | 45.0 | | | |
Non-operating income (loss) before taxes | (0.89) | | | | 2.97 | | | | | (102.7) | | | | 349.8 | | | |
Income tax (expense) benefit on non-operating income (loss) | 0.20 | | | | (0.67) | | | | | 23.1 | | | | (79.6) | | | |
| | | | | | | | | | | | | |
Net non-operating income (loss) | (0.69) | | | | 2.30 | | | | | (79.6) | | | | 270.2 | | | |
Net income | $ | 2.40 | | | | $ | 5.36 | | | | | $ | 276.5 | | | | $ | 630.6 | | | |
| | | | | | | | | | | | | |
Weighted average diluted shares outstanding | 115.1 | | | | 117.7 | | | | | | | | | | |
____________________
(a) GAAP is defined as accounting principles generally accepted in the United States of America.
(b) Income from insurance products is the sum of the insurance margins of the annuity, health and life product lines, less expenses allocated to the insurance product lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Insurance margin is management’s measure of the profitability of its annuity, health and life segments’ performance and consists of insurance policy income plus allocated investment income less insurance policy benefits, interest credited, commissions, advertising expense and amortization of acquisition costs.
(c) Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the funding agreement-backed notes ("FABN") program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders.
FINANCIAL SUMMARY (continued)
Management vs. GAAP Measures
(Dollars in millions, except per share data)
(Unaudited)
Shareholders’ equity, excluding accumulated other comprehensive income (loss), and book value per share, excluding accumulated other comprehensive income (loss), are non-GAAP measures that are utilized by management to view the business without the effect of accumulated other comprehensive income (loss) which is primarily attributable to fluctuations in interest rates associated with fixed maturities, available for sale. Management views the business in this manner because the Company has the ability and generally, the intent, to hold investments to maturity and meaningful trends can be more easily identified without the fluctuations. In addition, shareholders' equity excludes net operating loss carryforwards in our non-GAAP return on equity measures as such assets are not discounted and, accordingly, will not provide a return to shareholders until after it is realized as a reduction to taxes that would otherwise be paid. Management believes that excluding this value from the equity component of this measure enhances the understanding of the effect these non-discounted assets have on operating returns.
_____________________________________________________________________________________________________
| | | | | | | | | | | |
| Quarter ended |
| December 31, |
| 2023 | | 2022 |
| | | |
Trailing twelve months return on equity (a) | 14.0 | % | | 26.5 | % |
Trailing twelve months operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) (6) | 9.8 | % | | 10.8 | % |
Trailing twelve months operating return, excluding significant items, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) (6) | 8.6 | % | | 10.3 | % |
| | | |
| | | |
Shareholders’ equity | $ | 2,215.6 | | | $ | 1,768.8 | |
Accumulated other comprehensive loss | 1,576.8 | | | 1,957.3 | |
| | | |
Shareholders’ equity, excluding accumulated other comprehensive loss | 3,792.4 | | | 3,726.1 | |
Net operating loss carryforwards | (79.6) | | | (169.0) | |
Shareholders' equity, excluding accumulated other comprehensive loss and net operating loss carryforwards | $ | 3,712.8 | | | $ | 3,557.1 | |
| | | |
Book value per diluted share | $ | 19.83 | | | $ | 15.14 | |
Accumulated other comprehensive loss | 14.11 | | | 16.75 | |
| | | |
Book value per diluted share, excluding accumulated other comprehensive loss (a non-GAAP financial measure) (2) | $ | 33.94 | | | $ | 31.89 | |
____________________
(a) Calculated using average shareholders’ equity for the measurement period.
INSURANCE OPERATIONS
Annuity products accounted for 23 percent of the Company’s insurance margin for the quarter and annuity premiums collected increased 2 percent in 4Q23 compared to 4Q22.
Health products accounted for 53 percent of the Company’s insurance margin for the quarter and 64 percent of insurance policy income.
Life products accounted for 24 percent of the Company’s insurance margin for the quarter and 35 percent of insurance policy income.
Sales of health products were up 5 percent and sales of life products were up 8 percent in 4Q23 compared to 4Q22.
ANNUITY COLLECTED PREMIUMS
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | |
| Quarter ended December 31, | | |
| 2023 | | 2022 | | % change |
Annuity collected premiums | $ | 438.3 | | | $ | 431.0 | | | 2 | |
INSURANCE POLICY INCOME
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | |
| Quarter ended December 31, | | |
| 2023 | | 2022 | | % change |
Annuity | $ | 8.0 | | | $ | 6.0 | | | 33 | |
Health | 398.3 | | | 403.6 | | | (1) | |
Life | 219.4 | | | 216.4 | | | 1 | |
Total insurance policy income | $ | 625.7 | | | $ | 626.0 | | | — | |
SALES MEASURED AS NEW ANNUALIZED PREMIUMS FOR
LIFE AND HEALTH PRODUCTS
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | |
| Quarter ended December 31, | | |
| 2023 | | 2022 | | % change |
Health | $ | 52.2 | | | $ | 49.9 | | | 5 | |
Life | 43.9 | | | 40.8 | | | 8 | |
Total new annualized premiums (4) | $ | 96.1 | | | $ | 90.7 | | | 6 | |
INSURANCE MARGIN
(Amounts in millions, except per share data)
(Unaudited)
Insurance margin is management’s measure of profitability of its annuity, health and life product lines' performance and consists of insurance policy income plus allocated investment income less insurance policy benefits, interest credited, commissions, advertising expense and amortization of acquisition costs. Income from insurance products is the sum of the insurance margins of the annuity, health and life product lines, less expenses allocated to the insurance product lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Management believes this information helps provide a better understanding of the business and a more meaningful analysis of our operations. Income from insurance products, a non-GAAP measure, is a component of net operating income, which is reconciled to net income in the Financial Summary section above.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Quarter ended |
| December 31, 2023 | | % of insurance policy income | | | December 31, 2022 | | % of insurance policy income | | % change |
Margin | | | | | | | | | | |
Annuity interest margin | $ | 63.6 | | | | | | $ | 50.8 | | | | | 25 | |
Life insurance interest margin | — | | | | | | 0.4 | | | | | (100) | |
Total interest-sensitive margin | 63.6 | | | | | | 51.2 | | | | | 24 | |
Insurance margin | | | | | | | | | | |
Health | 146.4 | | | 37 | | | | 140.4 | | | 35 | | | 4 | |
Life (a) | 64.6 | | | 29 | | | | 42.9 | | | 20 | | | 51 | |
Total other insurance margin | 211.0 | | | 34 | | | | 183.3 | | | 30 | | | 15 | |
| | | | | | | | | | |
Total insurance margin | 274.6 | | | | | | 234.5 | | | | | |
| | | | | | | | | | |
Allocated expenses | (138.8) | | | | | | (149.1) | | | | | |
Income from insurance products | $ | 135.8 | | | | | | $ | 85.4 | | | | | |
| | | | | | | | | | |
Per diluted share | $ | 1.19 | | | | | | $ | 0.73 | | | | | |
Weighted average diluted shares | 113.7 | | | | | | 116.7 | | | | | |
____________________
(a) Net of $15.7 million and $20.3 million of non-deferred television advertising expense related to our direct distribution channel in the 2023 and 2022 periods, respectively.
Total allocated expenses were $138.8 million, down 7 percent from 4Q22.
Total insurance margins in the quarters ended December 31, 2023 and 2022, were favorably impacted by $33.9 million and $0.7 million, respectively, resulting from our comprehensive annual actuarial review. See pages 19 and 21 for a summary of the impact of significant items.
ANNUITY RESULTS BY PRODUCT TYPE
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | |
Annuity margin |
| Quarter ended |
| December 31, |
| 2023 | | 2022 |
Fixed indexed annuities | $ | 50.9 | | | $ | 41.3 | |
Fixed interest annuities | 7.7 | | | 7.8 | |
Other annuities | 5.0 | | | 1.7 | |
Total | $ | 63.6 | | | $ | 50.8 | |
| | | | | | | | | | | |
Annuity collected premiums |
| Quarter ended |
| December 31, |
| 2023 | | 2022 |
Annuity collected premiums | $ | 438.3 | | | $ | 431.0 | |
| | | | | | | | | | | |
Average net insurance liabilities (5) |
| Quarter ended |
| December 31, |
| 2023 | | 2022 |
Fixed indexed annuities | $ | 9,508.7 | | | $ | 9,054.2 | |
Fixed interest annuities | 1,600.9 | | | 1,652.6 | |
Other annuities | 447.5 | | | 473.6 | |
Total | $ | 11,557.1 | | | $ | 11,180.4 | |
| | | | | | | | | | | |
Margin/average net insurance liabilities (a) |
| Quarter ended |
| December 31, |
| 2023 | | 2022 |
Fixed indexed annuities | 2.14 | % | | 1.82 | % |
Fixed interest annuities | 1.92 | % | | 1.89 | % |
Other annuities | 4.47 | % | | 1.44 | % |
Total | 2.20 | % | | 1.82 | % |
____________________
(a) Defined as annualized quarterly annuity margin divided by average net insurance liabilities (5).
Annuity margins were impacted by our comprehensive annual actuarial review as summarized below:
| | | | | | | | | | | |
| Quarter ended |
| December 31, |
| 2023 | | 2022 |
Fixed indexed annuities | $ | 9.4 | | | $ | (3.2) | |
Other annuities | 3.5 | | | — | |
Net favorable (unfavorable) impact on annuity margins | $ | 12.9 | | | $ | (3.2) | |
HEALTH INSURANCE RESULTS BY PRODUCT TYPE
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Health margin |
| Quarter ended |
| December 31, |
| 2023 | | 2022 | | |
| Amount | | % of insurance policy income | | Amount | | % of insurance policy income | | % change |
Supplemental health and other health | $ | 108.4 | | | 61 | | | $ | 60.3 | | | 34 | | | 80 | |
Medicare supplement | 21.3 | | | 14 | | | 37.9 | | | 23 | | | (44) | |
Long-term care | 16.7 | | | 25 | | | 42.2 | | | 64 | | | (60) | |
Total | $ | 146.4 | | | 37 | | | $ | 140.4 | | | 35 | | | 4 | |
| | | | | | | | | | | | | | | | | |
Health insurance policy income |
| Quarter ended | | |
| December 31, | | |
| 2023 | | 2022 | | % change |
Supplemental health and other health | $ | 178.1 | | | $ | 175.3 | | | 2 | |
Medicare supplement | 153.9 | | | 162.3 | | | (5) | |
Long-term care | 66.3 | | | 66.0 | | | — | |
Total | $ | 398.3 | | | $ | 403.6 | | | (1) | |
| | | | | | | | | | | | | | | | | |
Health NAP (4) |
| Quarter ended | | |
| December 31, | | |
| 2023 | | 2022 | | % change |
Supplemental health and other health | $ | 29.6 | | | $ | 33.3 | | | (11) | |
Medicare supplement | 11.5 | | | 10.4 | | | 11 | |
Long-term care | 11.1 | | | 6.2 | | | 79 | |
Total | $ | 52.2 | | | $ | 49.9 | | | 5 | |
Health margins were impacted by our comprehensive annual actuarial review as summarized below:
| | | | | | | | | | | |
| Quarter ended |
| December 31, |
| 2023 | | 2022 |
Supplemental health | $ | 41.9 | | | $ | 1.9 | |
Medicare supplement | (10.6) | | | — | |
Long-term care | (9.0) | | | 16.4 | |
Net favorable impact on health margins | $ | 22.3 | | | $ | 18.3 | |
LIFE INSURANCE RESULTS BY PRODUCT TYPE
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Life margin |
| Quarter ended | | |
| December 31, | | |
| 2023 | | 2022 | | |
| Amount | | % of insurance policy income | | Amount | | % of insurance policy income | | % change |
Life insurance interest margin | $ | — | | | | | $ | 0.4 | | | | | (100) | |
Life insurance margin: | | | | | | | | | |
Traditional life | 35.7 | | | 21 | | | 22.1 | | | 13 | | | 62 | |
Interest sensitive life | 28.9 | | | 63 | | | 20.8 | | | 47 | | | 39 | |
Subtotal | 64.6 | | | 29 | | | 42.9 | | | 20 | | | 51 | |
Total margin | $ | 64.6 | | | | | $ | 43.3 | | | | | 49 | |
| | | | | | | | | | | | | | | | | |
Life insurance policy income |
| Quarter ended | | |
| December 31, | | |
| 2023 | | 2022 | | % change |
Traditional life | $ | 173.2 | | | $ | 172.2 | | | 1 | |
Interest sensitive life | 46.2 | | | 44.2 | | | 5 | |
Total | $ | 219.4 | | | $ | 216.4 | | | 1 | |
| | | | | | | | | | | | | | | | | |
Life NAP (4) |
| Quarter ended | | |
| December 31, | | |
| 2023 | | 2022 | | % change |
Traditional life | $ | 35.5 | | | $ | 33.2 | | | 7 | |
Interest sensitive life | 8.4 | | | 7.6 | | | 11 | |
Total | $ | 43.9 | | | $ | 40.8 | | | 8 | |
| | | | | | | | | | | | | | | | | |
Average net insurance liabilities (5) and interest margin | | |
| Quarter ended | | |
| December 31, | | |
| 2023 | | 2022 | | % change |
Interest sensitive life products | $ | 1,045.8 | | | $ | 1,026.9 | | | 2 | |
Interest margin/average net insurance liabilities (5) | — | % | | 0.16 | % | | (100) | |
Life margins were impacted by our comprehensive annual actuarial review as summarized below:
| | | | | | | | | | | |
| Quarter ended |
| December 31, |
| 2023 | | 2022 |
Traditional life | $ | (5.2) | | | $ | (13.0) | |
Interest-sensitive life | 3.9 | | | (1.4) | |
Net unfavorable impact on life margins | $ | (1.3) | | | $ | (14.4) | |
QUARTERLY AVERAGE EXCLUSIVE PRODUCING AGENTS
| | | | | | | | | | | | | | | | | |
| Average Exclusive Producing Agent Count |
| Quarter ended | | |
| December 31, | | % |
| 2023 | | 2022 | | change |
Consumer | | | | | |
Agents (a) (c) | 4,224 | | | 3,882 | | | 9 | |
Registered agents (b) (c) | 708 | | | 695 | | | 2 | |
Worksite (a) (c) | 349 | | | 275 | | | 27 | |
____________________
(a) Producing agents represent the monthly average of exclusive agents that have submitted at least one policy in the month.
(b) Registered agents are dually licensed as insurance agents and financial representatives who can buy and sell
securities for clients, and/or investment advisors who can provide ongoing investment advice for clients.
(c) Agent counts represent the average of the last 3 months.
INVESTMENTS
INVESTMENT INCOME NOT ALLOCATED TO PRODUCT LINES
(Dollars in millions, except per share data)
Management uses investment income not allocated to product lines as the measure to evaluate the performance of the investment segment. It is defined as net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the FABN program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. We also view investment income not allocated to product lines per diluted share as an important and useful measure to evaluate performance of the investment segment as it takes into consideration our share repurchase program.
| | | | | | | | | | | | | | | | | |
| Quarter ended December 31, | | |
| 2023 | | 2022 | | % change |
Net investment income | $ | 465.2 | | | $ | 315.7 | | | 47 | |
Allocated to product lines: | | | | | |
Annuity | (132.2) | | | (123.6) | | | 7 | |
Health | (74.2) | | | (73.7) | | | 1 | |
Life | (36.1) | | | (35.8) | | | 1 | |
Equity returns credited to policyholder account balances | (105.2) | | | 6.1 | | | (1,825) | |
Amounts allocated to product lines and credited to policyholder account balances | (347.7) | | | (227.0) | | | 53 | |
Impact of annual option forfeitures related to fixed indexed annuity surrenders | 3.2 | | | (1.0) | | | (420) | |
Amount related to variable interest entities and other non-operating items | (16.2) | | | (18.6) | | | (13) | |
Interest expense on corporate debt | (15.7) | | | (15.6) | | | 1 | |
Interest expense on financing arrangements | (1.3) | | | — | | | N/A |
Interest expense on investment borrowings from the Federal Home Loan Bank program | (30.5) | | | (16.1) | | | 89 | |
Expenses related to FABN program | (7.6) | | | (7.6) | | | — | |
Less amounts credited to deferred compensation plans (offsetting investment income) | (11.1) | | | (4.6) | | | 141 | |
Total adjustments | (79.2) | | | (63.5) | | | |
Investment income not allocated to product lines | $ | 38.3 | | | $ | 25.2 | | | 52 | |
| | | | | |
Per diluted share | $ | 0.34 | | | $ | 0.22 | | | |
INVESTMENT PORTFOLIO
(Dollars in millions)
The composition of the investment portfolio at December 31, 2023 is as follows:
| | | | | | | | | | | |
| $ | | % of total |
Fixed maturities, available for sale, at fair value | $ | 21,506.2 | | | 82 | |
Equity securities at fair value | 96.9 | | | 1 | |
Mortgage loans | 2,064.1 | | | 8 | |
Policy loans | 128.5 | | | — | |
Trading securities | 222.7 | | | 1 | |
Investments held by variable interest entities | 768.6 | | | 3 | |
Other invested assets | 1,353.4 | | | 5 | |
Total investment portfolio | $ | 26,140.4 | | | 100 | |
Fixed maturities, available for sale, at amortized cost by asset class as of December 31, 2023 are as follows:
| | | | | | | | | | | | | | | | | |
| Investment grade | | Below investment grade | | Total |
Corporate securities | $ | 12,590.8 | | | $ | 596.1 | | | $ | 13,186.9 | |
United States Treasury securities and obligations of the United States government and agencies | 207.6 | | | — | | | 207.6 | |
States and political subdivisions | 2,887.2 | | | 9.6 | | | 2,896.8 | |
Foreign governments | 92.7 | | | — | | | 92.7 | |
Asset-backed securities | 1,364.5 | | | 111.7 | | | 1,476.2 | |
Agency residential mortgage-backed securities | 639.0 | | | — | | | 639.0 | |
Non-agency residential mortgage-backed securities | 1,170.8 | | | 499.3 | | (a) | 1,670.1 | |
Collateralized loan obligations | 1,042.5 | | | — | | | 1,042.5 | |
Commercial mortgage-backed securities | 2,386.9 | | | 100.5 | | | 2,487.4 | |
| | | | | |
Total | $ | 22,382.0 | | | $ | 1,317.2 | | | $ | 23,699.2 | |
____________________
(a) Certain structured securities rated below investment grade by Nationally Recognized Statistical Rating Organizations may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the National Association of Insurance Commissioners (NAIC).
The fair value of CNO’s available for sale fixed maturity portfolio was $21.5 billion compared with an amortized cost of $23.7 billion. Net unrealized losses were comprised of gross unrealized gains of $160.7 million and gross unrealized losses of $2,310.8 million. The allowance for credit losses was $42.9 million at December 31, 2023.
At both amortized cost and fair value, 94 percent of fixed maturities, available for sale, were rated “investment grade”.
Non-Operating Items
Net investment gains in 4Q23 were $1.4 million including the favorable change in the allowance for credit losses of $21.8 million which was recorded in earnings. Net investment losses in 4Q22 were $27.2 million including the unfavorable change in the allowance for credit losses of $5.7 million which was recorded in earnings.
During 4Q23 and 4Q22, we recognized an increase (decrease) in earnings of $8.8 million and $(9.0) million, respectively, due to the net change in market value of investments recognized in earnings.
During 4Q23 and 4Q22, we recognized a decrease in earnings of $124.6 million and $16.4 million, respectively, resulting from changes in the estimated fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities. Such amounts include the impacts of changes in market interest rates and equity impacts used to determine the estimated fair values of the embedded derivatives and market risk benefits.
In 4Q23 and 4Q22, other non-operating items included an increase (decrease) in earnings of $(10.3) million and $0.2 million, respectively, for the mark-to-market change in the agent deferred compensation plan liability which was impacted by changes in the underlying actuarial assumptions used to value the liability. We recognize the mark-to-market change in the estimated value of this liability through earnings as assumptions change. In addition, other non-operating items in 4Q22 included a one-time restructuring charge of $7.1 million primarily related to an early retirement program.
Statutory (based on non-GAAP measures) and GAAP Capital Information
The consolidated statutory risk-based capital ratio of our U.S. based insurance subsidiaries was estimated at 402% at December 31, 2023, reflecting estimated 4Q23 statutory operating income of $18 million (and $131 million during 2023) and the payment of insurance company dividends, net of capital contributions, to the holding company of $433.4 million during 4Q23 (and $492.1 million, net of capital contributions, during 2023). During 4Q23, the holding company also contributed $264.2 million to CNO Bermuda Re (a wholly-owned Bermuda reinsurance company) in connection with an initial reinsurance transaction between CNO Bermuda Re and one of our U.S. based insurance subsidiaries.
During 4Q23, we repurchased $80.0 million of common stock under our securities repurchase program (including $10.6 million of repurchases settled in 1Q24). We repurchased 3.0 million common shares at an average cost of $27.29 per share. As of December 31, 2023, we had 109.4 million shares outstanding and had authority to repurchase up to an additional $521.8 million of our common stock. During 4Q23, dividends paid on common stock totaled $16.7 million.
Unrestricted cash and investments held by our holding company were $256 million at December 31, 2023, compared to $167 million at December 31, 2022.
Book value per common share was $20.26 at December 31, 2023 compared to $15.47 at December 31, 2022. Book value per diluted share, excluding accumulated other comprehensive income (loss) (2), was $33.94 at December 31, 2023, compared to $31.89 at December 31, 2022.
The debt-to-capital ratio was 34.0% and 39.2% at December 31, 2023 and 2022, respectively. Our debt-to-total capital ratio, excluding accumulated other comprehensive income (loss) (3) was 23.1% and 23.4% at December 31, 2023 and 2022, respectively.
Return on equity for the years ended December 31, 2023 and 2022, was 14.0% and 26.5%, respectively. Operating return, excluding significant items, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (6) for the years ended December 31, 2023 and 2022, was 8.6% and 10.3%, respectively.
In this news release, CNO includes non-GAAP measures to enhance investors’ understanding of management’s view of the business. The non-GAAP measures are not a substitute for GAAP, but rather a supplement to increase transparency by providing a broader perspective. CNO’s definitions of non-GAAP measures may differ from other companies’ definitions. More detailed information including various GAAP and non-GAAP measurements are located at CNOinc.com in the Investors section under SEC Filings.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS:
This press release may contain forward-looking statements within the meaning of federal securities laws. These prospective statements reflect management’s current expectations, but are not guarantees of future performance. Accordingly, please refer to CNO’s cautionary statement regarding forward-looking statements, and the business environment in which the Company operates, contained in the Company’s Form 10-K for the year ended December 31, 2022 and any subsequent Form 10-Q or Form 10-K on file with the Securities and Exchange Commission and on the Company’s website at CNOinc.com in the Investors section. CNO specifically disclaims any obligation to update or revise any forward-looking statement because of new information, future developments or otherwise.
EARNINGS RELEASE CONFERENCE CALL WEBCAST:
The Company will host a conference call to discuss results on February 7, 2024 at 12:00 p.m. Eastern Time. During the call, we will be referring to a presentation that will be available at the Investors section of the company's website.
To participate by dial-in, please register at https://www.netroadshow.com/events/login?show=fd791d0a&confId=60315. Upon registering, you will be provided with call details and a registrant ID used to track attendance on the conference call. Reminders will also be sent to registered participants via email.
For those investors who prefer to listen to the call online, we will be broadcasting the call live via webcast. The event can be accessed through the Investors section of the company's website: ir.CNOinc.com. Participants should go to the website at least 15 minutes before the event to register and download any necessary audio software.
ABOUT CNO FINANCIAL GROUP
CNO Financial Group, Inc. (NYSE: CNO) secures the future of middle-income America. CNO provides life and health insurance, annuities, financial services and workforce benefits solutions through our family of brands, including Bankers Life, Colonial Penn, Optavise and Washington National. Our customers work hard to save for the future, and we help protect their health, income, and retirement needs with 3.2 million policies and $35 billion in total assets. Our 3,500 associates, 4,600 exclusive agents and more than 5,000 independent partner agents guide individuals, families and businesses through a lifetime of financial decisions. For more information, visit CNOinc.com.
CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
(Dollars in millions)
(unaudited)
| | | | | | | | | | | |
| December 31, 2023 | | December 31, 2022 |
ASSETS | | | |
Investments: | | | |
Fixed maturities, available for sale, at fair value (net of allowance for credit losses: 2023 - $42.9 and 2022 - $56.0; amortized cost: 2023 - $23,699.2 and 2022 - $23,384.2) | $ | 21,506.2 | | | $ | 20,353.4 | |
Equity securities at fair value | 96.9 | | | 135.3 | |
Mortgage loans (net of allowance for credit losses: 2023 - $15.4 and 2022 - $8.0) | 2,064.1 | | | 1,411.9 | |
Policy loans | 128.5 | | | 121.6 | |
Trading securities | 222.7 | | | 207.9 | |
Investments held by variable interest entities (net of allowance for credit losses: 2023 - $3.1 and 2022 - $5.5; amortized cost: 2023 - $787.6 and 2022 - $1,134.2) | 768.6 | | | 1,077.6 | |
Other invested assets | 1,353.4 | | | 1,034.7 | |
Total investments | 26,140.4 | | | 24,342.4 | |
Cash and cash equivalents - unrestricted | 774.5 | | | 575.7 | |
Cash and cash equivalents held by variable interest entities | 114.5 | | | 69.2 | |
Accrued investment income | 251.5 | | | 235.6 | |
Present value of future profits | 180.7 | | | 203.7 | |
Deferred acquisition costs | 1,944.4 | | | 1,770.9 | |
Reinsurance receivables (net of allowance for credit losses: 2023 - $3.0 and 2022 - $2.0) | 4,040.7 | | | 4,223.4 | |
Market risk benefit asset | 75.4 | | | 65.3 | |
Income tax assets, net | 936.2 | | | 1,063.4 | |
Assets held in separate accounts | 3.1 | | | 2.7 | |
Other assets | 641.1 | | | 580.8 | |
Total assets | $ | 35,102.5 | | | $ | 33,133.1 | |
LIABILITIES AND SHAREHOLDERS' EQUITY | | | |
Liabilities: | | | |
Liabilities for insurance products: | | | |
Policyholder account balances | $ | 15,667.8 | | | $ | 15,234.2 | |
Future policy benefits | 11,928.2 | | | 11,240.2 | |
Market risk benefit liability | 7.4 | | | 11.3 | |
Liability for life insurance policy claims | 62.1 | | | 64.1 | |
Unearned and advanced premiums | 218.9 | | | 235.0 | |
Liabilities related to separate accounts | 3.1 | | | 2.7 | |
Other liabilities | 848.8 | | | 693.9 | |
Investment borrowings | 2,189.3 | | | 1,639.5 | |
Borrowings related to variable interest entities | 820.8 | | | 1,104.6 | |
Notes payable – direct corporate obligations | 1,140.5 | | | 1,138.8 | |
Total liabilities | 32,886.9 | | | 31,364.3 | |
Commitments and Contingencies | | | |
Shareholders' equity: | | | |
Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2023 - 109,357,540 and 2022 - 114,343,070) | 1.1 | | | 1.1 | |
Additional paid-in capital | 1,891.5 | | | 2,033.8 | |
Accumulated other comprehensive loss | (1,576.8) | | | (1,957.3) | |
Retained earnings | 1,899.8 | | | 1,691.2 | |
Total shareholders' equity | 2,215.6 | | | 1,768.8 | |
Total liabilities and shareholders' equity | $ | 35,102.5 | | | $ | 33,133.1 | |
CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF OPERATIONS
(Dollars in millions, except per share data)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended | | Year ended |
| December 31, | | December 31, |
| 2023 | | 2022 | | 2023 | | 2022 |
Revenues: | | | | | | | |
Insurance policy income | $ | 625.7 | | | $ | 626.0 | | | $ | 2,505.5 | | | $ | 2,499.8 | |
Net investment income: | | | | | | | |
General account assets | 325.1 | | | 294.8 | | | 1,250.2 | | | 1,179.0 | |
Policyholder and other special-purpose portfolios | 140.1 | | | 20.9 | | | 249.5 | | | (163.1) | |
Investment gains (losses): | | | | | | | |
Realized investment losses | (11.3) | | | (21.5) | | | (69.3) | | | (17.9) | |
Other investment gains (losses) | 21.5 | | | (14.7) | | | 0.3 | | | (117.5) | |
| | | | | | | |
Total investment gains (losses) | 10.2 | | | (36.2) | | | (69.0) | | | (135.4) | |
Fee revenue and other income | 69.4 | | | 68.1 | | | 210.6 | | | 196.5 | |
Total revenues | 1,170.5 | | | 973.6 | | | 4,146.8 | | | 3,576.8 | |
Benefits and expenses: | | | | | | | |
Insurance policy benefits | 743.5 | | | 583.2 | | | 2,318.2 | | | 1,615.4 | |
Liability for future policy benefits remeasurement loss | (30.0) | | | (17.9) | | | (21.2) | | | (15.6) | |
Change in fair value of market risk benefits | 15.3 | | | (22.3) | | | (21.3) | | | (140.2) | |
Interest expense | 63.7 | | | 47.8 | | | 238.6 | | | 137.0 | |
Amortization of deferred acquisition costs and present value of future profits | 58.9 | | | 54.3 | | | 227.4 | | | 212.8 | |
| | | | | | | |
| | | | | | | |
Other operating costs and expenses | 273.0 | | | 280.0 | | | 1,048.3 | | | 950.9 | |
Total benefits and expenses | 1,124.4 | | | 925.1 | | | 3,790.0 | | | 2,760.3 | |
Income before income taxes | 46.1 | | | 48.5 | | | 356.8 | | | 816.5 | |
| | | | | | | |
Income tax expense on period income | 9.8 | | | 10.5 | | | 80.3 | | | 185.9 | |
| | | | | | | |
Net income | $ | 36.3 | | | $ | 38.0 | | | $ | 276.5 | | | $ | 630.6 | |
Earnings per common share: | | | | | | | |
Basic: | | | | | | | |
Weighted average shares outstanding | 111,591,000 | | | 114,422,000 | | | 113,275,000 | | | 115,733,000 | |
Net income | $ | .33 | | | $ | .33 | | | $ | 2.44 | | | $ | 5.45 | |
Diluted: | | | | | | | |
Weighted average shares outstanding | 113,657,000 | | | 116,653,000 | | | 115,124,000 | | | 117,717,000 | |
Net income | $ | .32 | | | $ | .33 | | | $ | 2.40 | | | $ | 5.36 | |
NOTES
(1)Management believes that an analysis of Net income applicable to common stock before: (i) net realized investment gains or losses from sales, impairments and the change in allowance for credit losses, net of taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities, net of taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) loss related to reinsurance transaction, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; and (viii) other non-operating items consisting primarily of earnings attributable to variable interest entities, net of taxes ("Net operating income," a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry. Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the company's underlying fundamentals. A reconciliation of Net operating income to Net income applicable to common stock is provided in the tables on pages 2 and 3. Additional information concerning this non-GAAP measure is included in our periodic filings with the Securities and Exchange Commission that are available in the "Investors - SEC Filings" section of CNO's website, CNOinc.com.
(2)Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised and restricted stock and performance units were vested. The dilution from options, restricted shares and performance units is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period. In addition, the calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.
(3)The calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.
(4)Measured by new annualized premiums for life and health products, which includes 10% of single premium whole life deposits and 100% of all other premiums (excluding annuities). Sales of third-party products are excluded.
(5)Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account balances for annuity products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsurance business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities.
(6)The following summarizes the calculations of: (i) operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); (ii) operating return, excluding significant items, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); and (iii) return on equity are as follows (dollars in millions):
| | | | | | | | | | | | | | | | | |
| | | Year ended |
| | | 4Q23 | | 4Q22 |
Net operating income | $ | 356.1 | | | $ | 360.4 | |
| | | | | |
Net operating income, excluding significant items | $ | 312.8 | | | $ | 342.5 | |
| | | | | |
Net income | $ | 276.5 | | | $ | 630.6 | |
| | | | | |
Average common equity, excluding accumulated other | | | |
| comprehensive income (loss) and net operating loss | | | |
| carryforwards (a non-GAAP financial measure) | $ | 3,631.5 | | | $ | 3,323.3 | |
| | | | | |
Average common shareholders' equity | $ | 1,977.5 | | | $ | 2,384.1 | |
| | | | | |
Operating return on equity, excluding accumulated other | | | |
| comprehensive income (loss) and net operating loss | | | |
| carryforwards (a non-GAAP financial measure) | 9.8 | % | | 10.8 | % |
| | | | | |
Operating return, excluding significant items, on equity, excluding | | | |
| accumulated other comprehensive income (loss) and net | | | |
| operating loss carryforwards (a non-GAAP financial measure) | 8.6 | % | | 10.3 | % |
| | | | | |
Return on equity | 14.0 | % | | 26.5 | % |
The following summarizes: (i) net operating income; (ii) significant items; (iii) net operating income, excluding significant items; and (iv) net income (loss) (dollars in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Net operating | | | | |
| | | | | | Net operating | | income, | | | | |
| | | | | | income, | | excluding | | | | Net |
| | | | | | excluding | | significant | | | | income - |
| | Net operating | | Significant | | significant | | items - trailing | | Net | | trailing |
| | income | | items | | items (a) | | four quarters | | income (loss) | | four quarters |
1Q22 | | $ | 64.5 | | | $ | — | | | $ | 64.5 | | | $ | 373.2 | | | $ | 183.4 | | | $ | 491.7 | |
2Q22 | | 135.1 | | | (17.4) | | (b) | 117.7 | | | 393.4 | | | 233.3 | | | 677.3 | |
3Q22 | | 77.9 | | | — | | | 77.9 | | | 360.9 | | | 175.9 | | | 749.8 | |
4Q22 | | 82.9 | | | (0.5) | | (c) | 82.4 | | | 342.5 | | | 38.0 | | | 630.6 | |
1Q23 | | 58.6 | | | — | | | 58.6 | | | 336.6 | | | (0.8) | | | 446.4 | |
2Q23 | | 62.3 | | | — | | | 62.3 | | | 281.2 | | | 73.7 | | | 286.8 | |
3Q23 | | 101.3 | | | (16.9) | | (d) | 84.4 | | | 287.7 | | | 167.3 | | | 278.2 | |
4Q23 | | 133.9 | | | (26.4) | | (e) | 107.5 | | | 312.8 | | | 36.3 | | | 276.5 | |
| | | | | | | | | | | | |
(a) See note (7) for additional information. |
| | | | | | | | | | | | |
(b) Comprised of an experience refund of $22.5 million related to a reinsurance agreement, net of tax expense of $5.1 million. |
| | | | | | | | | | | | |
(c) Comprised of $.7 million of the net favorable impact arising from our comprehensive annual actuarial review, net of tax expense of $.2 million. |
| | | | | | | | | | | | |
(d) Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals, net of tax expense of $4.8 million. |
| | | | | | | | | | | | |
(e) Comprised of $33.9 million of the net favorable impact arising from our comprehensive annual actuarial review, net of tax expense of $7.5 million. |
A reconciliation of pre-tax operating earnings (a non-GAAP financial measure) to net income is as follows (dollars in millions):
| | | | | | | | | | | | | | | | | |
| | | Year ended December 31, |
| | | 2023 | | 2022 |
Pre-tax operating earnings (a non-GAAP financial measure) | $ | 459.5 | | | $ | 466.7 | |
Income tax expense | (103.4) | | | (106.3) | |
Net operating income | 356.1 | | | 360.4 | |
Non-operating items: | | | |
Net realized investment losses from sales, impairments and change in allowance for credit losses | (62.7) | | | (62.2) | |
Net change in market value of investments recognized in earnings | (6.3) | | | (73.2) | |
Changes in fair value of embedded derivative liabilities and market risk benefits | (29.9) | | | 440.2 | |
Fair value changes related to the agent deferred compensation plan | (3.5) | | | 48.9 | |
| | | |
Other | (0.3) | | | (3.9) | |
Non-operating income (loss) before taxes | (102.7) | | | 349.8 | |
| | | |
Income tax (expense) benefit on non-operating income (loss) | 23.1 | | | (79.6) | |
| | | |
Net non-operating income (loss) | (79.6) | | | 270.2 | |
Net income | $ | 276.5 | | | $ | 630.6 | |
| | | | | |
A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders’ equity, is as follows (dollars in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | 4Q21 |
Consolidated capital, excluding accumulated other comprehensive | | | | | | | |
| income (loss) and net operating loss carryforwards | | | | | | | |
| (a non-GAAP financial measure) | | | | | | | $ | 3,067.3 | |
Net operating loss carryforwards | | | | | | | 243.7 | |
Accumulated other comprehensive income | | | | | | | 373.7 | |
Common shareholders' equity | | | | | | | $ | 3,684.7 | |
| | | | | | | | | |
| | | 1Q22 | | 2Q22 | | 3Q22 | | 4Q22 |
Consolidated capital, excluding accumulated other comprehensive | | | | | | | |
| income (loss) and net operating loss carryforwards | | | | | | | |
| (a non-GAAP financial measure) | $ | 3,141.7 | | | $ | 3,329.0 | | | $ | 3,510.3 | | | $ | 3,557.1 | |
Net operating loss carryforwards | 238.2 | | | 214.7 | | | 190.9 | | | 169.0 | |
Accumulated other comprehensive loss | (561.5) | | | (1,415.8) | | | (1,837.8) | | | (1,957.3) | |
Common shareholders' equity | $ | 2,818.4 | | | $ | 2,127.9 | | | $ | 1,863.4 | | | $ | 1,768.8 | |
| | | | | | | | | |
| | | 1Q23 | | 2Q23 | | 3Q23 | | 4Q23 |
Consolidated capital, excluding accumulated other comprehensive | | | | | | | |
| income (loss) and net operating loss carryforwards | | | | | | | |
| (a non-GAAP financial measure) | $ | 3,543.8 | | | $ | 3,603.0 | | | $ | 3,744.2 | | | $ | 3,712.8 | |
Net operating loss carryforwards | 152.4 | | | 126.3 | | | 102.6 | | | 79.6 | |
Accumulated other comprehensive loss | (1,664.4) | | | (1,733.5) | | | (1,956.7) | | | (1,576.8) | |
Common shareholders' equity | $ | 2,031.8 | | | $ | 1,995.8 | | | $ | 1,890.1 | | | $ | 2,215.6 | |
| | | | | | | | | |
A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders’ equity, is as follows (dollars in millions):
| | | | | | | | | | | | | | | | | |
| | | Trailing four quarter average |
| | | 4Q23 | | 4Q22 |
Consolidated capital, excluding accumulated other comprehensive | | | |
| income (loss) and net operating loss carryforwards | | | |
| (a non-GAAP financial measure) | $ | 3,631.5 | | | $ | 3,323.3 | |
Net operating loss carryforwards | 126.4 | | | 212.5 | |
Accumulated other comprehensive loss | (1,780.4) | | | (1,151.7) | |
Common shareholders' equity | $ | 1,977.5 | | | $ | 2,384.1 | |
(7) The tables below summarize the financial impact of significant items on our net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results (dollars in millions, except per share data).
| | | | | | | | | | | | | | | | | | | | |
| | Year ended |
| | December 31, 2023 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin | | | | | | |
Annuity margin | | $ | 235.0 | | | $ | (12.9) | | (a) | $ | 222.1 | |
Health margin | | 494.3 | | | (22.3) | | (a) | 472.0 | |
Life margin | | 229.7 | | | 1.3 | | (a) | 231.0 | |
Total insurance product margin | | 959.0 | | | (33.9) | | | 925.1 | |
Allocated expenses | | (599.0) | | | — | | | (599.0) | |
Income from insurance products | | 360.0 | | | (33.9) | | | 326.1 | |
Fee income | | 31.0 | | | — | | | 31.0 | |
Investment income not allocated to product lines | | 120.2 | | | — | | | 120.2 | |
Expenses not allocated to product lines | | (51.7) | | | (21.7) | | (b) | (73.4) | |
Operating earnings before taxes | | 459.5 | | | (55.6) | | | 403.9 | |
Income tax (expense) benefit on operating income | | (103.4) | | | 12.3 | | | (91.1) | |
Net operating income | | $ | 356.1 | | | $ | (43.3) | | | $ | 312.8 | |
| | | | | | |
Net operating income per diluted share | | $ | 3.09 | | | $ | (0.37) | | | $ | 2.72 | |
___________
(a)Comprised of $33.9 million of the net favorable impact arising from our comprehensive annual actuarial review.
(b)Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | December 31, 2023 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin | | | | | | |
Annuity margin | | $ | 63.6 | | | $ | (12.9) | | (a) | $ | 50.7 | |
Health margin | | 146.4 | | | (22.3) | | (a) | 124.1 | |
Life margin | | 64.6 | | | 1.3 | | (a) | 65.9 | |
Total insurance product margin | | 274.6 | | | (33.9) | | | 240.7 | |
Allocated expenses | | (138.8) | | | — | | | (138.8) | |
Income from insurance products | | 135.8 | | | (33.9) | | | 101.9 | |
Fee income | | 17.8 | | | — | | | 17.8 | |
Investment income not allocated to product lines | | 38.3 | | | — | | | 38.3 | |
Expenses not allocated to product lines | | (19.8) | | | — | | | (19.8) | |
Operating earnings before taxes | | 172.1 | | | (33.9) | | | 138.2 | |
Income tax (expense) benefit on operating income | | (38.2) | | | 7.5 | | | (30.7) | |
Net operating income | | $ | 133.9 | | | $ | (26.4) | | | $ | 107.5 | |
| | | | | | |
Net operating income per diluted share | | $ | 1.18 | | | $ | (0.23) | | | $ | 0.95 | |
___________
(a)Comprised of $33.9 million of the net favorable impact arising from our comprehensive annual actuarial review.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | September 30, 2023 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin | | | | | | |
Annuity margin | | $ | 57.0 | | | $ | — | | | $ | 57.0 | |
Health margin | | 123.2 | | | — | | | 123.2 | |
Life margin | | 59.8 | | | — | | | 59.8 | |
Total insurance product margin | | 240.0 | | | — | | | 240.0 | |
Allocated expenses | | (153.2) | | | — | | | (153.2) | |
Income from insurance products | | 86.8 | | | — | | | 86.8 | |
Fee income | | (2.9) | | | — | | | (2.9) | |
Investment income not allocated to product lines | | 38.4 | | | — | | | 38.4 | |
Expenses not allocated to product lines | | 7.5 | | | (21.7) | | (a) | (14.2) | |
Operating earnings before taxes | | 129.8 | | | (21.7) | | | 108.1 | |
Income tax (expense) benefit on operating income | | (28.5) | | | 4.8 | | | (23.7) | |
Net operating income | | $ | 101.3 | | | $ | (16.9) | | | $ | 84.4 | |
| | | | | | |
Net operating income per diluted share | | $ | 0.88 | | | $ | (0.14) | | | $ | 0.74 | |
___________
(a)Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals.
| | | | | | | | | | | | | | | | | | | | |
| | Year ended |
| | December 31, 2022 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin | | | | | | |
Annuity margin | | $ | 226.9 | | | $ | 3.2 | | (a) | $ | 230.1 | |
Health margin | | 504.4 | | | (18.3) | | (a) | 486.1 | |
Life margin | | 205.2 | | | 14.4 | | (a) | 219.6 | |
Total insurance product margin | | 936.5 | | | (0.7) | | | 935.8 | |
Allocated expenses | | (596.6) | | | — | | | (596.6) | |
Income from insurance products | | 339.9 | | | (0.7) | | | 339.2 | |
Fee income | | 23.7 | | | — | | | 23.7 | |
Investment income not allocated to product lines | | 143.9 | | | — | | | 143.9 | |
Expenses not allocated to product lines | | (40.8) | | | (22.5) | | (b) | (63.3) | |
Operating earnings before taxes | | 466.7 | | | (23.2) | | | 443.5 | |
Income tax (expense) benefit on operating income | | (106.3) | | | 5.3 | | | (101.0) | |
Net operating income | | $ | 360.4 | | | $ | (17.9) | | | $ | 342.5 | |
| | | | | | |
Net operating income per diluted share | | $ | 3.06 | | | $ | (0.15) | | | $ | 2.91 | |
___________
(a)Comprised of $0.7 million of the net favorable impact arising from our comprehensive annual actuarial review.
(b)Comprised of an experience refund of $22.5 million related to a reinsurance agreement.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | December 31, 2022 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin | | | | | | |
Annuity margin | | $ | 50.8 | | | $ | 3.2 | | (a) | $ | 54.0 | |
Health margin | | 140.4 | | | (18.3) | | (a) | 122.1 | |
Life margin | | 43.3 | | | 14.4 | | (a) | 57.7 | |
Total insurance product margin | | 234.5 | | | (0.7) | | | 233.8 | |
Allocated expenses | | (149.1) | | | — | | | (149.1) | |
Income from insurance products | | 85.4 | | | (0.7) | | | 84.7 | |
Fee income | | 9.2 | | | — | | | 9.2 | |
Investment income not allocated to product lines | | 25.2 | | | — | | | 25.2 | |
Expenses not allocated to product lines | | (12.8) | | | — | | | (12.8) | |
Operating earnings before taxes | | 107.0 | | | (0.7) | | | 106.3 | |
Income tax (expense) benefit on operating income | | (24.1) | | | 0.2 | | | (23.9) | |
Net operating income | | $ | 82.9 | | | $ | (0.5) | | | $ | 82.4 | |
| | | | | | |
Net operating income per diluted share | | $ | 0.71 | | | $ | — | | | $ | 0.71 | |
___________
(a)Comprised of $0.7 million of the net favorable impact arising from our comprehensive annual actuarial review.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | June 30, 2022 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin | | | | | | |
Annuity margin | | $ | 60.1 | | | $ | — | | | $ | 60.1 | |
Health margin | | 125.4 | | | — | | | 125.4 | |
Life margin | | 70.2 | | | — | | | 70.2 | |
Total insurance product margin | | 255.7 | | | — | | | 255.7 | |
Allocated expenses | | (152.2) | | | — | | | (152.2) | |
Income from insurance products | | 103.5 | | | — | | | 103.5 | |
Fee income | | 3.2 | | | — | | | 3.2 | |
Investment income not allocated to product lines | | 64.6 | | | — | | | 64.6 | |
Expenses not allocated to product lines | | 2.9 | | | (22.5) | | (a) | (19.6) | |
Operating earnings before taxes | | 174.2 | | | (22.5) | | | 151.7 | |
Income tax (expense) benefit on operating income | | (39.1) | | | 5.1 | | | (34.0) | |
Net operating income | | $ | 135.1 | | | $ | (17.4) | | | $ | 117.7 | |
| | | | | | |
Net operating income per diluted share | | $ | 1.15 | | | $ | (0.15) | | | $ | 1.00 | |
___________
(a)Comprised of an experience refund of $22.5 million related to a reinsurance agreement.
For further information:
CNO News Media
Valerie Dolenga
Valerie.Dolenga@CNOinc.com
CNO Investor Relations
Adam Auvil
Adam.Auvil@CNOinc.com
Exhibit 99.2
| | | | | | | | | | | | | | | | | |
| | | | | |
| | | | | |
Quarterly Financial Supplement - 4Q2023 | | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
February 6, 2024 | | | | | |
| | | | | |
| | | | | | | | | | | | | | |
Table of Contents | | | | Page |
| | | | |
Consolidated balance sheet | | | | 3 |
Consolidated statement of operations | | | | 4 |
Financial summary | | | | 5 |
Insurance operations | | | | 6 |
Margin from insurance products | | | | 7-9 |
Collected premiums from annuity and interest sensitive life products and insurance policy income | | | | 10 |
Health and life new annualized premiums | | | | 11 |
Computation of weighted average shares outstanding | | | | 12 |
Annuities - account value rollforwards | | | | 13 |
Consolidated statutory information of U.S. based insurance subsidiaries | | | | 14 |
Investment income not allocated to product lines and investment income allocated to product lines | | | | 15-18 |
Other investment data | | | | 18 |
Significant items | | | | 19-20 |
Notes | | | | 21-22 |
CNO FINANCIAL GROUP, INC.
CONSOLIDATED BALANCE SHEET
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Mar-22 | | Jun-22 | | Sep-22 | | Dec-22 | | Mar-23 | | Jun-23 | | Sep-23 | | Dec-23 |
Assets | | | | | | | | | | | | | | | |
Investments: | | | | | | | | | | | | | | | |
Fixed maturities, available for sale, at fair value | $ | 23,479.4 | | | $ | 21,362.7 | | | $ | 20,301.1 | | | $ | 20,353.4 | | | $ | 21,107.1 | | | $ | 20,959.7 | | | $ | 20,305.2 | | | $ | 21,506.2 | |
Equity securities at fair value | 91.0 | | | 136.9 | | | 135.8 | | | 135.3 | | | 106.1 | | | 96.4 | | | 95.5 | | | 96.9 | |
Mortgage loans | 1,213.3 | | | 1,215.3 | | | 1,227.3 | | | 1,411.9 | | | 1,676.1 | | | 1,825.9 | | | 1,971.3 | | | 2,064.1 | |
Policy loans | 119.5 | | | 119.5 | | | 120.2 | | | 121.6 | | | 123.0 | | | 124.2 | | | 126.4 | | | 128.5 | |
Trading securities | 223.0 | | | 198.9 | | | 223.3 | | | 207.9 | | | 208.1 | | | 218.9 | | | 221.2 | | | 222.7 | |
Investments held by variable interest entities | 1,180.8 | | | 1,107.7 | | | 1,099.2 | | | 1,077.6 | | | 1,017.9 | | | 948.2 | | | 858.1 | | | 768.6 | |
Other invested assets | 1,121.8 | | | 1,086.6 | | | 1,028.6 | | | 1,034.7 | | | 1,097.1 | | | 1,176.7 | | | 1,119.9 | | | 1,353.4 | |
Total investments | 27,428.8 | | | 25,227.6 | | | 24,135.5 | | | 24,342.4 | | | 25,335.4 | | | 25,350.0 | | | 24,697.6 | | | 26,140.4 | |
Cash and cash equivalents - unrestricted | 546.0 | | | 567.2 | | | 498.0 | | | 575.7 | | | 425.0 | | | 457.7 | | | 460.8 | | | 774.5 | |
Cash and cash equivalents held by variable interest entities | 48.0 | | | 52.2 | | | 55.5 | | | 69.2 | | | 97.1 | | | 104.2 | | | 122.0 | | | 114.5 | |
Accrued investment income | 227.9 | | | 224.1 | | | 236.0 | | | 235.6 | | | 241.3 | | | 242.1 | | | 252.3 | | | 251.5 | |
Present value of future profits | 223.2 | | | 216.4 | | | 210.0 | | | 203.7 | | | 197.6 | | | 191.8 | | | 186.2 | | | 180.7 | |
Deferred acquisition costs | 1,659.6 | | | 1,697.4 | | | 1,731.4 | | | 1,770.9 | | | 1,811.3 | | | 1,857.7 | | | 1,897.5 | | | 1,944.4 | |
Reinsurance receivables | 4,387.0 | | | 4,288.0 | | | 4,218.6 | | | 4,223.4 | | | 4,189.6 | | | 4,029.2 | | | 4,053.2 | | | 4,040.7 | |
Market risk benefit asset | 16.9 | | | 37.3 | | | 56.3 | | | 65.3 | | | 57.8 | | | 66.0 | | | 89.3 | | | 75.4 | |
Income tax assets, net | 773.1 | | | 951.9 | | | 1,023.9 | | | 1,063.4 | | | 988.1 | | | 1,007.1 | | | 1,039.8 | | | 936.2 | |
Assets held in separate accounts | 3.6 | | | 3.0 | | | 2.7 | | | 2.7 | | | 2.8 | | | 3.0 | | | 2.9 | | | 3.1 | |
Other assets | 671.0 | | | 566.9 | | | 552.2 | | | 580.8 | | | 669.0 | | | 745.1 | | | 705.8 | | | 641.1 | |
Total assets | $ | 35,985.1 | | | $ | 33,832.0 | | | $ | 32,720.1 | | | $ | 33,133.1 | | | $ | 34,015.0 | | | $ | 34,053.9 | | | $ | 33,507.4 | | | $ | 35,102.5 | |
Liabilities | | | | | | | | | | | | | | | |
Liabilities for insurance products: | | | | | | | | | | | | | | | |
Policyholder account balances | $ | 14,725.6 | | | $ | 14,959.4 | | | $ | 15,079.7 | | | $ | 15,234.2 | | | $ | 15,302.9 | | | $ | 15,387.7 | | | $ | 15,481.8 | | | $ | 15,667.8 | |
Future policy benefits | 13,206.1 | | | 11,784.9 | | | 10,815.5 | | | 11,240.2 | | | 11,623.3 | | | 11,479.6 | | | 10,829.9 | | | 11,928.2 | |
Market risk benefit liability | 63.8 | | | 29.9 | | | 13.7 | | | 11.3 | | | 17.6 | | | 10.5 | | | 3.1 | | | 7.4 | |
Liability for life insurance policy claims | 94.1 | | | 66.2 | | | 63.9 | | | 64.1 | | | 67.6 | | | 64.6 | | | 60.8 | | | 62.1 | |
Unearned and advanced premiums | 250.0 | | | 243.4 | | | 238.2 | | | 235.0 | | | 243.5 | | | 233.6 | | | 221.2 | | | 218.9 | |
Liabilities related to separate accounts | 3.6 | | | 3.0 | | | 2.7 | | | 2.7 | | | 2.8 | | | 3.0 | | | 2.9 | | | 3.1 | |
Other liabilities | 912.3 | | | 713.2 | | | 749.4 | | | 693.9 | | | 681.3 | | | 898.9 | | | 869.6 | | | 848.8 | |
Investment borrowings | 1,640.5 | | | 1,640.2 | | | 1,639.9 | | | 1,639.5 | | | 1,839.6 | | | 1,839.5 | | | 2,089.4 | | | 2,189.3 | |
Borrowings related to variable interest entities | 1,133.1 | | | 1,125.9 | | | 1,115.3 | | | 1,104.6 | | | 1,065.4 | | | 1,001.0 | | | 918.5 | | | 820.8 | |
Notes payable - direct corporate obligations | 1,137.6 | | | 1,138.0 | | | 1,138.4 | | | 1,138.8 | | | 1,139.2 | | | 1,139.7 | | | 1,140.1 | | | 1,140.5 | |
Total liabilities | 33,166.7 | | | 31,704.1 | | | 30,856.7 | | | 31,364.3 | | | 31,983.2 | | | 32,058.1 | | | 31,617.3 | | | 32,886.9 | |
Shareholders' equity | | | | | | | | | | | | | | | |
Common stock | 1.2 | | | 1.1 | | | 1.1 | | | 1.1 | | | 1.1 | | | 1.1 | | | 1.1 | | | 1.1 | |
Additional paid-in capital | 2,085.7 | | | 2,032.7 | | | 2,030.6 | | | 2,033.8 | | | 2,021.1 | | | 1,997.9 | | | 1,965.3 | | | 1,891.5 | |
Retained earnings | 1,293.0 | | | 1,509.9 | | | 1,669.5 | | | 1,691.2 | | | 1,674.0 | | | 1,730.3 | | | 1,880.4 | | | 1,899.8 | |
Total shareholders' equity before accumulated other comprehensive income (loss) | 3,379.9 | | | 3,543.7 | | | 3,701.2 | | | 3,726.1 | | | 3,696.2 | | | 3,729.3 | | | 3,846.8 | | | 3,792.4 | |
Accumulated other comprehensive income (loss) | (561.5) | | | (1,415.8) | | | (1,837.8) | | | (1,957.3) | | | (1,664.4) | | | (1,733.5) | | | (1,956.7) | | | (1,576.8) | |
Total shareholders' equity | 2,818.4 | | | 2,127.9 | | | 1,863.4 | | | 1,768.8 | | | 2,031.8 | | | 1,995.8 | | | 1,890.1 | | | 2,215.6 | |
Total liabilities and shareholders' equity | $ | 35,985.1 | | | $ | 33,832.0 | | | $ | 32,720.1 | | | $ | 33,133.1 | | | $ | 34,015.0 | | | $ | 34,053.9 | | | $ | 33,507.4 | | | $ | 35,102.5 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Mar-22 | | Jun-22 | | Sep-22 | | Dec-22 | | Mar-23 | | Jun-23 | | Sep-23 | | Dec-23 |
| | | | | | | | | | | | | | | |
Book value per common share | $ | 24.04 | | | $ | 18.54 | | | $ | 16.29 | | | $ | 15.47 | | | $ | 17.68 | | | $ | 17.56 | | | $ | 16.85 | | | $ | 20.26 | |
| | | | | | | | | | | | | | | |
Book value per common share, excluding accumulated other comprehensive income (loss) (1) (2) | $ | 28.83 | | | $ | 30.87 | | | $ | 32.36 | | | $ | 32.59 | | | $ | 32.17 | | | $ | 32.81 | | | $ | 34.30 | | | $ | 34.68 | |
| | | | | | | | | | | | | | | |
Book value per diluted share (1) (3) | $ | 28.28 | | | $ | 30.50 | | | $ | 31.91 | | | $ | 31.89 | | | $ | 31.82 | | | $ | 32.34 | | | $ | 33.75 | | | $ | 33.94 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
Revenues | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 625.0 | | | $ | 625.6 | | | $ | 623.2 | | | $ | 626.0 | | | $ | 2,499.8 | | | $ | 625.5 | | | $ | 628.3 | | | $ | 626.0 | | | $ | 625.7 | | | $ | 2,505.5 | |
Net investment income: | | | | | | | | | | | | | | | | | | | |
General account assets | 277.5 | | | 317.7 | | | 289.0 | | | 294.8 | | | 1,179.0 | | | 292.2 | | | 308.1 | | | 324.8 | | | 325.1 | | | 1,250.2 | |
Policyholder and other special-purpose portfolios | (69.3) | | | (93.8) | | | (20.9) | | | 20.9 | | | (163.1) | | | 50.8 | | | 91.6 | | | (33.0) | | | 140.1 | | | 249.5 | |
Investment gains (losses): | | | | | | | | | | | | | | | | | | | |
Realized investment gains (losses) | 18.8 | | | (7.0) | | | (8.2) | | | (21.5) | | | (17.9) | | | (14.6) | | | (21.8) | | | (21.6) | | | (11.3) | | | (69.3) | |
Other investment gains (losses) | (51.5) | | | (41.8) | | | (9.5) | | | (14.7) | | | (117.5) | | | — | | | (13.5) | | | (7.7) | | | 21.5 | | | 0.3 | |
| | | | | | | | | | | | | | | | | | | |
Total investment gains (losses) | (32.7) | | | (48.8) | | | (17.7) | | | (36.2) | | | (135.4) | | | (14.6) | | | (35.3) | | | (29.3) | | | 10.2 | | | (69.0) | |
Fee revenue and other income | 42.4 | | | 54.3 | | | 31.7 | | | 68.1 | | | 196.5 | | | 52.1 | | | 30.1 | | | 59.0 | | | 69.4 | | | 210.6 | |
Total revenues | 842.9 | | | 855.0 | | | 905.3 | | | 973.6 | | | 3,576.8 | | | 1,006.0 | | | 1,022.8 | | | 947.5 | | | 1,170.5 | | | 4,146.8 | |
| | | | | | | | | | | | | | | | | | | |
Benefits and expenses | | | | | | | | | | | | | | | | | | | |
Insurance policy benefits | 333.9 | | | 302.2 | | | 396.1 | | | 583.2 | | | 1,615.4 | | | 609.7 | | | 565.9 | | | 399.1 | | | 743.5 | | | 2,318.2 | |
Liability for future policy benefits remeasurement (gain) loss | 7.0 | | | 0.3 | | | (5.0) | | | (17.9) | | | (15.6) | | | 0.6 | | | 8.3 | | | (0.1) | | | (30.0) | | | (21.2) | |
Change in fair value of market risk benefits | (32.7) | | | (50.3) | | | (34.9) | | | (22.3) | | | (140.2) | | | 14.8 | | | (17.6) | | | (33.8) | | | 15.3 | | | (21.3) | |
Interest expense | 23.8 | | | 27.8 | | | 37.6 | | | 47.8 | | | 137.0 | | | 54.7 | | | 57.6 | | | 62.6 | | | 63.7 | | | 238.6 | |
Amortization of deferred acquisition costs and present value of future profits | 52.3 | | | 52.7 | | | 53.5 | | | 54.3 | | | 212.8 | | | 55.5 | | | 56.0 | | | 57.0 | | | 58.9 | | | 227.4 | |
| | | | | | | | | | | | | | | | | | | |
Other operating costs and expenses | 218.3 | | | 222.5 | | | 230.1 | | | 280.0 | | | 950.9 | | | 271.7 | | | 256.5 | | | 247.1 | | | 273.0 | | | 1,048.3 | |
Total benefits and expenses | 602.6 | | | 555.2 | | | 677.4 | | | 925.1 | | | 2,760.3 | | | 1,007.0 | | | 926.7 | | | 731.9 | | | 1,124.4 | | | 3,790.0 | |
| | | | | | | | | | | | | | | | | | | |
Income (loss) before income taxes | 240.3 | | | 299.8 | | | 227.9 | | | 48.5 | | | 816.5 | | | (1.0) | | | 96.1 | | | 215.6 | | | 46.1 | | | 356.8 | |
Income tax expense (benefit) on period income (loss) | 56.9 | | | 66.5 | | | 52.0 | | | 10.5 | | | 185.9 | | | (0.2) | | | 22.4 | | | 48.3 | | | 9.8 | | | 80.3 | |
| | | | | | | | | | | | | | | | | | | |
Net income (loss) | $ | 183.4 | | | $ | 233.3 | | | $ | 175.9 | | | $ | 38.0 | | | $ | 630.6 | | | $ | (0.8) | | | $ | 73.7 | | | $ | 167.3 | | | $ | 36.3 | | | $ | 276.5 | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
FINANCIAL SUMMARY
(Dollars in millions, except per share data)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
Insurance product margin (4) | | | | | | | | | | | | | | | | | | | |
Annuity margin | $ | 55.9 | | | $ | 60.1 | | | $ | 60.1 | | | $ | 50.8 | | | $ | 226.9 | | | $ | 57.3 | | | $ | 57.1 | | | $ | 57.0 | | | $ | 63.6 | | | $ | 235.0 | |
Health margin | 115.3 | | | 125.4 | | | 123.3 | | | 140.4 | | | 504.4 | | | 116.5 | | | 108.2 | | | 123.2 | | | 146.4 | | | 494.3 | |
Life margin | 36.0 | | | 70.2 | | | 55.7 | | | 43.3 | | | 205.2 | | | 47.4 | | | 57.9 | | | 59.8 | | | 64.6 | | | 229.7 | |
Total insurance product margin | 207.2 | | | 255.7 | | | 239.1 | | | 234.5 | | | 936.5 | | | 221.2 | | | 223.2 | | | 240.0 | | | 274.6 | | | 959.0 | |
Allocated expenses | (144.8) | | | (152.2) | | | (150.5) | | | (149.1) | | | (596.6) | | | (157.5) | | | (149.5) | | | (153.2) | | | (138.8) | | | (599.0) | |
Income from insurance products (5) | 62.4 | | | 103.5 | | | 88.6 | | | 85.4 | | | 339.9 | | | 63.7 | | | 73.7 | | | 86.8 | | | 135.8 | | | 360.0 | |
Fee income | 9.9 | | | 3.2 | | | 1.4 | | | 9.2 | | | 23.7 | | | 15.5 | | | 0.6 | | | (2.9) | | | 17.8 | | | 31.0 | |
Investment income not allocated to product lines (9) | 27.0 | | | 64.6 | | | 27.1 | | | 25.2 | | | 143.9 | | | 15.5 | | | 28.0 | | | 38.4 | | | 38.3 | | | 120.2 | |
Expenses not allocated to product lines | (14.8) | | | 2.9 | | | (16.1) | | | (12.8) | | | (40.8) | | | (18.3) | | | (21.1) | | | 7.5 | | | (19.8) | | | (51.7) | |
Operating earnings before taxes | 84.5 | | | 174.2 | | | 101.0 | | | 107.0 | | | 466.7 | | | 76.4 | | | 81.2 | | | 129.8 | | | 172.1 | | | 459.5 | |
Income tax expense on operating income | (20.0) | | | (39.1) | | | (23.1) | | | (24.1) | | | (106.3) | | | (17.8) | | | (18.9) | | | (28.5) | | | (38.2) | | | (103.4) | |
Net operating income (10) | 64.5 | | | 135.1 | | | 77.9 | | | 82.9 | | | 360.4 | | | 58.6 | | | 62.3 | | | 101.3 | | | 133.9 | | | 356.1 | |
Net realized investment gains (losses) from sales, impairments and change in allowance for credit losses | (7.2) | | | (27.1) | | | (0.7) | | | (27.2) | | | (62.2) | | | (12.7) | | | (31.3) | | | (20.1) | | | 1.4 | | | (62.7) | |
Net change in market value of investments recognized in earnings | (25.5) | | | (21.7) | | | (17.0) | | | (9.0) | | | (73.2) | | | (1.9) | | | (4.0) | | | (9.2) | | | 8.8 | | | (6.3) | |
Fair value changes related to agent deferred compensation plan | 22.7 | | | 14.0 | | | 12.0 | | | 0.2 | | | 48.9 | | | — | | | — | | | 6.8 | | | (10.3) | | | (3.5) | |
Changes in fair value of embedded derivative liabilities and market risk benefits | 165.4 | | | 160.6 | | | 130.6 | | | (16.4) | | | 440.2 | | | (65.1) | | | 50.4 | | | 109.4 | | | (124.6) | | | (29.9) | |
| | | | | | | | | | | | | | | | | | | |
Other | 0.4 | | | (0.2) | | | 2.0 | | | (6.1) | | | (3.9) | | | 2.3 | | | (0.2) | | | (1.1) | | | (1.3) | | | (0.3) | |
Net non-operating income (loss) before taxes | 155.8 | | | 125.6 | | | 126.9 | | | (58.5) | | | 349.8 | | | (77.4) | | | 14.9 | | | 85.8 | | | (126.0) | | | (102.7) | |
Income tax (expense) benefit on non-operating income (loss) | (36.9) | | | (27.4) | | | (28.9) | | | 13.6 | | | (79.6) | | | 18.0 | | | (3.5) | | | (19.8) | | | 28.4 | | | 23.1 | |
| | | | | | | | | | | | | | | | | | | |
Net non-operating income (loss) | 118.9 | | | 98.2 | | | 98.0 | | | (44.9) | | | 270.2 | | | (59.4) | | | 11.4 | | | 66.0 | | | (97.6) | | | (79.6) | |
Net income (loss) | $ | 183.4 | | | $ | 233.3 | | | $ | 175.9 | | | $ | 38.0 | | | $ | 630.6 | | | $ | (0.8) | | | $ | 73.7 | | | $ | 167.3 | | | $ | 36.3 | | | $ | 276.5 | |
Per diluted share | | | | | | | | | | | | | | | | | | | |
Net operating income | $ | 0.54 | | | $ | 1.15 | | | $ | 0.67 | | | $ | 0.71 | | | $ | 3.06 | | | $ | 0.51 | | | $ | 0.54 | | | $ | 0.88 | | | $ | 1.18 | | | $ | 3.09 | |
Net non-operating income (loss) | 0.98 | | | 0.84 | | | 0.85 | | | (0.38) | | | 2.30 | | | (0.52) | | | 0.10 | | | 0.58 | | | (0.86) | | | (0.69) | |
Net income (loss) | $ | 1.52 | | | $ | 1.99 | | | $ | 1.52 | | | $ | 0.33 | | | $ | 5.36 | | | $ | (0.01) | | | $ | 0.64 | | | $ | 1.46 | | | $ | 0.32 | | | $ | 2.40 | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Insurance Operations
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
Insurance product margin (4) | | | | | | | | | | | | | | | | | | | |
Annuity: | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 5.0 | | | $ | 5.8 | | | $ | 6.3 | | | $ | 6.0 | | | $ | 23.1 | | | $ | 5.1 | | | $ | 8.1 | | | $ | 7.2 | | | $ | 8.0 | | | $ | 28.4 | |
Net investment income (5) (6) | 117.5 | | | 117.8 | | | 121.1 | | | 123.6 | | | 480.0 | | | 125.4 | | | 127.7 | | | 131.0 | | | 132.2 | | | 516.3 | |
Insurance policy benefits | (9.5) | | | (6.8) | | | (6.5) | | | (15.5) | | | (38.3) | | | (8.7) | | | (10.6) | | | (9.8) | | | 0.1 | | | (29.0) | |
Interest credited (6) | (42.5) | | | (41.4) | | | (44.8) | | | (46.8) | | | (175.5) | | | (48.1) | | | (50.6) | | | (53.4) | | | (57.3) | | | (209.4) | |
Amortization and non-deferred commissions | (14.6) | | | (15.3) | | | (16.0) | | | (16.5) | | | (62.4) | | | (16.4) | | | (17.5) | | | (18.0) | | | (19.4) | | | (71.3) | |
Annuity margin | 55.9 | | | 60.1 | | | 60.1 | | | 50.8 | | | 226.9 | | | 57.3 | | | 57.1 | | | 57.0 | | | 63.6 | | | 235.0 | |
Health: | | | | | | | | | | | | | | | | | | | |
Insurance policy income | 406.7 | | | 403.5 | | | 403.5 | | | 403.6 | | | 1,617.3 | | | 401.4 | | | 397.1 | | | 397.8 | | | 398.3 | | | 1,594.6 | |
Net investment income (5) | 73.3 | | | 73.0 | | | 73.3 | | | 73.7 | | | 293.3 | | | 74.0 | | | 74.3 | | | 74.2 | | | 74.2 | | | 296.7 | |
Insurance policy benefits | (323.1) | | | (309.9) | | | (310.8) | | | (293.7) | | | (1,237.5) | | | (318.1) | | | (322.7) | | | (308.5) | | | (285.6) | | | (1,234.9) | |
Amortization and non-deferred commissions | (41.6) | | | (41.2) | | | (42.7) | | | (43.2) | | | (168.7) | | | (40.8) | | | (40.5) | | | (40.3) | | | (40.5) | | | (162.1) | |
Health margin | 115.3 | | | 125.4 | | | 123.3 | | | 140.4 | | | 504.4 | | | 116.5 | | | 108.2 | | | 123.2 | | | 146.4 | | | 494.3 | |
Life: | | | | | | | | | | | | | | | | | | | |
Insurance policy income | 213.3 | | | 216.3 | | | 213.4 | | | 216.4 | | | 859.4 | | | 219.0 | | | 223.1 | | | 221.0 | | | 219.4 | | | 882.5 | |
Net investment income (5) (7) | 35.5 | | | 35.2 | | | 35.4 | | | 35.8 | | | 141.9 | | | 36.3 | | | 36.1 | | | 36.3 | | | 36.1 | | | 144.8 | |
Insurance policy benefits | (153.1) | | | (127.7) | | | (138.7) | | | (155.8) | | | (575.3) | | | (147.2) | | | (142.8) | | | (140.7) | | | (139.3) | | | (570.0) | |
Interest credited (7) | (12.0) | | | (11.7) | | | (12.6) | | | (12.7) | | | (49.0) | | | (12.1) | | | (12.2) | | | (12.1) | | | (12.9) | | | (49.3) | |
Amortization and non-deferred commissions | (18.4) | | | (19.3) | | | (19.7) | | | (20.1) | | | (77.5) | | | (19.9) | | | (20.8) | | | (22.1) | | | (23.0) | | | (85.8) | |
Advertising expense | (29.3) | | | (22.6) | | | (22.1) | | | (20.3) | | | (94.3) | | | (28.7) | | | (25.5) | | | (22.6) | | | (15.7) | | | (92.5) | |
Life margin | 36.0 | | | 70.2 | | | 55.7 | | | 43.3 | | | 205.2 | | | 47.4 | | | 57.9 | | | 59.8 | | | 64.6 | | | 229.7 | |
Total insurance product margin | 207.2 | | | 255.7 | | | 239.1 | | | 234.5 | | | 936.5 | | | 221.2 | | | 223.2 | | | 240.0 | | | 274.6 | | | 959.0 | |
Allocated expenses: | | | | | | | | | | | | | | | | | | | |
Branch office expenses | (18.1) | | | (15.4) | | | (16.5) | | | (12.3) | | | (62.3) | | | (19.8) | | | (15.9) | | | (16.3) | | | (12.9) | | | (64.9) | |
Other allocated expenses | (126.7) | | | (136.8) | | | (134.0) | | | (136.8) | | | (534.3) | | | (137.7) | | | (133.6) | | | (136.9) | | | (125.9) | | | (534.1) | |
Income from insurance products (8) | 62.4 | | | 103.5 | | | 88.6 | | | 85.4 | | | 339.9 | | | 63.7 | | | 73.7 | | | 86.8 | | | 135.8 | | | 360.0 | |
Fee income | 9.9 | | | 3.2 | | | 1.4 | | | 9.2 | | | 23.7 | | | 15.5 | | | 0.6 | | | (2.9) | | | 17.8 | | | 31.0 | |
Investment income not allocated to product lines (9) | 27.0 | | | 64.6 | | | 27.1 | | | 25.2 | | | 143.9 | | | 15.5 | | | 28.0 | | | 38.4 | | | 38.3 | | | 120.2 | |
Expenses not allocated to product lines | (14.8) | | | 2.9 | | | (16.1) | | | (12.8) | | | (40.8) | | | (18.3) | | | (21.1) | | | 7.5 | | | (19.8) | | | (51.7) | |
Operating earnings before taxes | 84.5 | | | 174.2 | | | 101.0 | | | 107.0 | | | 466.7 | | | 76.4 | | | 81.2 | | | 129.8 | | | 172.1 | | | 459.5 | |
Income tax expense on operating income | (20.0) | | | (39.1) | | | (23.1) | | | (24.1) | | | (106.3) | | | (17.8) | | | (18.9) | | | (28.5) | | | (38.2) | | | (103.4) | |
Net operating income (10) | $ | 64.5 | | | $ | 135.1 | | | $ | 77.9 | | | $ | 82.9 | | | $ | 360.4 | | | $ | 58.6 | | | $ | 62.3 | | | $ | 101.3 | | | $ | 133.9 | | | $ | 356.1 | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Margin from Annuity Products
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
Annuity margin (4): | | | | | | | | | | | | | | | | | | | |
Fixed indexed annuities | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 3.0 | | | $ | 3.7 | | | $ | 3.6 | | | $ | 4.2 | | | $ | 14.5 | | | $ | 3.6 | | | $ | 5.5 | | | $ | 5.1 | | | $ | 5.5 | | | $ | 19.7 | |
Net investment income (5) (6) | 90.1 | | | 91.4 | | | 95.0 | | | 97.3 | | | 373.8 | | | 98.8 | | | 101.2 | | | 104.4 | | | 105.9 | | | 410.3 | |
Insurance policy benefits | (4.6) | | | (3.1) | | | (2.0) | | | (10.3) | | | (20.0) | | | (4.1) | | | (4.2) | | | (4.3) | | | 2.5 | | | (10.1) | |
Interest credited (6) | (30.4) | | | (29.5) | | | (33.0) | | | (34.6) | | | (127.5) | | | (36.4) | | | (38.9) | | | (41.5) | | | (45.1) | | | (161.9) | |
Amortization and non-deferred commissions | (13.3) | | | (14.1) | | | (14.7) | | | (15.3) | | | (57.4) | | | (15.4) | | | (16.0) | | | (16.5) | | | (17.9) | | | (65.8) | |
Margin from fixed indexed annuities | $ | 44.8 | | | $ | 48.4 | | | $ | 48.9 | | | $ | 41.3 | | | $ | 183.4 | | | $ | 46.5 | | | $ | 47.6 | | | $ | 47.2 | | | $ | 50.9 | | | $ | 192.2 | |
Average net insurance liabilities (11) | $ | 8,486.3 | | | $ | 8,711.0 | | | $ | 8,902.9 | | | $ | 9,054.2 | | | $ | 8,788.6 | | | $ | 9,183.8 | | | $ | 9,276.0 | | | $ | 9,381.0 | | | $ | 9,508.7 | | | $ | 9,337.3 | |
Margin/average net insurance liabilities (12) | 2.11 | % | | 2.22 | % | | 2.20 | % | | 1.82 | % | | 2.09 | % | | 2.03 | % | | 2.05 | % | | 2.01 | % | | 2.14 | % | | 2.06 | % |
Fixed interest annuities | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 0.1 | | | $ | 0.3 | | | $ | 0.2 | | | $ | 0.2 | | | $ | 0.8 | | | $ | 0.3 | | | $ | 0.2 | | | $ | 0.3 | | | $ | 0.2 | | | $ | 1.0 | |
Net investment income (5) | 21.5 | | | 20.6 | | | 20.3 | | | 20.6 | | | 83.0 | | | 20.9 | | | 20.9 | | | 21.0 | | | 20.8 | | | 83.6 | |
Insurance policy benefits | (0.4) | | | (0.6) | | | 0.1 | | | (0.2) | | | (1.1) | | | (0.1) | | | — | | | (0.1) | | | (0.3) | | | (0.5) | |
Interest credited | (11.5) | | | (11.3) | | | (11.2) | | | (11.7) | | | (45.7) | | | (11.1) | | | (11.1) | | | (11.4) | | | (11.6) | | | (45.2) | |
Amortization and non-deferred commissions | (1.2) | | | (1.1) | | | (1.2) | | | (1.1) | | | (4.6) | | | (0.9) | | | (1.3) | | | (1.4) | | | (1.4) | | | (5.0) | |
Margin from fixed interest annuities | $ | 8.5 | | | $ | 7.9 | | | $ | 8.2 | | | $ | 7.8 | | | $ | 32.4 | | | $ | 9.1 | | | $ | 8.7 | | | $ | 8.4 | | | $ | 7.7 | | | $ | 33.9 | |
Average net insurance liabilities (11) | $ | 1,761.2 | | | $ | 1,712.5 | | | $ | 1,675.9 | | | $ | 1,652.6 | | | $ | 1,700.5 | | | $ | 1,630.9 | | | $ | 1,613.1 | | | $ | 1,603.0 | | | $ | 1,600.9 | | | $ | 1,612.0 | |
Margin/average net insurance liabilities (12) | 1.93 | % | | 1.85 | % | | 1.96 | % | | 1.89 | % | | 1.91 | % | | 2.23 | % | | 2.16 | % | | 2.10 | % | | 1.92 | % | | 2.10 | % |
Other annuities | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 1.9 | | | $ | 1.8 | | | $ | 2.5 | | | $ | 1.6 | | | $ | 7.8 | | | $ | 1.2 | | | $ | 2.4 | | | $ | 1.8 | | | $ | 2.3 | | | $ | 7.7 | |
Net investment income (5) | 5.9 | | | 5.8 | | | 5.8 | | | 5.7 | | | 23.2 | | | 5.7 | | | 5.6 | | | 5.6 | | | 5.5 | | | 22.4 | |
Insurance policy benefits | (4.5) | | | (3.1) | | | (4.6) | | | (5.0) | | | (17.2) | | | (4.5) | | | (6.4) | | | (5.4) | | | (2.1) | | | (18.4) | |
Interest credited | (0.6) | | | (0.6) | | | (0.6) | | | (0.5) | | | (2.3) | | | (0.6) | | | (0.6) | | | (0.5) | | | (0.6) | | | (2.3) | |
Amortization and non-deferred commissions | (0.1) | | | (0.1) | | | (0.1) | | | (0.1) | | | (0.4) | | | (0.1) | | | (0.2) | | | (0.1) | | | (0.1) | | | (0.5) | |
Margin from other annuities | $ | 2.6 | | | $ | 3.8 | | | $ | 3.0 | | | $ | 1.7 | | | $ | 11.1 | | | $ | 1.7 | | | $ | 0.8 | | | $ | 1.4 | | | $ | 5.0 | | | $ | 8.9 | |
Average net insurance liabilities (11) | $ | 490.2 | | | $ | 484.2 | | | $ | 478.8 | | | $ | 473.6 | | | $ | 481.7 | | | $ | 469.5 | | | $ | 462.5 | | | $ | 455.6 | | | $ | 447.5 | | | $ | 458.8 | |
Margin/average net insurance liabilities (12) | 2.12 | % | | 3.14 | % | | 2.51 | % | | 1.44 | % | | 2.30 | % | | 1.45 | % | | 0.69 | % | | 1.23 | % | | 4.47 | % | | 1.94 | % |
Total annuity margin | $ | 55.9 | | | $ | 60.1 | | | $ | 60.1 | | | $ | 50.8 | | | $ | 226.9 | | | $ | 57.3 | | | $ | 57.1 | | | $ | 57.0 | | | $ | 63.6 | | | $ | 235.0 | |
Average net insurance liabilities (11) | $ | 10,737.7 | | | $ | 10,907.7 | | | $ | 11,057.6 | | | $ | 11,180.4 | | | $ | 10,970.8 | | | $ | 11,284.2 | | | $ | 11,351.6 | | | $ | 11,439.6 | | | $ | 11,557.1 | | | $ | 11,408.1 | |
Margin/average net insurance liabilities (12) | 2.08 | % | | 2.20 | % | | 2.17 | % | | 1.82 | % | | 2.07 | % | | 2.03 | % | | 2.01 | % | | 1.99 | % | | 2.20 | % | | 2.06 | % |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Margin from Health Products
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
Health margin (4): | | | | | | | | | | | | | | | | | | | |
Supplemental health | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 173.5 | | | $ | 172.0 | | | $ | 173.5 | | | $ | 175.3 | | | $ | 694.3 | | | $ | 179.0 | | | $ | 176.2 | | | $ | 177.9 | | | $ | 178.1 | | | $ | 711.2 | |
Net investment income (5) | 37.4 | | | 37.6 | | | 37.7 | | | 38.2 | | | 150.9 | | | 38.6 | | | 38.9 | | | 39.0 | | | 38.8 | | | 155.3 | |
Insurance policy benefits | (129.3) | | | (128.1) | | | (125.8) | | | (125.6) | | | (508.8) | | | (128.2) | | | (128.9) | | | (128.0) | | | (81.0) | | | (466.1) | |
Amortization and non-deferred commissions | (25.5) | | | (25.5) | | | (26.9) | | | (27.6) | | | (105.5) | | | (26.1) | | | (26.3) | | | (26.1) | | | (27.5) | | | (106.0) | |
Margin from supplemental health | $ | 56.1 | | | $ | 56.0 | | | $ | 58.5 | | | $ | 60.3 | | | $ | 230.9 | | | $ | 63.3 | | | $ | 59.9 | | | $ | 62.8 | | | $ | 108.4 | | | $ | 294.4 | |
Margin/insurance policy income | 32 | % | | 33 | % | | 34 | % | | 34 | % | | 33 | % | | 35 | % | | 34 | % | | 35 | % | | 61 | % | | 41 | % |
Medicare supplement | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 166.8 | | | $ | 165.1 | | | $ | 163.6 | | | $ | 162.3 | | | $ | 657.8 | | | $ | 156.5 | | | $ | 155.3 | | | $ | 154.2 | | | $ | 153.9 | | | $ | 619.9 | |
Net investment income (5) | 1.3 | | | 1.4 | | | 1.4 | | | 1.3 | | | 5.4 | | | 1.3 | | | 1.2 | | | 1.1 | | | 1.3 | | | 4.9 | |
Insurance policy benefits | (120.5) | | | (114.1) | | | (113.9) | | | (113.4) | | | (461.9) | | | (120.5) | | | (113.4) | | | (107.4) | | | (123.4) | | | (464.7) | |
Amortization and non-deferred commissions | (13.0) | | | (12.6) | | | (12.4) | | | (12.3) | | | (50.3) | | | (11.2) | | | (10.8) | | | (10.7) | | | (10.5) | | | (43.2) | |
Margin from Medicare supplement | $ | 34.6 | | | $ | 39.8 | | | $ | 38.7 | | | $ | 37.9 | | | $ | 151.0 | | | $ | 26.1 | | | $ | 32.3 | | | $ | 37.2 | | | $ | 21.3 | | | $ | 116.9 | |
Margin/insurance policy income | 21 | % | | 24 | % | | 24 | % | | 23 | % | | 23 | % | | 17 | % | | 21 | % | | 24 | % | | 14 | % | | 19 | % |
Long-term care | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 66.4 | | | $ | 66.4 | | | $ | 66.4 | | | $ | 66.0 | | | $ | 265.2 | | | $ | 65.9 | | | $ | 65.6 | | | $ | 65.7 | | | $ | 66.3 | | | $ | 263.5 | |
Net investment income (5) | 34.6 | | | 34.0 | | | 34.2 | | | 34.2 | | | 137.0 | | | 34.1 | | | 34.2 | | | 34.1 | | | 34.1 | | | 136.5 | |
Insurance policy benefits | (73.3) | | | (67.7) | | | (71.1) | | | (54.7) | | | (266.8) | | | (69.4) | | | (80.4) | | | (73.1) | | | (81.2) | | | (304.1) | |
Amortization and non-deferred commissions | (3.1) | | | (3.1) | | | (3.4) | | | (3.3) | | | (12.9) | | | (3.5) | | | (3.4) | | | (3.5) | | | (2.5) | | | (12.9) | |
Margin from long-term care | $ | 24.6 | | | $ | 29.6 | | | $ | 26.1 | | | $ | 42.2 | | | $ | 122.5 | | | $ | 27.1 | | | $ | 16.0 | | | $ | 23.2 | | | $ | 16.7 | | | $ | 83.0 | |
Margin/insurance policy income | 37 | % | | 45 | % | | 39 | % | | 64 | % | | 46 | % | | 41 | % | | 24 | % | | 35 | % | | 25 | % | | 31 | % |
Total health margin | $ | 115.3 | | | $ | 125.4 | | | $ | 123.3 | | | $ | 140.4 | | | $ | 504.4 | | | $ | 116.5 | | | $ | 108.2 | | | $ | 123.2 | | | $ | 146.4 | | | $ | 494.3 | |
Margin/insurance policy income | 28 | % | | 31 | % | | 31 | % | | 35 | % | | 31 | % | | 29 | % | | 27 | % | | 31 | % | | 37 | % | | 31 | % |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Margin from Life Products
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
Life margin (4): | | | | | | | | | | | | | | | | | | | |
Interest sensitive life | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 43.1 | | | $ | 43.8 | | | $ | 43.5 | | | $ | 44.2 | | | $ | 174.6 | | | $ | 44.5 | | | $ | 45.3 | | | $ | 45.1 | | | $ | 46.2 | | | $ | 181.1 | |
Net investment income (5) (7) | 13.0 | | | 12.8 | | | 12.9 | | | 12.9 | | | 51.6 | | | 13.1 | | | 12.7 | | | 12.9 | | | 12.8 | | | 51.5 | |
Insurance policy benefits | (21.2) | | | (15.8) | | | (20.5) | | | (17.7) | | | (75.2) | | | (18.2) | | | (17.1) | | | (18.1) | | | (12.3) | | | (65.7) | |
Interest credited (7) | (11.9) | | | (11.5) | | | (12.4) | | | (12.5) | | | (48.3) | | | (12.0) | | | (12.0) | | | (11.9) | | | (12.8) | | | (48.7) | |
Amortization and non-deferred commissions | (5.7) | | | (5.9) | | | (5.9) | | | (5.7) | | | (23.2) | | | (4.6) | | | (4.8) | | | (5.1) | | | (5.0) | | | (19.5) | |
Margin from interest sensitive life | $ | 17.3 | | | $ | 23.4 | | | $ | 17.6 | | | $ | 21.2 | | | $ | 79.5 | | | $ | 22.8 | | | $ | 24.1 | | | $ | 22.9 | | | $ | 28.9 | | | $ | 98.7 | |
Average net insurance liabilities (11) | $ | 1,009.4 | | | $ | 1,016.4 | | | $ | 1,019.2 | | | $ | 1,026.9 | | | $ | 1,018.0 | | | $ | 1,032.0 | | | $ | 1,035.4 | | | $ | 1,039.6 | | | $ | 1,045.8 | | | $ | 1,038.2 | |
Interest margin | $ | 1.1 | | | $ | 1.3 | | | $ | 0.5 | | | $ | 0.4 | | | $ | 3.3 | | | $ | 1.1 | | | $ | 0.7 | | | $ | 1.0 | | | $ | — | | | $ | 2.8 | |
Interest margin/average net insurance liabilities (12) | 0.44 | % | | 0.51 | % | | 0.20 | % | | 0.16 | % | | 0.32 | % | | 0.43 | % | | 0.27 | % | | 0.38 | % | | — | % | | 0.27 | % |
Underwriting margin | $ | 16.2 | | | $ | 22.1 | | | $ | 17.1 | | | $ | 20.8 | | | $ | 76.2 | | | $ | 21.7 | | | $ | 23.4 | | | $ | 21.9 | | | $ | 28.9 | | | $ | 95.9 | |
Underwriting margin/insurance policy income | 38 | % | | 50 | % | | 39 | % | | 47 | % | | 44 | % | | 49 | % | | 52 | % | | 49 | % | | 63 | % | | 53 | % |
Traditional life | | | | | | | | | | | | | | | | | | | |
Insurance policy income | $ | 170.2 | | | $ | 172.5 | | | $ | 169.9 | | | $ | 172.2 | | | $ | 684.8 | | | $ | 174.5 | | | $ | 177.8 | | | $ | 175.9 | | | $ | 173.2 | | | $ | 701.4 | |
Net investment income (5) | 22.5 | | | 22.4 | | | 22.5 | | | 22.9 | | | 90.3 | | | 23.2 | | | 23.4 | | | 23.4 | | | 23.3 | | | 93.3 | |
Insurance policy benefits | (131.9) | | | (111.9) | | | (118.2) | | | (138.1) | | | (500.1) | | | (129.0) | | | (125.7) | | | (122.6) | | | (127.0) | | | (504.3) | |
Interest credited | (0.1) | | | (0.2) | | | (0.2) | | | (0.2) | | | (0.7) | | | (0.1) | | | (0.2) | | | (0.2) | | | (0.1) | | | (0.6) | |
Amortization and non-deferred commissions | (12.7) | | | (13.4) | | | (13.8) | | | (14.4) | | | (54.3) | | | (15.3) | | | (16.0) | | | (17.0) | | | (18.0) | | | (66.3) | |
Advertising expense | (29.3) | | | (22.6) | | | (22.1) | | | (20.3) | | | (94.3) | | | (28.7) | | | (25.5) | | | (22.6) | | | (15.7) | | | (92.5) | |
Margin from traditional life | $ | 18.7 | | | $ | 46.8 | | | $ | 38.1 | | | $ | 22.1 | | | $ | 125.7 | | | $ | 24.6 | | | $ | 33.8 | | | $ | 36.9 | | | $ | 35.7 | | | $ | 131.0 | |
Margin/insurance policy income | 11 | % | | 27 | % | | 22 | % | | 13 | % | | 18 | % | | 14 | % | | 19 | % | | 21 | % | | 21 | % | | 19 | % |
Margin excluding advertising expense/insurance policy income | 28 | % | | 40 | % | | 35 | % | | 25 | % | | 32 | % | | 31 | % | | 33 | % | | 34 | % | | 30 | % | | 32 | % |
Total life margin | $ | 36.0 | | | $ | 70.2 | | | $ | 55.7 | | | $ | 43.3 | | | $ | 205.2 | | | $ | 47.4 | | | $ | 57.9 | | | $ | 59.8 | | | $ | 64.6 | | | $ | 229.7 | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Collected Premiums From Annuity and Interest Sensitive Life Products
and Insurance Policy Income
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
Collected premiums from annuity and interest-sensitive life products: | | | | | | | | | | | | | | | | | | | |
Annuities | $ | 368.6 | | | $ | 435.0 | | | $ | 370.0 | | | $ | 431.0 | | | $ | 1,604.6 | | | $ | 370.9 | | | $ | 401.8 | | | $ | 372.2 | | | $ | 438.3 | | | $ | 1,583.2 | |
Interest-sensitive life | 56.6 | | | 56.6 | | | 56.6 | | | 58.1 | | | 227.9 | | | 58.2 | | | 60.3 | | | 58.3 | | | 60.2 | | | 237.0 | |
Total collected premiums from annuity and interest-sensitive life products | $ | 425.2 | | | $ | 491.6 | | | $ | 426.6 | | | $ | 489.1 | | | $ | 1,832.5 | | | $ | 429.1 | | | $ | 462.1 | | | $ | 430.5 | | | $ | 498.5 | | | $ | 1,820.2 | |
| | | | | | | | | | | | | | | | | | | |
Insurance policy income: | | | | | | | | | | | | | | | | | | | |
Annuity products | | | | | | | | | | | | | | | | | | | |
Fixed indexed annuities | $ | 3.0 | | | $ | 3.7 | | | $ | 3.6 | | | $ | 4.2 | | | $ | 14.5 | | | $ | 3.6 | | | $ | 5.5 | | | $ | 5.1 | | | $ | 5.5 | | | $ | 19.7 | |
Fixed interest annuities | 0.1 | | | 0.3 | | | 0.2 | | | 0.2 | | | 0.8 | | | 0.3 | | | 0.2 | | | 0.3 | | | 0.2 | | | 1.0 | |
Other annuities | 1.9 | | | 1.8 | | | 2.5 | | | 1.6 | | | 7.8 | | | 1.2 | | | 2.4 | | | 1.8 | | | 2.3 | | | 7.7 | |
Total annuity insurance policy income | 5.0 | | | 5.8 | | | 6.3 | | | 6.0 | | | 23.1 | | | 5.1 | | | 8.1 | | | 7.2 | | | 8.0 | | | 28.4 | |
Health products | | | | | | | | | | | | | | | | | | | |
Supplemental health | 173.5 | | | 172.0 | | | 173.5 | | | 175.3 | | | 694.3 | | | 179.0 | | | 176.2 | | | 178.0 | | | 178.1 | | | 711.3 | |
Medicare supplement | 166.8 | | | 165.1 | | | 163.6 | | | 162.3 | | | 657.8 | | | 156.5 | | | 155.3 | | | 154.1 | | | 153.9 | | | 619.8 | |
Long-term care | 66.4 | | | 66.4 | | | 66.4 | | | 66.0 | | | 265.2 | | | 65.9 | | | 65.6 | | | 65.7 | | | 66.3 | | | 263.5 | |
Total health insurance policy income | 406.7 | | | 403.5 | | | 403.5 | | | 403.6 | | | 1,617.3 | | | 401.4 | | | 397.1 | | | 397.8 | | | 398.3 | | | 1,594.6 | |
Life products | | | | | | | | | | | | | | | | | | | |
Interest-sensitive life | 43.1 | | | 43.8 | | | 43.5 | | | 44.1 | | | 174.5 | | | 44.5 | | | 45.3 | | | 45.1 | | | 46.2 | | | 181.1 | |
Traditional life | 170.2 | | | 172.5 | | | 169.9 | | | 172.3 | | | 684.9 | | | 174.5 | | | 177.8 | | | 175.9 | | | 173.2 | | | 701.4 | |
Total life insurance policy income | 213.3 | | | 216.3 | | | 213.4 | | | 216.4 | | | 859.4 | | | 219.0 | | | 223.1 | | | 221.0 | | | 219.4 | | | 882.5 | |
Total insurance policy income | $ | 625.0 | | | $ | 625.6 | | | $ | 623.2 | | | $ | 626.0 | | | $ | 2,499.8 | | | $ | 625.5 | | | $ | 628.3 | | | $ | 626.0 | | | $ | 625.7 | | | $ | 2,505.5 | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Health and Life
New Annualized Premiums ("NAP")
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
Consumer Division | | | | | | | | | | | | | | | | | | | |
Health products: | | | | | | | | | | | | | | | | | | | |
Supplemental health | $ | 15.5 | | | $ | 16.7 | | | $ | 19.3 | | | $ | 24.6 | | | $ | 76.1 | | | $ | 17.4 | | | $ | 18.7 | | | $ | 19.2 | | | $ | 19.2 | | | $ | 74.5 | |
Medicare supplement | 6.5 | | | 6.9 | | | 8.0 | | | 10.4 | | | 31.8 | | | 7.8 | | | 8.9 | | | 8.7 | | | 11.5 | | | 36.9 | |
Long-term care | 6.8 | | | 6.1 | | | 6.0 | | | 6.2 | | | 25.1 | | | 6.2 | | | 5.7 | | | 8.9 | | | 11.1 | | | 31.9 | |
Total Consumer Division health NAP | 28.8 | | | 29.7 | | | 33.3 | | | 41.2 | | | 133.0 | | | 31.4 | | | 33.3 | | | 36.8 | | | 41.8 | | | 143.3 | |
Life products: | | | | | | | | | | | | | | | | | | | |
Interest sensitive life | 5.1 | | | 4.8 | | | 4.6 | | | 4.4 | | | 18.9 | | | 4.6 | | | 6.3 | | | 4.4 | | | 4.5 | | | 19.8 | |
Traditional life | 48.2 | | | 44.3 | | | 38.2 | | | 33.2 | | | 163.9 | | | 49.7 | | | 46.0 | | | 41.9 | | | 35.5 | | | 173.1 | |
Total Consumer Division life NAP | 53.3 | | | 49.1 | | | 42.8 | | | 37.6 | | | 182.8 | | | 54.3 | | | 52.3 | | | 46.3 | | | 40.0 | | | 192.9 | |
Total Consumer Division health and life NAP | $ | 82.1 | | | $ | 78.8 | | | $ | 76.1 | | | $ | 78.8 | | | $ | 315.8 | | | $ | 85.7 | | | $ | 85.6 | | | $ | 83.1 | | | $ | 81.8 | | | $ | 336.2 | |
Worksite Division | | | | | | | | | | | | | | | | | | | |
Health products: | | | | | | | | | | | | | | | | | | | |
Supplemental health | $ | 6.0 | | | $ | 7.7 | | | $ | 8.9 | | | $ | 8.7 | | | $ | 31.3 | | | $ | 8.1 | | | $ | 9.8 | | | $ | 11.5 | | | $ | 10.4 | | | $ | 39.8 | |
Life products: | | | | | | | | | | | | | | | | | | | |
Interest sensitive life | 2.5 | | | 2.3 | | | 2.3 | | | 3.2 | | | 10.3 | | | 2.8 | | | 3.3 | | | 3.7 | | | 3.9 | | | 13.7 | |
Total Worksite Division health and life NAP | $ | 8.5 | | | $ | 10.0 | | | $ | 11.2 | | | $ | 11.9 | | | $ | 41.6 | | | $ | 10.9 | | | $ | 13.1 | | | $ | 15.2 | | | $ | 14.3 | | | $ | 53.5 | |
Total NAP (both divisions) | | | | | | | | | | | | | | | | | | | |
Health products: | | | | | | | | | | | | | | | | | | | |
Supplemental health | $ | 21.5 | | | $ | 24.4 | | | $ | 28.2 | | | $ | 33.3 | | | $ | 107.4 | | | $ | 25.5 | | | $ | 28.5 | | | $ | 30.7 | | | $ | 29.6 | | | $ | 114.3 | |
Medicare supplement | 6.5 | | | 6.9 | | | 8.0 | | | 10.4 | | | 31.8 | | | 7.8 | | | 8.9 | | | 8.7 | | | 11.5 | | | 36.9 | |
Long-term care | 6.8 | | | 6.1 | | | 6.0 | | | 6.2 | | | 25.1 | | | 6.2 | | | 5.7 | | | 8.9 | | | 11.1 | | | 31.9 | |
Total health NAP | 34.8 | | | 37.4 | | | 42.2 | | | 49.9 | | | 164.3 | | | 39.5 | | | 43.1 | | | 48.3 | | | 52.2 | | | 183.1 | |
Life products: | | | | | | | | | | | | | | | | | | | |
Interest sensitive life | 7.6 | | | 7.1 | | | 6.9 | | | 7.6 | | | 29.2 | | | 7.4 | | | 9.6 | | | 8.1 | | | 8.4 | | | 33.5 | |
Traditional life | 48.2 | | | 44.3 | | | 38.2 | | | 33.2 | | | 163.9 | | | 49.7 | | | 46.0 | | | 41.9 | | | 35.5 | | | 173.1 | |
Total life NAP | 55.8 | | | 51.4 | | | 45.1 | | | 40.8 | | | 193.1 | | | 57.1 | | | 55.6 | | | 50.0 | | | 43.9 | | | 206.6 | |
Total NAP | $ | 90.6 | | | $ | 88.8 | | | $ | 87.3 | | | $ | 90.7 | | | $ | 357.4 | | | $ | 96.6 | | | $ | 98.7 | | | $ | 98.3 | | | $ | 96.1 | | | $ | 389.7 | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Computation of Weighted Average Shares Outstanding
(Shares in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 (a) | | 2023 | | 2023 | | 2023 | | 2023 |
Basic | | | | | | | | | | | | | | | | | | | |
Shares outstanding, beginning of period | 120,377.2 | | | 117,241.0 | | | 114,795.3 | | | 114,367.3 | | | 120,377.2 | | | 114,343.1 | | | 114,905.2 | | | 113,673.9 | | | 112,163.2 | | | 114,343.1 | |
Weighted average share activity during the period: | | | | | | | | | | | | | | | | | | | |
Shares repurchased | (2,098.0) | | | (1,774.6) | | | (467.6) | | | (145.1) | | | (5,579.4) | | | (255.7) | | | (675.8) | | | (1,006.4) | | | (630.0) | | | (2,201.3) | |
Amounts related to employee benefit plans | 488.5 | | | 76.9 | | | 26.6 | | | 200.8 | | | 1,273.6 | | | 671.8 | | | 45.9 | | | 23.5 | | | 61.2 | | | 1,571.6 | |
Shares withheld for the payment of the exercise price and taxes related to employee benefit plans | (145.5) | | | (10.2) | | | (0.6) | | | (0.9) | | | (338.6) | | | (214.3) | | | (1.8) | | | (1.9) | | | (3.8) | | | (438.9) | |
Weighted average basic shares outstanding during the period | 118,622.2 | | | 115,533.1 | | | 114,353.7 | | | 114,422.1 | | | 115,732.8 | | | 114,544.9 | | | 114,273.5 | | | 112,689.1 | | | 111,590.6 | | | 113,274.5 | |
Basic shares outstanding, end of period | 117,241.0 | | | 114,795.3 | | | 114,367.3 | | | 114,343.1 | | | 114,343.1 | | | 114,905.2 | | | 113,673.9 | | | 112,163.2 | | | 109,357.5 | | | 109,357.5 | |
Diluted | | | | | | | | | | | | | | | | | | | |
Weighted average basic shares outstanding | 118,622.2 | | | 115,533.1 | | | 114,353.7 | | | 114,422.1 | | | 115,732.8 | | | 114,544.9 | | | 114,273.5 | | | 112,689.1 | | | 111,590.6 | | | 113,274.5 | |
Common stock equivalent shares related to: | | | | | | | | | | | | | | | | | | | |
Employee benefit plans | 2,379.9 | | | 1,752.5 | | | 1,574.8 | | | 2,231.1 | | | 1,984.5 | | | — | | | 1,376.1 | | | 1,772.8 | | | 2,066.6 | | | 1,849.5 | |
Weighted average diluted shares outstanding during the period | 121,002.1 | | | 117,285.6 | | | 115,928.5 | | | 116,653.2 | | | 117,717.3 | | | 114,544.9 | | | 115,649.6 | | | 114,461.9 | | | 113,657.2 | | | 115,124.0 | |
Diluted shares outstanding, end of period | 119,502.6 | | | 116,203.1 | | | 115,970.6 | | | 116,842.1 | | | 116,842.1 | | | 116,176.0 | | | 115,303.3 | | | 113,974.7 | | | 111,750.3 | | | 111,750.3 | |
| | | | | | | | | | | | | | | | | | | |
___________
(a) Equivalent common shares of 2,182.5 were not included in the weighted average shares outstanding due to the net loss recognized in 1Q23.
CNO FINANCIAL GROUP, INC.
Annuities - Account Value Rollforwards
(Dollars in millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
Fixed indexed annuities | | | | | | | | | | | | | | | | | | | |
Balance, beginning of period excluding contracts 100% ceded | $ | 8,681.0 | | | $ | 8,902.0 | | | $ | 9,162.9 | | | $ | 9,320.0 | | | $ | 8,681.0 | | | $ | 9,490.4 | | | $ | 9,584.3 | | | $ | 9,707.7 | | | $ | 9,819.2 | | | $ | 9,490.4 | |
Issuances (funds collected from new business) | 354.6 | | | 411.3 | | | 346.0 | | | 397.3 | | | 1,509.2 | | | 323.3 | | | 351.6 | | | 321.7 | | | 377.1 | | | 1,373.7 | |
Premiums received (premiums collected from inforce business) | 0.1 | | | — | | | 0.1 | | | 0.1 | | | 0.3 | | | 0.4 | | | (0.2) | | | 0.1 | | | (0.2) | | | 0.1 | |
Policy charges | (3.0) | | | (3.6) | | | (3.8) | | | (4.0) | | | (14.4) | | | (4.0) | | | (5.2) | | | (5.2) | | | (5.3) | | | (19.7) | |
Surrenders and withdrawals | (133.7) | | | (127.2) | | | (127.7) | | | (178.9) | | | (567.5) | | | (178.2) | | | (182.6) | | | (177.6) | | | (199.9) | | | (738.3) | |
Benefit payments | (67.3) | | | (58.1) | | | (67.0) | | | (55.4) | | | (247.8) | | | (59.2) | | | (63.1) | | | (62.7) | | | (58.9) | | | (243.9) | |
Interest credited | 65.7 | | | 32.6 | | | 4.5 | | | 4.8 | | | 107.6 | | | 6.1 | | | 17.2 | | | 29.4 | | | 59.9 | | | 112.6 | |
Other | 4.6 | | | 5.9 | | | 5.0 | | | 6.5 | | | 22.0 | | | 5.5 | | | 5.7 | | | 5.8 | | | 7.3 | | | 24.3 | |
Balance, end of period excluding contracts 100% ceded | $ | 8,902.0 | | | $ | 9,162.9 | | | $ | 9,320.0 | | | $ | 9,490.4 | | | $ | 9,490.4 | | | $ | 9,584.3 | | | $ | 9,707.7 | | | $ | 9,819.2 | | | $ | 9,999.2 | | | $ | 9,999.2 | |
| | | | | | | | | | | | | | | | | | | |
Fixed interest annuities | | | | | | | | | | | | | | | | | | | |
Balance, beginning of period excluding contracts 100% ceded | $ | 1,806.1 | | | $ | 1,751.8 | | | $ | 1,711.3 | | | $ | 1,679.3 | | | $ | 1,806.1 | | | $ | 1,663.1 | | | $ | 1,649.3 | | | $ | 1,636.6 | | | $ | 1,632.5 | | | $ | 1,663.1 | |
Issuances (funds collected from new business) | 10.5 | | | 20.0 | | | 21.7 | | | 31.5 | | | 83.7 | | | 45.3 | | | 45.8 | | | 48.4 | | | 57.5 | | | 197.0 | |
Premiums received (premiums collected from inforce business) | 1.1 | | | 1.0 | | | 0.8 | | | 0.8 | | | 3.7 | | | 0.7 | | | 0.9 | | | 0.5 | | | 0.6 | | | 2.7 | |
Policy charges | (0.1) | | | (0.2) | | | (0.2) | | | (0.2) | | | (0.7) | | | (0.2) | | | (0.2) | | | (0.3) | | | (0.3) | | | (1.0) | |
Surrenders and withdrawals | (37.9) | | | (40.7) | | | (34.4) | | | (36.2) | | | (149.2) | | | (43.3) | | | (42.1) | | | (39.3) | | | (39.9) | | | (164.6) | |
Benefit payments | (39.6) | | | (31.9) | | | (31.4) | | | (24.2) | | | (127.1) | | | (27.7) | | | (28.2) | | | (24.9) | | | (26.1) | | | (106.9) | |
Interest credited | 11.5 | | | 11.4 | | | 11.4 | | | 11.8 | | | 46.1 | | | 11.3 | | | 11.2 | | | 11.7 | | | 11.9 | | | 46.1 | |
Other | 0.2 | | | (0.1) | | | 0.1 | | | 0.3 | | | 0.5 | | | 0.1 | | | (0.1) | | | (0.2) | | | 0.2 | | | — | |
Balance, end of period excluding contracts 100% ceded | $ | 1,751.8 | | | $ | 1,711.3 | | | $ | 1,679.3 | | | $ | 1,663.1 | | | $ | 1,663.1 | | | $ | 1,649.3 | | | $ | 1,636.6 | | | $ | 1,632.5 | | | $ | 1,636.4 | | | $ | 1,636.4 | |
| | | | | | | | | | | | | | | | | | | |
Total annuities | | | | | | | | | | | | | | | | | | | |
Balance, beginning of period excluding contracts 100% ceded | $ | 10,487.1 | | | $ | 10,653.8 | | | $ | 10,874.2 | | | $ | 10,999.3 | | | $ | 10,487.1 | | | $ | 11,153.5 | | | $ | 11,233.6 | | | $ | 11,344.3 | | | $ | 11,451.7 | | | $ | 11,153.5 | |
Issuances (funds collected from new business) | 365.1 | | | 431.3 | | | 367.7 | | | 428.8 | | | 1,592.9 | | | 368.6 | | | 397.4 | | | 370.1 | | | 434.6 | | | 1,570.7 | |
Premiums received (premiums collected from inforce business) | 1.2 | | | 1.0 | | | 0.9 | | | 0.9 | | | 4.0 | | | 1.1 | | | 0.7 | | | 0.6 | | | 0.4 | | | 2.8 | |
Policy charges | (3.1) | | | (3.8) | | | (4.0) | | | (4.2) | | | (15.1) | | | (4.2) | | | (5.4) | | | (5.5) | | | (5.6) | | | (20.7) | |
Surrenders and withdrawals | (171.6) | | | (167.9) | | | (162.1) | | | (215.1) | | | (716.7) | | | (221.5) | | | (224.7) | | | (216.9) | | | (239.8) | | | (902.9) | |
Benefit payments | (106.9) | | | (90.0) | | | (98.4) | | | (79.6) | | | (374.9) | | | (86.9) | | | (91.3) | | | (87.6) | | | (85.0) | | | (350.8) | |
Interest credited | 77.2 | | | 44.0 | | | 15.9 | | | 16.6 | | | 153.7 | | | 17.4 | | | 28.4 | | | 41.1 | | | 71.8 | | | 158.7 | |
Other | 4.8 | | | 5.8 | | | 5.1 | | | 6.8 | | | 22.5 | | | 5.6 | | | 5.6 | | | 5.6 | | | 7.5 | | | 24.3 | |
Balance, end of period excluding contracts 100% ceded | $ | 10,653.8 | | | $ | 10,874.2 | | | $ | 10,999.3 | | | $ | 11,153.5 | | | $ | 11,153.5 | | | $ | 11,233.6 | | | $ | 11,344.3 | | | $ | 11,451.7 | | | $ | 11,635.6 | | | $ | 11,635.6 | |
| | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Consolidated Statutory Information of U.S. Based Insurance Subsidiaries (13)
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 (a) | | 2023 (a) |
| | | | | | | | | | | | | | | | | | | |
Net gain from operations before interest expense and federal income taxes | $ | 26.7 | | | $ | 87.7 | | | $ | 78.4 | | | $ | 75.0 | | | $ | 267.8 | | | $ | 58.3 | | | $ | 55.6 | | | $ | 54.0 | | | $ | 67.4 | | | $ | 235.3 | |
Interest expense on surplus debentures held by parent company | 12.0 | | | 12.2 | | | 20.1 | | | 14.6 | | | 58.9 | | | 15.9 | | | 16.6 | | | 31.6 | | | 17.9 | | | 82.0 | |
Net gain from operations before federal income taxes | 14.7 | | | 75.5 | | | 58.3 | | | 60.4 | | | 208.9 | | | 42.4 | | | 39.0 | | | 22.4 | | | 49.5 | | | 153.3 | |
Federal income tax expense (benefit) | (15.8) | | | (17.6) | | | (7.0) | | | (14.6) | | | (55.0) | | | 3.3 | | | 1.9 | | | (15.0) | | | 31.8 | | | 22.0 | |
Net gain from operations before net realized capital gains (losses) | 30.5 | | | 93.1 | | | 65.3 | | | 75.0 | | | 263.9 | | | 39.1 | | | 37.1 | | | 37.4 | | | 17.7 | | | 131.3 | |
Net realized capital gains (losses) | — | | | (11.2) | | | (0.6) | | | (14.1) | | | (25.9) | | | (1.3) | | | (20.6) | | | (6.2) | | | 1.8 | | | (26.3) | |
Net income | $ | 30.5 | | | $ | 81.9 | | | $ | 64.7 | | | $ | 60.9 | | | $ | 238.0 | | | $ | 37.8 | | | $ | 16.5 | | | $ | 31.2 | | | $ | 19.5 | | | $ | 105.0 | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Capital and surplus | $ | 1,738.0 | | | $ | 1,796.9 | | | $ | 1,847.0 | | | $ | 1,849.8 | | | $ | 1,849.8 | | | $ | 1,831.3 | | | $ | 1,857.0 | | | $ | 1,932.6 | | | $ | 1,558.9 | | | $ | 1,558.9 | |
Asset valuation reserve (AVR) | 319.5 | | | 306.7 | | | 304.7 | | | 305.8 | | | 305.8 | | | 317.8 | | | 316.5 | | | 333.9 | | | 352.5 | | | 352.5 | |
Capital, surplus and AVR | 2,057.5 | | | 2,103.6 | | | 2,151.7 | | | 2,155.6 | | | 2,155.6 | | | 2,149.1 | | | 2,173.5 | | | 2,266.5 | | | 1,911.4 | | | 1,911.4 | |
Interest maintenance reserve (IMR) | 422.4 | | | 421.3 | | | 413.0 | | | 395.7 | | | 395.7 | | | 385.6 | | | 381.7 | | | 372.1 | | | 368.1 | | | 368.1 | |
Total statutory capital, surplus, AVR & IMR | $ | 2,479.9 | | | $ | 2,524.9 | | | $ | 2,564.7 | | | $ | 2,551.3 | | | $ | 2,551.3 | | | $ | 2,534.7 | | | $ | 2,555.2 | | | $ | 2,638.6 | | | $ | 2,279.5 | | | $ | 2,279.5 | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Risk-based capital ratio | 365 | % | | 360 | % | | 375 | % | | 384 | % | | 384 | % | | 380 | % | | 386 | % | | 392 | % | | 402 | % | | 402 | % |
| | | | | | | | | | | | | | | | | | | |
___________
(a) Such amounts are preliminary as the statutory basis financial statements of our U.S. based insurance subsidiaries for 4Q23 will be filed with the respective insurance regulators on or about March 1, 2024.
CNO FINANCIAL GROUP, INC.
Investment Income Not Allocated to Product Lines (9)
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| | 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
Net investment income | | $ | 208.2 | | | $ | 223.9 | | | $ | 268.1 | | | $ | 315.7 | | | $ | 1,015.9 | | | $ | 343.0 | | | $ | 399.7 | | | $ | 291.8 | | | $ | 465.2 | | | $ | 1,499.7 | |
Allocated to product lines: | | | | | | | | | | | | | | | | | | | | |
Annuity | | (117.5) | | | (117.8) | | | (121.1) | | | (123.6) | | | (480.0) | | | (125.4) | | | (127.7) | | | (131.0) | | | (132.2) | | | (516.3) | |
Health | | (73.3) | | | (73.0) | | | (73.3) | | | (73.7) | | | (293.3) | | | (74.0) | | | (74.3) | | | (74.2) | | | (74.2) | | | (296.7) | |
Life | | (35.5) | | | (35.2) | | | (35.4) | | | (35.8) | | | (141.9) | | | (36.3) | | | (36.1) | | | (36.3) | | | (36.1) | | | (144.8) | |
Equity returns credited to policyholder account balances | | 71.9 | | | 92.4 | | | 34.9 | | | 6.1 | | | 205.3 | | | (18.6) | | | (62.3) | | | 54.6 | | | (105.2) | | | (131.5) | |
Amounts allocated to product lines and credited to policyholder account balances | | (154.4) | | | (133.6) | | | (194.9) | | | (227.0) | | | (709.9) | | | (254.3) | | | (300.4) | | | (186.9) | | | (347.7) | | | (1,089.3) | |
Impact of annual option forfeitures related to fixed indexed annuity surrenders | | 1.6 | | | (0.5) | | | (1.1) | | | (1.0) | | | (1.0) | | | — | | | 1.4 | | | 2.5 | | | 3.2 | | | 7.1 | |
Amount related to variable interest entities and other non-operating items | | (7.2) | | | (9.1) | | | (13.6) | | | (18.6) | | | (48.5) | | | (20.9) | | | (19.0) | | | (18.7) | | | (16.2) | | | (74.8) | |
Interest expense on debt | | (15.7) | | | (15.6) | | | (15.6) | | | (15.6) | | | (62.5) | | | (15.7) | | | (15.6) | | | (15.7) | | | (15.7) | | | (62.7) | |
Interest expense on financing arrangements | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (1.1) | | | (1.3) | | | (2.4) | |
Interest expense on investment borrowings from the Federal Home Loan Bank ("FHLB") program | | (2.4) | | | (4.7) | | | (10.3) | | | (16.1) | | | (33.5) | | | (21.7) | | | (24.2) | | | (28.3) | | | (30.5) | | | (104.7) | |
Expenses related to the funding agreement-backed notes ("FABN") program (a) | | (7.3) | | | (7.6) | | | (7.5) | | | (7.6) | | | (30.0) | | | (7.6) | | | (7.6) | | | (7.6) | | | (7.6) | | | (30.4) | |
Less amounts credited to deferred compensation plans (offsetting investment income) | | 4.2 | | | 11.8 | | | 2.0 | | | (4.6) | | | 13.4 | | | (7.3) | | | (6.3) | | | 2.4 | | | (11.1) | | | (22.3) | |
Total adjustments | | (26.8) | | | (25.7) | | | (46.1) | | | (63.5) | | | (162.1) | | | (73.2) | | | (71.3) | | | (66.5) | | | (79.2) | | | (290.2) | |
Investment income not allocated to product lines | | $ | 27.0 | | | $ | 64.6 | | | $ | 27.1 | | | $ | 25.2 | | | $ | 143.9 | | | $ | 15.5 | | | $ | 28.0 | | | $ | 38.4 | | | $ | 38.3 | | | $ | 120.2 | |
| | | | | | | | | | | | | | | | | | | | |
___________
(a) Comprised of interest credited and amortization of deferred acquisition costs.
CNO FINANCIAL GROUP, INC.
Investment Income Not Allocated to Product Lines (9)
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| | 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
Investment income not allocated: | | | | | | | | | | | | | | | | | | | | |
Excluding variable components: | | | | | | | | | | | | | | | | | | | | |
From general account assets | | $ | 22.3 | | | $ | 27.1 | | | $ | 27.4 | | | $ | 30.7 | | | $ | 107.5 | | | $ | 24.9 | | | $ | 26.4 | | | $ | 27.2 | | | $ | 29.8 | | | $ | 108.3 | |
Other investment income | | 0.1 | | | 0.3 | | | 1.1 | | | 1.7 | | | 3.2 | | | 1.9 | | | 2.0 | | | 2.4 | | | 3.0 | | | 9.3 | |
Spread income: | | | | | | | | | | | | | | | | | | | | |
FHLB program: | | | | | | | | | | | | | | | | | | | | |
Investment income on matched assets | | 11.7 | | | 19.3 | | | 24.5 | | | 28.0 | | | 83.5 | | | 31.8 | | | 34.7 | | | 39.4 | | | 41.5 | | | 147.4 | |
Interest expense | | (2.4) | | | (4.7) | | | (10.3) | | | (16.1) | | | (33.5) | | | (21.7) | | | (24.2) | | | (28.3) | | | (30.5) | | | (104.7) | |
Net spread income on FHLB program | | 9.3 | | | 14.6 | | | 14.2 | | | 11.9 | | | 50.0 | | | 10.1 | | | 10.5 | | | 11.1 | | | 11.0 | | | 42.7 | |
FABN program: | | | | | | | | | | | | | | | | | | | | |
Investment income on matched assets | | 10.1 | | | 13.2 | | | 13.2 | | | 13.6 | | | 50.1 | | | 13.8 | | | 14.6 | | | 15.8 | | | 14.8 | | | 59.0 | |
Expenses (b) | | (7.3) | | | (7.6) | | | (7.5) | | | (7.6) | | | (30.0) | | | (7.6) | | | (7.6) | | | (7.6) | | | (7.6) | | | (30.4) | |
Net spread income on FABN program | | 2.8 | | | 5.6 | | | 5.7 | | | 6.0 | | | 20.1 | | | 6.2 | | | 7.0 | | | 8.2 | | | 7.2 | | | 28.6 | |
Interest expense on corporate debt | | (15.7) | | | (15.6) | | | (15.6) | | | (15.6) | | | (62.5) | | | (15.7) | | | (15.6) | | | (15.7) | | | (15.7) | | | (62.7) | |
Interest expense on financing arrangements | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (1.1) | | | (1.3) | | | (2.4) | |
Total excluding variable components | | 18.8 | | | 32.0 | | | 32.8 | | | 34.7 | | | 118.3 | | | 27.4 | | | 30.3 | | | 32.1 | | | 34.0 | | | 123.8 | |
Variable components: | | | | | | | | | | | | | | | | | | | | |
Net income from Corporate Owned Life Insurance ("COLI") supporting agent deferred compensation plan: | | | | | | | | | | | | | | | | | | | | |
Change in value of COLI investments | | (3.4) | | | (2.3) | | | (0.2) | | | 1.5 | | | (4.4) | | | 2.2 | | | 2.4 | | | 2.6 | | | 5.8 | | | 13.0 | |
Increase in liability for agent deferred compensation plan | | (1.5) | | | (1.5) | | | (1.5) | | | (1.6) | | | (6.1) | | | (1.6) | | | (1.6) | | | (1.7) | | | (1.6) | | | (6.5) | |
Net COLI income (loss) | | (4.9) | | | (3.8) | | | (1.7) | | | (0.1) | | | (10.5) | | | 0.6 | | | 0.8 | | | 0.9 | | | 4.2 | | | 6.5 | |
Other variable components: | | | | | | | | | | | | | | | | | | | | |
Alternative investment income (loss): | | | | | | | | | | | | | | | | | | | | |
Total | | 11.3 | | | 27.1 | | | (2.5) | | | (5.2) | | | 30.7 | | | (9.4) | | | 0.2 | | | 6.5 | | | 0.9 | | | (1.8) | |
Allocated to product lines | | (7.4) | | | (7.4) | | | (7.6) | | | (7.9) | | | (30.3) | | | (7.8) | | | (7.8) | | | (7.5) | | | (7.4) | | | (30.5) | |
Excess alternative investment income (loss) | | 3.9 | | | 19.7 | | | (10.1) | | | (13.1) | | | 0.4 | | | (17.2) | | | (7.6) | | | (1.0) | | | (6.5) | | | (32.3) | |
Prepayment and call income | | 5.2 | | | 14.9 | | | 3.7 | | | 1.6 | | | 25.4 | | | 0.1 | | | 0.1 | | | 0.1 | | | 0.2 | | | 0.5 | |
Trading account | | 2.7 | | | 1.5 | | | 1.8 | | | 1.7 | | | 7.7 | | | 2.6 | | | 1.3 | | | 1.3 | | | 1.3 | | | 6.5 | |
Hedge variance related to fixed indexed products | | (1.0) | | | (0.4) | | | 0.2 | | | (0.1) | | | (1.3) | | | — | | | (1.0) | | | (0.3) | | | (1.2) | | | (2.5) | |
Impact of annual option forfeitures related to fixed indexed annuity surrenders | | 1.6 | | | (0.5) | | | (1.1) | | | (1.0) | | | (1.0) | | | — | | | 1.4 | | | 2.5 | | | 3.2 | | | 7.1 | |
Other (a) | | 0.7 | | | 1.2 | | | 1.5 | | | 1.5 | | | 4.9 | | | 2.0 | | | 2.7 | | | 2.8 | | | 3.1 | | | 10.6 | |
Total variable components | | 8.2 | | | 32.6 | | | (5.7) | | | (9.5) | | | 25.6 | | | (11.9) | | | (2.3) | | | 6.3 | | | 4.3 | | | (3.6) | |
Total investment income not allocated to product lines | | $ | 27.0 | | | $ | 64.6 | | | $ | 27.1 | | | $ | 25.2 | | | $ | 143.9 | | | $ | 15.5 | | | $ | 28.0 | | | $ | 38.4 | | | $ | 38.3 | | | $ | 120.2 | |
| | | | | | | | | | | | | | | | | | | | |
___________
(a) Includes impacts of changes in projected cash flows and other investment income.
(b) Comprised of interest credited and amortization of deferred acquisition costs.
CNO FINANCIAL GROUP, INC.
Investment Income Allocated to Product Lines (5)
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| | 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
Average net insurance liabilities (11) | | | | | | | | | | | | | | | | | | | | |
Annuity: | | | | | | | | | | | | | | | | | | | | |
Fixed indexed annuities | | $ | 8,486.3 | | | $ | 8,711.0 | | | $ | 8,902.9 | | | $ | 9,054.2 | | | $ | 8,788.6 | | | $ | 9,183.8 | | | $ | 9,276.0 | | | $ | 9,381.0 | | | $ | 9,508.7 | | | $ | 9,337.3 | |
Fixed interest annuities | | 1,761.2 | | | 1,712.5 | | | 1,675.9 | | | 1,652.6 | | | 1,700.5 | | | 1,630.9 | | | 1,613.1 | | | 1,603.0 | | | 1,600.9 | | | 1,612.0 | |
Other annuities | | 490.2 | | | 484.2 | | | 478.8 | | | 473.6 | | | 481.7 | | | 469.5 | | | 462.5 | | | 455.6 | | | 447.5 | | | 458.8 | |
Total annuity average net insurance liabilities (11) | | 10,737.7 | | | 10,907.7 | | | 11,057.6 | | | 11,180.4 | | | 10,970.8 | | | 11,284.2 | | | 11,351.6 | | | 11,439.6 | | | 11,557.1 | | | 11,408.1 | |
Health: | | | | | | | | | | | | | | | | | | | | |
Supplemental health | | 3,215.6 | | | 3,250.7 | | | 3,278.3 | | | 3,308.8 | | | 3,263.3 | | | 3,331.0 | | | 3,350.6 | | | 3,365.8 | | | 3,356.9 | | | 3,351.1 | |
Medicare supplement | | 129.5 | | | 140.3 | | | 135.1 | | | 121.9 | | | 131.7 | | | 124.2 | | | 118.7 | | | 107.1 | | | 106.7 | | | 114.2 | |
Long-term care | | 2,639.2 | | | 2,650.1 | | | 2,658.0 | | | 2,659.4 | | | 2,651.7 | | | 2,659.8 | | | 2,670.5 | | | 2,681.9 | | | 2,692.5 | | | 2,676.1 | |
Total health average net insurance liabilities (11) | | 5,984.3 | | | 6,041.1 | | | 6,071.4 | | | 6,090.1 | | | 6,046.7 | | | 6,115.0 | | | 6,139.8 | | | 6,154.8 | | | 6,156.1 | | | 6,141.4 | |
Life: | | | | | | | | | | | | | | | | | | | | |
Interest sensitive | | 1,009.4 | | | 1,016.4 | | | 1,019.2 | | | 1,026.9 | | | 1,018.0 | | | 1,032.0 | | | 1,035.4 | | | 1,039.6 | | | 1,045.8 | | | 1,038.2 | |
Traditional | | 1,957.1 | | | 1,951.0 | | | 1,943.7 | | | 1,956.1 | | | 1,952.0 | | | 1,973.0 | | | 1,975.3 | | | 1,981.8 | | | 1,989.0 | | | 1,979.8 | |
Total life average net insurance liabilities (11) | | 2,966.5 | | | 2,967.4 | | | 2,962.9 | | | 2,983.0 | | | 2,970.0 | | | 3,005.0 | | | 3,010.7 | | | 3,021.4 | | | 3,034.8 | | | 3,018.0 | |
Total average net insurance liabilities (11) | | $ | 19,688.5 | | | $ | 19,916.2 | | | $ | 20,091.9 | | | $ | 20,253.5 | | | $ | 19,987.5 | | | $ | 20,404.2 | | | $ | 20,502.1 | | | $ | 20,615.8 | | | $ | 20,748.0 | | | $ | 20,567.5 | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Average yield on allocated investments | | | | | | | | | | | | | | | | | | | | |
Annuity: | | | | | | | | | | | | | | | | | | | | |
Fixed indexed annuities | | 4.25 | % | | 4.20 | % | | 4.27 | % | | 4.30 | % | | 4.25 | % | | 4.30 | % | | 4.36 | % | | 4.45 | % | | 4.45 | % | | 4.39 | % |
Fixed interest annuities | | 4.88 | % | | 4.81 | % | | 4.85 | % | | 4.99 | % | | 4.88 | % | | 5.13 | % | | 5.18 | % | | 5.24 | % | | 5.20 | % | | 5.19 | % |
Other annuities | | 4.81 | % | | 4.79 | % | | 4.85 | % | | 4.81 | % | | 4.82 | % | | 4.86 | % | | 4.84 | % | | 4.92 | % | | 4.92 | % | | 4.88 | % |
Average yield on investments allocated to annuities | | 4.38 | % | | 4.32 | % | | 4.38 | % | | 4.42 | % | | 4.38 | % | | 4.45 | % | | 4.50 | % | | 4.58 | % | | 4.58 | % | | 4.53 | % |
Health: | | | | | | | | | | | | | | | | | | | | |
Supplemental health | | 4.65 | % | | 4.63 | % | | 4.60 | % | | 4.62 | % | | 4.62 | % | | 4.64 | % | | 4.64 | % | | 4.63 | % | | 4.62 | % | | 4.63 | % |
Medicare supplement | | 4.11 | % | | 4.01 | % | | 4.01 | % | | 4.06 | % | | 4.05 | % | | 4.13 | % | | 4.19 | % | | 4.25 | % | | 4.42 | % | | 4.24 | % |
Long-term care | | 5.24 | % | | 5.13 | % | | 5.15 | % | | 5.14 | % | | 5.17 | % | | 5.13 | % | | 5.12 | % | | 5.09 | % | | 5.07 | % | | 5.10 | % |
Average yield on investments allocated to health products | | 4.90 | % | | 4.83 | % | | 4.83 | % | | 4.84 | % | | 4.85 | % | | 4.84 | % | | 4.84 | % | | 4.82 | % | | 4.82 | % | | 4.83 | % |
Life: | | | | | | | | | | | | | | | | | | | | |
Interest sensitive | | 5.15 | % | | 5.04 | % | | 5.06 | % | | 5.02 | % | | 5.07 | % | | 5.08 | % | | 4.91 | % | | 4.96 | % | | 4.90 | % | | 4.96 | % |
Traditional | | 4.60 | % | | 4.59 | % | | 4.63 | % | | 4.68 | % | | 4.63 | % | | 4.70 | % | | 4.74 | % | | 4.72 | % | | 4.69 | % | | 4.71 | % |
Average yield on investments allocated to life products | | 4.79 | % | | 4.74 | % | | 4.78 | % | | 4.80 | % | | 4.78 | % | | 4.83 | % | | 4.80 | % | | 4.81 | % | | 4.76 | % | | 4.80 | % |
Total average yield | | 4.60 | % | | 4.54 | % | | 4.57 | % | | 4.60 | % | | 4.58 | % | | 4.62 | % | | 4.65 | % | | 4.69 | % | | 4.68 | % | | 4.66 | % |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Allocated investment income | | | | | | | | | | | | | | | | | | | | |
Annuity: | | | | | | | | | | | | | | | | | | | | |
Fixed indexed annuities | | $ | 90.1 | | | $ | 91.4 | | | $ | 95.0 | | | $ | 97.3 | | | $ | 373.8 | | | $ | 98.8 | | | $ | 101.2 | | | $ | 104.4 | | | $ | 105.9 | | | $ | 410.3 | |
Fixed interest annuities | | 21.5 | | | 20.6 | | | 20.3 | | | 20.6 | | | 83.0 | | | 20.9 | | | 20.9 | | | 21.0 | | | 20.8 | | | 83.6 | |
Other annuities | | 5.9 | | | 5.8 | | | 5.8 | | | 5.7 | | | 23.2 | | | 5.7 | | | 5.6 | | | 5.6 | | | 5.5 | | | 22.4 | |
Total investment income allocated to annuities | | 117.5 | | | 117.8 | | | 121.1 | | | 123.6 | | | 480.0 | | | 125.4 | | | 127.7 | | | 131.0 | | | 132.2 | | | 516.3 | |
Health: | | | | | | | | | | | | | | | | | | | | |
Supplemental health | | 37.4 | | | 37.6 | | | 37.7 | | | 38.2 | | | 150.9 | | | 38.6 | | | 38.9 | | | 39.0 | | | 38.8 | | | 155.3 | |
Medicare supplement | | 1.3 | | | 1.4 | | | 1.4 | | | 1.3 | | | 5.4 | | | 1.3 | | | 1.2 | | | 1.1 | | | 1.3 | | | 4.9 | |
Long-term care | | 34.6 | | | 34.0 | | | 34.2 | | | 34.2 | | | 137.0 | | | 34.1 | | | 34.2 | | | 34.1 | | | 34.1 | | | 136.5 | |
Total investment income allocated to health products | | 73.3 | | | 73.0 | | | 73.3 | | | 73.7 | | | 293.3 | | | 74.0 | | | 74.3 | | | 74.2 | | | 74.2 | | | 296.7 | |
Life: | | | | | | | | | | | | | | | | | | | | |
Interest sensitive | | 13.0 | | | 12.8 | | | 12.9 | | | 12.9 | | | 51.6 | | | 13.1 | | | 12.7 | | | 12.9 | | | 12.8 | | | 51.5 | |
Traditional | | 22.5 | | | 22.4 | | | 22.5 | | | 22.9 | | | 90.3 | | | 23.2 | | | 23.4 | | | 23.4 | | | 23.3 | | | 93.3 | |
Total investment income allocated to life products | | 35.5 | | | 35.2 | | | 35.4 | | | 35.8 | | | 141.9 | | | 36.3 | | | 36.1 | | | 36.3 | | | 36.1 | | | 144.8 | |
Total allocated investment income | | $ | 226.3 | | | $ | 226.0 | | | $ | 229.8 | | | $ | 233.1 | | | $ | 915.2 | | | $ | 235.7 | | | $ | 238.1 | | | $ | 241.5 | | | $ | 242.5 | | | $ | 957.8 | |
| | | | | | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
Investment Income Not Allocated to Product Lines (9)
(Dollars in millions)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | 1Q | | 2Q | | 3Q | | 4Q | | YTD | | 1Q | | 2Q | | 3Q | | 4Q | | YTD |
| | 2022 | | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 | | 2023 |
General account assets investment income | | $ | 277.5 | | | $ | 317.7 | | | $ | 289.0 | | | $ | 294.8 | | | $ | 1,179.0 | | | $ | 292.2 | | | $ | 308.1 | | | $ | 324.8 | | | $ | 325.1 | | | $ | 1,250.2 | |
Policyholder and other special purpose portfolio investment income (loss) | | (69.3) | | | (93.8) | | | (20.9) | | | 20.9 | | | (163.1) | | | 50.8 | | | 91.6 | | | (33.0) | | | 140.1 | | | 249.5 | |
Less equity returns credited to policyholders: | | | | | | | | | | | | | | | | | | | | |
Annuity | | 64.3 | | | 80.1 | | | 30.9 | | | 6.0 | | | 181.3 | | | (16.5) | | | (56.1) | | | 49.8 | | | (95.5) | | | (118.3) | |
Life | | 7.6 | | | 12.3 | | | 4.0 | | | 0.1 | | | 24.0 | | | (2.1) | | | (6.2) | | | 4.8 | | | (9.7) | | | (13.2) | |
Less amount related to variable interest entities | | (7.2) | | | (9.1) | | | (13.6) | | | (18.6) | | | (48.5) | | | (20.9) | | | (19.0) | | | (18.7) | | | (16.2) | | | (74.8) | |
Less amounts credited to deferred compensation plans | | 4.2 | | | 11.8 | | | 2.0 | | | (4.6) | | | 13.4 | | | (7.3) | | | (6.3) | | | 2.4 | | | (11.1) | | | (22.3) | |
Other special purpose portfolio investment income (loss) | | (0.4) | | | 1.3 | | | 2.4 | | | 3.8 | | | 7.1 | | | 4.0 | | | 4.0 | | | 5.3 | | | 7.6 | | | 20.9 | |
Adjusted net investment income | | 277.1 | | | 319.0 | | | 291.4 | | | 298.6 | | | 1,186.1 | | | 296.2 | | | 312.1 | | | 330.1 | | | 332.7 | | | 1,271.1 | |
Less amounts allocated to product lines | | | | | | | | | | | | | | | | | | | | |
Annuity | | (117.5) | | | (117.8) | | | (121.1) | | | (123.6) | | | (480.0) | | | (125.4) | | | (127.7) | | | (131.0) | | | (132.2) | | | (516.3) | |
Health | | (73.3) | | | (73.0) | | | (73.3) | | | (73.7) | | | (293.3) | | | (74.0) | | | (74.3) | | | (74.2) | | | (74.2) | | | (296.7) | |
Life | | (35.5) | | | (35.2) | | | (35.4) | | | (35.8) | | | (141.9) | | | (36.3) | | | (36.1) | | | (36.3) | | | (36.1) | | | (144.8) | |
Total investment income allocated to product lines | | (226.3) | | | (226.0) | | | (229.8) | | | (233.1) | | | (915.2) | | | (235.7) | | | (238.1) | | | (241.5) | | | (242.5) | | | (957.8) | |
Impact of annual option forfeitures related to fixed indexed annuity surrenders | | 1.6 | | | (0.5) | | | (1.1) | | | (1.0) | | | (1.0) | | | — | | | 1.4 | | | 2.5 | | | 3.2 | | | 7.1 | |
Less interest expense on investment borrowings from FHLB program | | (2.4) | | | (4.7) | | | (10.3) | | | (16.1) | | | (33.5) | | | (21.7) | | | (24.2) | | | (28.3) | | | (30.5) | | | (104.7) | |
Less expenses related to FABN program | | (7.3) | | | (7.6) | | | (7.5) | | | (7.6) | | | (30.0) | | | (7.6) | | | (7.6) | | | (7.6) | | | (7.6) | | | (30.4) | |
Less interest expense on debt | | (15.7) | | | (15.6) | | | (15.6) | | | (15.6) | | | (62.5) | | | (15.7) | | | (15.6) | | | (15.7) | | | (15.7) | | | (62.7) | |
Less interest expense on financing arrangements | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (1.1) | | | (1.3) | | | (2.4) | |
Investment income not allocated to product lines | | $ | 27.0 | | | $ | 64.6 | | | $ | 27.1 | | | $ | 25.2 | | | $ | 143.9 | | | $ | 15.5 | | | $ | 28.0 | | | $ | 38.4 | | | $ | 38.3 | | | $ | 120.2 | |
| | | | | | | | | | | | | | | | | | | | |
Other Investment Data
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | 1Q | | 2Q | | 3Q | | 4Q | | 1Q | | 2Q | | 3Q | | 4Q |
| | 2022 | | 2022 | | 2022 | | 2022 | | 2023 | | 2023 | | 2023 | | 2023 |
Average book value of invested assets and cash | | $ | 25,791.7 | | | $ | 25,954.0 | | | $ | 26,251.0 | | | $ | 26,484.1 | | | $ | 26,801.8 | | | $ | 26,900.3 | | | $ | 27,287.6 | | | $ | 27,648.7 | |
Net investment income from general account investments | | 277.5 | | | 317.7 | | | 289.0 | | | 294.8 | | | 292.2 | | | 308.1 | | | 324.8 | | | 325.1 | |
New money rate (14) | | 3.73 | % | | 5.53 | % | | 5.36 | % | | 5.96 | % | | 6.34 | % | | 6.32 | % | | 6.03 | % | | 6.92 | % |
Book yield (15) | | 4.53 | % | | 4.52 | % | | 4.54 | % | | 4.55 | % | | 4.56 | % | | 4.58 | % | | 4.60 | % | | 4.62 | % |
Earned yield (16) | | 4.50 | % | | 5.00 | % | | 4.35 | % | | 4.35 | % | | 4.22 | % | | 4.41 | % | | 4.55 | % | | 4.49 | % |
Pre-pay/call/make-whole income | | $ | 5.2 | | | $ | 14.9 | | | $ | 3.7 | | | $ | 1.6 | | | $ | 0.1 | | | $ | 0.1 | | | $ | 0.1 | | | $ | 0.2 | |
Alternative investment income (loss) | | 11.3 | | | 27.1 | | | (2.5) | | | (5.2) | | | (9.4) | | | 0.2 | | | 6.5 | | | 0.9 | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
CNO FINANCIAL GROUP, INC.
4Q23 Significant Items
(Dollars in millions, except per share amounts)
(Unaudited)
The table below summarizes the financial impact of significant items on our 4Q23 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | December 31, 2023 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin (4) | | | | | | |
Annuity margin | | $ | 63.6 | | | $ | (12.9) | | (a) | $ | 50.7 | |
Health margin | | 146.4 | | | (22.3) | | (a) | 124.1 | |
Life margin | | 64.6 | | | 1.3 | | (a) | 65.9 | |
Total insurance product margin | | 274.6 | | | (33.9) | | | 240.7 | |
Allocated expenses | | (138.8) | | | — | | | (138.8) | |
Income from insurance products (5) | | 135.8 | | | (33.9) | | | 101.9 | |
Fee income | | 17.8 | | | — | | | 17.8 | |
Investment income not allocated to product lines (9) | | 38.3 | | | — | | | 38.3 | |
Expenses not allocated to product lines | | (19.8) | | | — | | | (19.8) | |
Operating earnings before taxes | | 172.1 | | | (33.9) | | | 138.2 | |
Income tax (expense) benefit on operating income | | (38.2) | | | 7.5 | | | (30.7) | |
Net operating income (10) | | $ | 133.9 | | | $ | (26.4) | | | $ | 107.5 | |
| | | | | | |
Net operating income per diluted share | | $ | 1.18 | | | $ | (0.23) | | | $ | 0.95 | |
___________
(a)Comprised of $33.9 million of the net favorable impact arising from our comprehensive annual actuarial assumption and model review.
CNO FINANCIAL GROUP, INC.
3Q23 Significant Items
(Dollars in millions, except per share amounts)
(Unaudited)
The table below summarizes the financial impact of significant items on our 3Q23 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | September 30, 2023 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin (4) | | | | | | |
Annuity margin | | $ | 57.0 | | | $ | — | | | $ | 57.0 | |
Health margin | | 123.2 | | | — | | | 123.2 | |
Life margin | | 59.8 | | | — | | | 59.8 | |
Total insurance product margin | | 240.0 | | | — | | | 240.0 | |
Allocated expenses | | (153.2) | | | — | | | (153.2) | |
Income from insurance products (5) | | 86.8 | | | — | | | 86.8 | |
Fee income | | (2.9) | | | — | | | (2.9) | |
Investment income not allocated to product lines (9) | | 38.4 | | | — | | | 38.4 | |
Expenses not allocated to product lines | | 7.5 | | | (21.7) | | (a) | (14.2) | |
Operating earnings before taxes | | 129.8 | | | (21.7) | | | 108.1 | |
Income tax (expense) benefit on operating income | | (28.5) | | | 4.8 | | | (23.7) | |
Net operating income (10) | | $ | 101.3 | | | $ | (16.9) | | | $ | 84.4 | |
| | | | | | |
Net operating income per diluted share | | $ | 0.88 | | | $ | (0.14) | | | $ | 0.74 | |
___________
(a)Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals.
CNO FINANCIAL GROUP, INC.
4Q22 Significant Items
(Dollars in millions, except per share amounts)
(Unaudited)
The table below summarizes the financial impact of significant items on our 4Q22 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | December 31, 2022 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin (4) | | | | | | |
Annuity margin | | $ | 50.8 | | | $ | 3.2 | | (a) | $ | 54.0 | |
Health margin | | 140.4 | | | (18.3) | | (a) | 122.1 | |
Life margin | | 43.3 | | | 14.4 | | (a) | 57.7 | |
Total insurance product margin | | 234.5 | | | (0.7) | | | 233.8 | |
Allocated expenses | | (149.1) | | | — | | | (149.1) | |
Income from insurance products (5) | | 85.4 | | | (0.7) | | | 84.7 | |
Fee income | | 9.2 | | | — | | | 9.2 | |
Investment income not allocated to product lines (9) | | 25.2 | | | — | | | 25.2 | |
Expenses not allocated to product lines | | (12.8) | | | — | | | (12.8) | |
Operating earnings before taxes | | 107.0 | | | (0.7) | | | 106.3 | |
Income tax (expense) benefit on operating income | | (24.1) | | | 0.2 | | | (23.9) | |
Net operating income (10) | | $ | 82.9 | | | $ | (0.5) | | | $ | 82.4 | |
| | | | | | |
Net operating income per diluted share | | $ | 0.71 | | | $ | — | | | $ | 0.71 | |
___________
(a)Comprised of $.7 million of the net favorable impact arising from our comprehensive annual actuarial assumption and model review.
CNO FINANCIAL GROUP, INC.
2Q22 Significant Items
(Dollars in millions, except per share amounts)
(Unaudited)
The table below summarizes the financial impact of significant items on our 2Q22 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results.
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended |
| | June 30, 2022 |
| | Actual results | | Significant items | | Excluding significant items |
Insurance product margin (4) | | | | | | |
Annuity margin | | $ | 60.1 | | | $ | — | | | $ | 60.1 | |
Health margin | | 125.4 | | | — | | | 125.4 | |
Life margin | | 70.2 | | | — | | | 70.2 | |
Total insurance product margin | | 255.7 | | | — | | | 255.7 | |
Allocated expenses | | (152.2) | | | — | | | (152.2) | |
Income from insurance products (5) | | 103.5 | | | — | | | 103.5 | |
Fee income | | 3.2 | | | — | | | 3.2 | |
Investment income not allocated to product lines (9) | | 64.6 | | | — | | | 64.6 | |
Expenses not allocated to product lines | | 2.9 | | | (22.5) | | (a) | (19.6) | |
Operating earnings before taxes | | 174.2 | | | (22.5) | | | 151.7 | |
Income tax (expense) benefit on operating income | | (39.1) | | | 5.1 | | | (34.0) | |
Net operating income (10) | | $ | 135.1 | | | $ | (17.4) | | | $ | 117.7 | |
| | | | | | |
Net operating income per diluted share | | $ | 1.15 | | | $ | (0.15) | | | $ | 1.00 | |
___________
(a)Comprised of an experience refund of $22.5 million related to a reinsurance agreement.
Notes
(1)Excludes accumulated other comprehensive income (loss). Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.
(2)Shareholders' equity divided by common shares outstanding.
(3)Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised and restricted stock and performance units were vested. The dilution from options, restricted shares and performance units is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period.
(4)Insurance margin is management’s measure of profitability of its annuity, health and life product lines’ performance and consists of insurance policy income plus allocated investment income less insurance policy benefits, interest credited, commissions, advertising expense and amortization of acquisition costs. Income from insurance products is the sum of the insurance margins of the annuity, health and life product lines, less expenses allocated to the insurance product lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Management believes this information helps provide a better understanding of the business and a more meaningful analysis of results of our insurance product lines. Income from insurance products, a non-GAAP measure, is a component of net operating income, which is reconciled to net income on page 5 of this Quarterly Financial Supplement.
(5)Investment income is allocated to the product lines using the book yield of investments backing the block of business, which is applied to the average net insurance liabilities for the block in each period. See note (11) for definition of net insurance liabilities.
(6)Excludes the change in market values of the underlying options supporting the fixed indexed annuity products and corresponding amount credited to policyholder account balances. Such amounts were $(64.3) million, $(80.1) million, $(30.9) million, $(6.0) million, $16.5 million, $56.1 million, $(49.8) million and $95.5 million in 1Q22, 2Q22, 3Q22, 4Q22, 1Q23, 2Q23, 3Q23 and 4Q23, respectively.
(7)Excludes the change in market values of the underlying options supporting the fixed indexed life products and corresponding amount credited to policyholder account balances. Such amounts were $(7.6) million, $(12.3) million, $(4.0) million, $(.1) million, $2.1 million, $6.2 million, $(4.8) million and $9.7 million in 1Q22, 2Q22, 3Q22, 4Q22, 1Q23, 2Q23, 3Q23 and 4Q23, respectively.
(8)Income from insurance products is the sum of the insurance margins of the annuity, health and life product lines, less expenses allocated to the insurance lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Management believes this information helps provide a better understanding of the business and a more meaningful analysis of results of our insurance product lines. Income from insurance products, a non-GAAP measure, is a component of net operating income, which is reconciled to net income on page 5 of this Quarterly Financial Supplement.
(9)Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the FABN program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. Investment income not allocated to product lines includes investment income on investments in excess of of amounts allocated to product lines, investments held by our holding companies, the spread we earn from our Federal Home Loan Bank investment borrowing and FABN programs and variable components of investment income (including call and prepayment income, adjustments to returns on structured securities due to cash flow changes, income (loss) from company-owned life insurance ("COLI") and alternative investments income not allocated to product lines), net of interest expense on corporate debt and financing arrangements.
(10)Management believes that an analysis of Net income applicable to common stock before: (i) net realized investment gains or losses from sales, impairments and change in allowance for credit losses, net of taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities, net of taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) loss related to reinsurance transaction, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; and (viii) other non-operating items consisting primarily of earnings attributable to variable interest entities, net of taxes (“Net operating income,” a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry. Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the company's underlying fundamentals.
(11)Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account balances for annuity products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsurance business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities.
(12)Margin/average net insurance liabilities for quarterly periods is calculated by annualizing the quarters' margin divided by the average net insurance liabilities.
(13)Based on statutory accounting practices prescribed or permitted by regulatory authorities for CNO Financial's U.S. based insurance subsidiaries after appropriate elimination of intercompany accounts among such subsidiaries. Such accounting practices differ from GAAP.
(14)The new money rate is for the investments purchased during the period to support our insurance products and capital. It excludes the new money rate on investments purchased with investment borrowings under our Federal Home Loan Bank and FABN programs and investments purchased by the variable interest entities.
Notes (continued)
(15)Book yield on fixed maturity investments, excluding investments held in the: (i) Federal Home Loan Bank and FABN programs; and (ii) the investments held by the variable interest entities.
(16)Earned yield is the investment income earned during the period divided by the average book value of the investment portfolio, excluding: (i) investments held in the Federal Home Loan Bank and FABN programs; and (ii) the investments held by the variable interest entities.
CNO Financial Group 1 Fourth Quarter 2023 Financial and operating results for the period ended December 31, 2023 February 6, 2024 Unless otherwise specified, comparisons in this presentation are between 4Q22 and 4Q23. Exhibit 99.3
CNO Financial Group 2 Important Legal Information Certain statements made in this presentation should be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These include statements about future results of operations and capital plans. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ, including those included in our press release issued on February 6, 2024, our Quarterly Reports on Form 10-Q, our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. We assume no obligation to update this presentation, which speaks as of today’s date. Forward-Looking Statements This presentation contains financial measures that differ from the comparable measures under Generally Accepted Accounting Principles (GAAP). Reconciliations between those non-GAAP measures and the comparable GAAP measures are included in the Appendix, or on the page such measure is presented. While management believes the measures are useful to enhance understanding and comparability of our financial results, these non-GAAP measures should not be considered substitutes for the most directly comparable GAAP measures. Additional information concerning non-GAAP measures is included in our periodic filings with the Securities and Exchange Commission that are available in the “Investors – Financials – SEC Filings” section of CNO’s website, CNOinc.com. Non-GAAP Measures Effective January 1, 2023, we adopted ASU 2018-12 related to targeted improvements to the accounting for long-duration insurance contracts. Concurrent with the adoption of the new guidance, we updated the method of determining non- operating earnings for our fixed indexed annuities to better identify the volatile non-economic accounting impacts of that line of business. As a result of the adoption of the new guidance and methodology, certain historical amounts have changed. Our quarterly financial supplement – 4Q22 as recast to reflect the new standard is available in the “Investors – Financials – Quarterly Results” section of CNO’s website, CNOinc.com. Adoption of New Accounting Standard
CNO Financial Group 3
CNO Financial Group 4 2023 Year in Review Strong Operational Results Disciplined Execution Comparisons are between full year 2023 and 2022 unless otherwise specified. 1 A non-GAAP measure. See the Appendix for a reconciliation to the corresponding GAAP measure. Operating EPS1 of $3.09 Total NAP up 9%, benefiting from growing agent counts and multiple successful product launches throughout the year Producing agent count (“PAC”) growth every quarter of 2023 across both divisions, driven by strong recruiting and retention Consumer Division up 9% Worksite Division up 27% Stable underlying insurance product margins resulting from diversified product suite NII allocated to products up 5%, driven by sustained higher NMRs Solid fee revenue and income growth Capital and liquidity well above target levels Established CNO Bermuda Re and executed reinsurance transaction Fitch Insurer Financial Strength (IFS) rating upgraded to A High-quality investment portfolio delivering strong returns and credit performance Returned $233 million to shareholders Book value per diluted share excluding AOCI1 was $33.94, up 6% Exceptional operating performance underscores the health and strength of the business
CNO Financial Group 5 4Q FY 1Q 2Q 3Q 4Q FY vs. 4Q22 vs. FY22 New Annualized Premiums 1 Life $40.8 $193.1 $57.1 $55.6 $50.0 $43.9 $206.6 7.6% 7.0% Health 49.9 164.3 39.5 43.1 48.3 52.2 183.1 4.6% 11.4% Total Life and Health $90.7 $357.4 $96.6 $98.7 $98.3 $96.1 $389.7 6.0% 9.0% Collected Premiums Life $229.5 $911.8 $234.6 $236.6 $233.5 $232.3 $937.0 1.2% 2.8% Health 402.1 1,608.40 404.9 389.3 386.1 397.5 1,577.80 -1.1% -1.9% Total Life and Health $631.6 $2,520.2 $639.5 $625.9 $619.6 $629.8 $2,514.8 -0.3% -0.2% Annuity Collected Premiums $431.0 $1,604.6 $370.9 $401.8 $372.2 $438.3 $1,583.2 1.7% -1.3% Client Assets in BD and Advisory 2 $2,636.7 $2,636.7 $2,610.1 $2,928.1 $2,905.2 $3,168.0 $3,168.0 20.2% 20.2% Fee Revenue 3 $67.3 $169.3 $51.3 $29.4 $27.9 $69.0 $177.6 2.5% 4.9% % Change2022 2023 Sustained production momentum through 2023, well-positioned entering 2024 Growth Scorecard (dollars in millions) 1 Measured as 100% of new life and health annualized premiums, except for single premium whole life deposits, which are measured at 10% of annualized premium. 2 Client assets include cash and securities in brokerage, broker/dealer customer account assets custodied directly at fund companies and insurance carriers, and assets under management in advisory accounts. 3 Represents fee revenue from the sales of third-party insurance products; fees generated by our broker-dealer and registered investment advisor; fee revenue earned by Optavise (formerly known as DirectPath prior to its name change in April 2022, WBD merged into Optavise effective July 2023).
CNO Financial Group 6 Consumer Division Year in Review Strong Operational Results Disciplined Execution Total Life and Health NAP up 6%; up 4% vs 4Q22 Field agent NAP up 16% Life NAP up 6%, balanced across field and D2C Record D2C NAP in 2023 Health NAP up 8%; Medicare Advantage fee revenue up 14% Record Annuity collected premiums in 4Q23 PAC up 9%, fourth consecutive quarter of YoY growth Recruiting up 23% Client assets in brokerage and advisory up 20%, to a record $3.2B Strong agent retention and productivity throughout 2023 Aggressive new and refreshed product pipeline contributed meaningfully to growth in 2023 Investments to scale the MyHealthPolicy ecosystem led to ~90% of policies processed through the platform during AEP Achieved ~75% instant decision rate on eligible Simplified Issue Life business moved to automated underwriting Comparisons are between full year 2023 and 2022 unless otherwise specified. Sustained PAC growth drove strong production across multiple product lines
CNO Financial Group 7 Insurance sales momentum continuing, seventh consecutive quarter of PAC growth Worksite Division Year in Review Life and Health NAP up 29%; up 20% vs 4Q22 +20% growth in 5 of the last 6 quarters Accident product up 34% driven by 2Q23 product refresh PAC up 27%, first-year agent counts up 43% Agent referral program continued to drive growth in PAC and productivity Solid gains in agent productivity and retention Retention +20% 40% increase in first-year agent productivity Geographic expansion contributing ~25% of growth Successful launch of refreshed Critical Illness product Strong Operational Results Disciplined Execution Comparisons are between full year 2023 and 2022 unless otherwise specified.
CNO Financial Group 8 4Q23 Operating EPS1 up 34% excluding significant items Financial Highlights Earnings ResultsEarnings Drivers $356.1$360.4$133.9$82.9Net operating income1 $312.8$342.5$107.5$82.4 Net operating income excluding significant items1 115.1117.7113.7116.7 Weighted average shares outstanding (in millions) (dollars in millions, except per share amounts) 1 A non-GAAP measure. See the Appendix for a reconciliation to the corresponding GAAP measure. $0.71 $0.95 $1.18 $0.71 Net operating earnings per share1 4Q22 4Q23 Fourth Quarter 2023 4Q23 Operating EPS1 excl. significant items of $0.95, up 34% Solid insurance product margins NII allocated to products benefiting from sustained higher NMRs and growing asset base Variable investment income results improved Growth in fee income Significant items (pre-tax): $33.9 million of net favorable impacts arising from our annual actuarial review $80 million of share repurchases Solid free cash flow generation and enhanced capital management with CNO Bermuda Re Operating ROE1 excl. significant items of 8.6% Full Year 2023 FY23 Operating EPS1 excl. significant items of $2.72 Favorable impacts Generally strong and stable insurance product margins Investment income allocated to products Fee income Offsetting impacts Lower alternative investment income Elevated health claims in 2Q23 - since moderated Excluding significant items FY2022 FY2023 $2.72 $3.06 $3.09 $2.91
CNO Financial Group 9 Strong supplemental health and life margins, net favorable impact from annual actuarial review Insurance Product Margin 4Q22 1Q23 2Q23 3Q23 4Q23 Annuity $54.0 $57.3 $57.1 $57.0 $50.7 Fixed indexed annuities $44.5 $46.5 $47.6 $47.2 $41.5 Fixed interest annuities $7.8 $9.1 $8.7 $8.4 $7.7 Other annuities $1.7 $1.7 $0.8 $1.4 $1.5 Health $122.1 $116.5 $108.2 $123.2 $124.1 Supplemental health $58.4 $63.3 $59.9 $62.8 $66.5 Medicare supplement $37.9 $26.1 $32.3 $37.2 $31.9 Long-term care $25.8 $27.1 $16.0 $23.2 $25.7 Life $57.7 $47.4 $57.9 $59.8 $65.9 Interest sensitive life $22.6 $22.8 $24.1 $22.9 $25.0 Traditional life $35.1 $24.6 $33.8 $36.9 $40.9 Total Margin $233.8 $221.2 $223.2 $240.0 $240.7 4Q 2023 Highlights (dollars in millions) Insurance Product Margin Excluding Significant Items1 1 Excludes $3.2 million unfavorable annuity unlocking, $18.3 million favorable health unlocking and $14.4 million unfavorable life unlocking in 4Q22 and $12.9 million favorable annuity unlocking, $22.3 million favorable health unlocking and $1.3 million unfavorable life unlocking in 4Q23. See the Appendix for a reconciliation to the corresponding GAAP measure. Annual actuarial review Current period net benefit of $33.9 million, primarily due to Supplemental Health Quarterly go-forward income pattern changes beginning 4Q23 Supplemental health - $4 million FIA – ($2) million Med Supp – ($1) million Remaining product variance explanations FIA – moderating spreads offset by growth in the block Supp Health – growth in the block Med Supp – runoff of legacy block ISL – growth in the block and favorable claims experience Trad Life – lower non-deferrable advertising expense and growth in the block
CNO Financial Group 10 NII benefiting from strong NMRs, growing asset base and improved VII $25.2 $38.3 $- $50.0 $100.0 $150.0 $200.0 4Q 2022 4Q 2023 Investment Income Not Allocated to Product Lines $- $100.0 $200.0 $300.0 $400.0 4Q 2022 4Q 2023 Total Net Investment Income1 Annuity Health Life Not Allocated $280.8 $- $100.0 $200.0 $300.0 $400.0 4Q 2022 4Q 2023 Investment Income Allocated to Product Lines Annuity Health Life $242.5 Investment Results Average yield on allocated investments of 4.68% vs. 4.60% in 4Q22 Average net insurance liabilities2 up 2.4% YoY NII consistent with 3Q results with relative improvements in P.E. and continued growth of real asset returns 1 Reflects sum of allocated and non-allocated investment income. Refer to pages 15-18 of the financial supplement for more information on the components of net investment income. 2 Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account balances for annuity products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsurance business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities. $233.1 $258.3 New money rate of 6.92%, compared to 6.03% in 3Q23 and 5.96% in 4Q22 Average book value of invested assets up 4.4% YoY; 6th consecutive quarterly increase in book yield Earned yield of 4.49%, compared to 4.55% in 3Q23 and 4.35% in 4Q22 Investment income not allocated to product lines up $13 million Improved alternative investment returns YoY with relative improvements in PE and real asset returns (dollars in millions)
CNO Financial Group 11 Rising earnings power with stable credit trend Portfolio Composition $25 Billion of Invested Assets Highlights (Fair Value as of 12/31/2023) General Approach Positioned for relatively stable performance across credit cycles Focus on quality - margin against adverse development Calibrated allocation to risk asset categories – specific boundaries on the amount of high-risk assets we will own Low impairments through multiple cycles Embedded asset liability management Opportunistic investments enhance book yield and core earnings power High degree of liquidity: over 60% of portfolio in corporate and government bonds Up-in-quality positioning over past 12 months “BBB” allocation reduced by 290 bps in the last 12 months “A” and better allocation increased by 310 bps in the last 12 months Strong credit risk profile Capital efficient: 97% rated NAIC 1 or 2 Portfolio average rating A Significant credit enhancement in structured products and good performance in collateral including CMBS Diversified commercial and residential mortgage allocation IG Corporates, 43.2% Non-Agency RMBS, 6.2% Mortgage Loans, 7.4% HY Corporates, 2.1% CMBS, 8.9% Municipals, 9.8% ABS, 5.4% Govts/Agency, 3.6% CLO, 4.0% Equities, 0.4% Other, 2.7% Alternatives, 2.5% Policy Loans, 0.5% Cash, 3.4%
CNO Financial Group 12 1 The ratio of the combined capital of the U.S. based insurance companies to the minimum amount of capital appropriate to support the overall business operations, as determined based on the methodology developed by the National Association of Insurance Commissioners. 2 Excluding accumulated other comprehensive income (loss) (a non-GAAP measure). See the Appendix for a reconciliation to the corresponding GAAP measure. Debt to Capital2 Consolidated Risk Based Capital (RBC) Ratio1 Target leverage of 25 - 28% Debt covenant ceiling of 35% $334 million in debt capacity to top of target leverage range Target consolidated RBC ratio of approximately 375% RBC variability expected in periods of market volatility Holding Company Liquidity Target minimum holding company liquidity of $150 million Liquidity backstopped by $250 million undrawn revolver No outstanding debt maturities until 2025 386% 384% 402% 2021 2022 2023 $249 $167 $256 2021 2022 2023 25.6% 23.4% 23.1% 2021 2022 2023 Capital and liquidity above target levels, enhanced capital efficiency Capital and Liquidity Overview (dollars in millions)
CNO Financial Group 13 2024 Outlook1 1Excluding significant items. Earnings Free Cash Flow / Excess Capital Operating EPS range of $3.10 – $3.30 18.8% – 19.2% expense ratio ~23% effective tax rate $140 – $200 million of excess cash flow to holdco 375% consolidated RBC ratio target Minimum $150 million in holding company liquidity Target leverage of 25.0% - 28.0%
CNO Financial Group 14 Investment Highlights Sustainable growth initiatives in place Favorable demographic tailwinds Exclusive focus on underserved middle market Diverse and integrated "last mile" virtual and in-person model Strong balance sheet and solid free cash flow generation
CNO Financial Group 15 Questions and Answers
CNO Financial Group 16 Agent pilots, technology- driven customer experience enhancements Hybrid distribution Worksite B2B marketing, lead generation Share repurchases: $80 million in 4Q23, $165 million in 2023 Dividends: $17 million in 4Q23, $68 million in 2023 Highly selective M&A CNO Ventures; strategic minority investments largely in InsurTech LTC reinsurance (2018), Web Benefits Design (2019), DirectPath (2021), CNO Bermuda Re reinsurance (2023) Opportunistic transactions Return capital to shareholders Organic investments to sustain and grow the core businesses Disciplined and opportunistic approach to maximize shareholder value Excess Capital Allocation Strategy
CNO Financial Group 17 Cash Flow Profile 1 A non-GAAP measure. See the Appendix for a reconciliation to the corresponding GAAP measure. 2 Cash flows exclude acquisitions, dividend payments, stock repurchases, and financing transactions. (dollars in millions) 4Q22 4Q23 4Q22 4Q23 Net Operating Income1 82.9$ 133.9$ 360.4$ 356.1$ Holding Company Cash Flows: Net Dividends (Contributions) from/to Subsidiaries 44.4$ 176.3$ 156.7$ 252.7$ Management Fees 34.3 27.9 124.0 116.1 Surplus Debenture Interest 14.6 17.9 58.8 82.0 Earnings on Corporate Investments 3.2 3.8 9.7 15.0 Other (10.7) (7.2) 3.4 5.3 Holding Company Sources of Cash 2 85.8 218.7 352.6 471.1 Holding Company Expenses and Other (12.7) (16.0) (73.7) (79.6) Intercompany Tax Receipts (Payments) (4.7) 9.0 (32.0) 28.6 Tax Payments (9.3) (11.3) (22.9) (48.0) Interest Payments (28.3) (28.3) (60.8) (60.8) Excess Cash Flow to Holding Company 2 30.8 172.1 163.2 311.3 Share Repurchases (9.9) (70.2) (179.9) (154.6) Dividend Payments to Stockholders (16.1) (16.7) (64.8) (68.1) Net Change in Holding Company Cash and Investments 4.8 85.2 (81.5) 88.6 Cash and Investments, Beginning of Period 162.3 170.5 248.6 167.1 Cash and Investments, End of Period 167.1$ 255.6$ 167.1$ 255.6$ Trailing Twelve MonthsFor the Quarter
CNO Financial Group 18 Appendix 1: Quarter in Review Strong Operational Performance Broker-Dealer/Registered Investment Advisor Slide 19 Exclusive Agent Counts Slide 20 Building on Strong Track Record of Execution Expense Ratio Slide 21 New Money Rate Walk Slide 22 New Money Summary Slide 23 Commercial Mortgage Loans Slide 24 Commercial Mortgage-Backed Securities Slide 25 Long-Term Care Insurance Slide 26 Tax Asset Summary Slide 27
CNO Financial Group 19 Account values up 20% YoY; record $3.2 billion in client assets Broker-Dealer/Registered Investment Advisor 1 Client assets include cash and securities in brokerage, broker/dealer customer account assets custodied directly at fund companies and insurance carriers, and assets under management in advisory accounts. Prior periods have been restated to conform with current presentation. Bankers Life is the marketing brand of various affiliated companies of CNO Financial Group including, Bankers Life and Casualty Company, Bankers Life Securities, Inc., and Bankers Life Advisory Services, Inc. Non-affiliated insurance products are offered through Bankers Life General Agency, Inc. (dba BL General Insurance Agency, Inc., AK, AL, CA, NV, PA). Agents who are financial advisors are registered with Bankers Life Securities, Inc. Securities and variable annuity products and services are offered by Bankers Life Securities, Inc. Member FINRA/SIPC, (dba BL Securities, Inc., AL, GA, IA, IL, MI, NV, PA). Advisory products and services are offered by Bankers Life Advisory Services, Inc. SEC Registered Investment Adviser (dba BL Advisory Services, Inc., AL, GA, IA, MT, NV, PA). Home Office: 111 East Wacker Drive, Suite 1900, Chicago, IL 60601 (dollars in millions) 4Q 1Q 2Q 3Q 4Q Net New Client Assets in Brokerage (9.2)$ 7.9$ (4.2)$ 16.7$ (1.0)$ Brokerage and Advisory1 Advisory 31.8 54.2 41.8 47.8 18.7 Total 22.6$ 62.1$ 37.6$ 64.5$ 17.7$ Client Assets in Brokerage and Brokerage 1,495.5$ 1,563.5$ 1,626.1$ 1,597.6$ 1,729.8$ Advisory1 at end of period Advisory 1,141.2 1,046.6 1,302.0 1,307.6 1,438.2 Total 2,636.7$ 2,610.1$ 2,928.1$ 2,905.2$ 3,168.0$ 2022 2023
CNO Financial Group 20 Year-over-year PAC growth every quarter of 2023 across both divisions Exclusive Agent Counts 1 Producing agents represent the monthly average of exclusive agents that have submitted at least one policy in the month. 2 Registered agents are dually licensed as insurance agents and financial representatives who can buy and sell securities for clients, and/or investment advisors who can provide ongoing investment advice for clients. 3 Agent and representative counts represent the average of the last 3 months. % Change % Change Consumer 4Q 1Q 2Q 3Q 4Q vs. 3Q23 vs. 4Q22 Producing Field Agents1,3 3,882 3,985 4,279 4,267 4,224 -1.0% 8.8% Registered Agents2,3 695 695 695 701 708 1.0% 1.9% Worksite Producing Field Agents1,3 275 288 310 321 349 8.7% 26.9% 2022 2023
CNO Financial Group 21 1Q 2Q 3Q 4Q Allocated & Non Allocated Expenses 175.8$ 170.6$ 145.7$ 158.6$ Allocated & Non Allocated Expenses - YTD 175.8 346.4 492.1 650.7 Significant Items2 -$ -$ (21.7)$ -$ Significant Items - YTD2 - - (21.7) (21.7) Allocated & Non Allocated Expenses Excluding Significant Items 175.8$ 170.6$ 167.4$ 158.6$ Allocated & Non Allocated Expenses Excluding Significant Items- YTD 175.8 346.4 513.8 672.4 Policy Income and Net Investment Income Allocated to Products 861.2$ 866.4$ 867.5$ 868.2$ Policy Income and Net Investment Income Allocated to Products - YTD 861.2 1,727.6 2,595.1 3,463.3 Expense Ratio excluding Significant Items 20.4% 19.7% 19.3% 18.3% Expense Ratio excluding Significant Items - YTD 20.4% 20.1% 19.8% 19.4% 2023 Expense Ratio1 1 Expenses allocated to products plus not allocated to products, divided by the sum of insurance policy income and net investment income allocated to products. Results exclude significant items. 2 See page 30 for reconciliations of the significant items.
CNO Financial Group 22 Reflects relative value allocations to agencies and residential mortgage loans along with rising rates New Money Rate Walk 6.03% 0.42% 0.77% -0.28% -0.02% 6.92% 3Q23 NMR Yield Curve Spread Duration Direct Investment 4Q23 NMR
CNO Financial Group 23 New Money Summary 4Q23 General Account New Money Purchases Reflects opportunistic allocations to agencies, municipals, residential mortgage loans, as well as rising interest rates at the long end of the curve $ % GAAP YTM Duration Commercial Real Estate 65.2 18.2% 5.77% 6.70 Municipals 62.8 17.5% 6.38% 11.93 Residential Mortgage Loans 55.4 15.4% 7.39% 2.70 IG Corp BBB 50.8 14.2% 7.15% 5.71 RMBS 39.2 10.9% 6.51% 12.55 HY Corp 29.8 8.3% 11.28% 3.70 IG Corp AAA-A 20.5 5.7% 6.09% 12.49 Alternatives 16.5 4.6% 5.67% 7.36 ABS 13.8 3.9% 6.80% 1.98 EM 4.9 1.4% 5.92% 13.49 Total 358.96 100% 6.92% 7.52 Commercial Real Estate 18% Municipals 18% Residential Mortgage Loans 15% IG Corp BBB 14% RMBS 11% HY Corp 8% IG Corp AAA-A 6% Alternatives 5% ABS 4% EM 1%
CNO Financial Group 24 Prop Type % AUM Avg LTV Apartment 38.4% 48.1% Industrial 26.5% 40.5% Mixed Use 1.3% 46.5% Office 12.2% 59.6% Other 7.2% 29.4% Retail 14.3% 43.2% 47.7% 20.9% 20.5% 10.3% 0.5% 0.0% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% >2.00x 1.70x - 2.00x 1.40x - 1.70x 1.15x - 1.40x 1.00x - 1.15x <1.00x 40.6% 20.5% 27.3% 6.5% 3.5% 1.5% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% < 40% 40-50% 50-60% 60-70% 70-80% >80% Commercial Mortgage Loans Our CRE loan portfolio emphasizes lower risk sectors Our CRE loan portfolio is conservatively margined with cushion for adverse development We emphasize stabilized cash flowing properties DSCR Our CRE loan portfolio is not significantly exposed to near term maturity default risk (dollars in millions) % o f T ot al A U M LTV Apartment 38% Industrial 26% Other 7% Mixed Use 1% Retail 14% Office 12% $37.8 $12.6 $53.6 $83.7 2024 2025 2026 2027 Maturities
CNO Financial Group 25 $7 $8 $9 $12 $13 $19 $22 $26 32.50 10% 6% -1% -7% -10% -19% -24% -29% -40% 11% 17% 22% 50% <10 10-15 15-30 >30 Source: NAIC Loss Scenario Our CMBS investments have significant structural cushion for collateral losses Our holdings have limited loss content in severe scenarios Change in CRE Values – NAIC Scenarios BearBull Estimated Life of Portfolio CNO Principal Loss Our CMBS allocation is tilted toward lower risk property types Our CMBS allocation is highly rated - 91% AAA/AA/A categories 73% of our CMBS investments are considered ‘no-loss’ in 2023 NAIC scenario testing Market consistent estimates of collateral losses range from lows of 4% to highs of 8%. 2023 Fed stress test CRE loss rate of 9%. % L os s Ab so rb in g Su bo rd in at io n in S tr uc tu re AAA $2,020.2 AA+ $83.9 AA $36.2 AA- $171.3 A+ $77.9 A $81.8 A- $83.5 BBB+ $37.8 BBB $40.6 BBB- $23.6 BB+ $43.6 BB $1.8 CNO Index Multifamily Office Other Industrial Retail Hotel Commercial Mortgage-Backed Securities (dollars in millions) Mean
CNO Financial Group 26 New sales (~$35 million annually) focused on short duration products 99% of new sales for policies with 2 years or less in benefits Average benefit period of 12 months New business 25% reinsured since 2008 Reserve assumptions informed by historical experience No morbidity improvement No mortality improvement Minimal future rate increases Favorable economic profile Total LTC is just 13.2% of overall CNO insurance liabilities Downside risk significantly reduced after 2018 reinsurance transaction Average maximum benefit at issuance is $162 per day for inforce block Block Highlights Less than 25% of policies have inflation benefits 2.4% of policies have lifetime benefits and the average non-lifetime benefit period is ~1.5 years Average attained age is 74.4 years Long-Term Care Insurance Highly differentiated inforce block; prudently managed
CNO Financial Group 27 Value of NOLs and deferred tax assets (DTAs) related to tax strategy Details Total estimated economic value of tax assets related to our NOLs and tax strategy of approximately $206 million @ 10% discount rate ($1.84 on a per share basis). Life NOLs have been fully utilized. Non- life NOLs are expected to offset 100% of non-life taxable income and 35% of life taxable income through 2023. $330 (dollars in millions) $330 million/$2.95 per diluted share value of NOLs and DTAs related to tax strategy Tax Asset Summary as of December 31, 2023 Non-Life NOLs $77 DTAs related to tax strategy $253
CNO Financial Group 28 Appendix 2: Financial Exhibits Non-GAAP Financial Measures Slides 29 - 46
CNO Financial Group 29 Insurance product margin Annuity 63.6$ (12.9)$ (1) 50.7$ Health 146.4 (22.3) (1) 124.1 Life 64.6 1.3 (1) 65.9 Total insurance product margin 274.6 (33.9) 240.7 Allocated expenses (138.8) - (138.8) Income from insurance products 135.8 (33.9) 101.9 Fee income 17.8 - 17.8 Investment income not allocated to product lines 38.3 - 38.3 Expenses not allocated to product lines (19.8) - (19.8) Operating earnings before taxes 172.1 (33.9) 138.2 Income tax (expense) benefit on operating income (38.2) 7.5 (30.7) Net operating income (2) 133.9$ (26.4)$ 107.5$ Net operating income per diluted share (2) 1.18$ 0.23$ 0.95$ Three months ended December 31, 2023 Actual results Significant items Excluding significant items (dollars in millions, except per-share amounts) (1) Impacts arising from our comprehensive annual actuarial review. (2) A non-GAAP measure. See pages 35 and 37 for a reconciliation to the corresponding GAAP measure. The table below summarizes the financial impact of significant items on our 4Q23 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. 4Q23 Significant Items
CNO Financial Group 30 Insurance product margin Annuity 57.0$ -$ 57.0$ Health 123.2 - 123.2 Life 59.8 - 59.8 Total insurance product margin 240.0 - 240.0 Allocated expenses (153.2) - (153.2) Income from insurance products 86.8 - 86.8 Fee income (2.9) - (2.9) Investment income not allocated to product lines 38.4 - 38.4 Expenses not allocated to product lines 7.5 (21.7) (1) (14.2) Operating earnings before taxes 129.8 (21.7) 108.1 Income tax (expense) benefit on operating income (28.5) 4.8 (23.7) Net operating income (2) 101.3$ (16.9)$ 84.4$ Net operating income per diluted share (2) 0.88$ (0.14)$ 0.74$ Three months ended September 30, 2023 Actual results Significant items Excluding significant items (dollars in millions, except per-share amounts) (1) Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals. (2) A non-GAAP measure. See pages 35 and 37 for a reconciliation to the corresponding GAAP measure. The table below summarizes the financial impact of significant items on our 3Q23 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. 3Q23 Significant Items
CNO Financial Group 31 Insurance product margin Annuity 50.8$ 3.2$ (1) 54.0$ Health 140.4 (18.3) (1) 122.1 Life 43.3 14.4 (1) 57.7 Total insurance product margin 234.5 (0.7) 233.8 Allocated expenses (149.1) - (149.1) Income from insurance products 85.4 (0.7) 84.7 Fee income 9.2 - 9.2 Investment income not allocated to product lines 25.2 - 25.2 Expenses not allocated to product lines (12.8) (12.8) Operating earnings before taxes 107.0 (0.7) 106.3 Income tax (expense) benefit on operating income (24.1) 0.2 (23.9) Net operating income (2) 82.9$ (0.5)$ 82.4$ Net operating income per diluted share (2) 0.71$ -$ 0.71$ Three months ended December 31, 2022 Actual results Significant items Excluding significant items (dollars in millions, except per-share amounts) (1) Impacts arising from our comprehensive annual actuarial review. (2) A non-GAAP measure. See pages 35 and 37 for a reconciliation to the corresponding GAAP measure. The table below summarizes the financial impact of significant items on our 4Q22 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. 4Q22 Significant Items
CNO Financial Group 32 Insurance product margin Annuity 60.1$ -$ 60.1$ Health 125.4 - 125.4 Life 70.2 - 70.2 Total insurance product margin 255.7 - 255.7 Allocated expenses (152.2) - (152.2) Income from insurance products 103.5 - 103.5 Fee income 3.2 - 3.2 Investment income not allocated to product lines 64.6 - 64.6 Expenses not allocated to product lines 2.9 (22.5) (1) (19.6) Operating earnings before taxes 174.2 (22.5) 151.7 Income tax (expense) benefit on operating income (39.1) 5.1 (34.0) Net operating income (2) 135.1$ (17.4)$ 117.7$ Net operating income per diluted share (2) 1.15$ (0.15)$ 1.00$ Three months ended June 30, 2022 Actual results Significant items Excluding significant items (dollars in millions, except per-share amounts) (1) Comprised of an experience refund of $22.5 million related to a reinsurance agreement. (2) A non-GAAP measure. See pages 35 and 37 for a reconciliation to the corresponding GAAP measure. The table below summarizes the financial impact of significant items on our 2Q22 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. 2Q22 Significant Items
CNO Financial Group 33 Actual Results Significant Items Excluding significant items Insurance product margin Annuity 235.0$ (12.9)$ (1) 222.1$ Health 494.3 (22.3) (1) 472.0 Life 229.7 1.3 (1) 231.0 Total insurance product margin 959.0 (33.9) 925.1 Allocated expenses (599.0) - (599.0) Income from insurance products 360.0 (33.9) 326.1 Fee income 31.0 - 31.0 Investment income not allocated to product lines 120.2 - 120.2 Expenses not allocated to product lines (51.7) (21.7) (2) (73.4) Operating earnings before taxes 459.5 (55.6) 403.9 Income tax (expense) benefit on operating income (103.4) 12.3 (91.1) Net operating income (3) 356.1$ (43.3)$ 312.8$ Net operating income per diluted share (3) 3.09$ (0.37)$ 2.72$ December 31, 2023 Year ended (dollars in millions, except per-share amounts) (1) Comprised of $33.9 million of net favorable impacts arising from our actuarial review. [4Q23] (2) Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals. [3Q23] (3) A non-GAAP measure. See pages 35 and 37 for a reconciliation to the corresponding GAAP measure. The table below summarizes the financial impact of significant items on our 2023 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. 2023 Significant Items
CNO Financial Group 34 Insurance product margin Annuity 226.9$ 3.2$ (1) 230.1$ Health 504.4 (18.3) (1) 486.1 Life 205.2 14.4 (1) 219.6 Total insurance product margin 936.5 (0.7) 935.8 Allocated expenses (596.6) - (596.6) Income from insurance products 339.9 (0.7) 339.2 Fee income 23.7 - 23.7 Investment income not allocated to product lines 143.9 - 143.9 Expenses not allocated to product lines (40.8) (22.5) (2) (63.3) Operating earnings before taxes 466.7 (23.2) 443.5 Income tax (expense) benefit on operating income (106.3) 5.3 (101.0) Net operating income (3) 360.4$ (17.9)$ 342.5$ Net operating income per diluted share (3) 3.06$ (0.15)$ 2.91$ Year ended December 31, 2022 Actual results Significant items Excluding significant items (dollars in millions, except per-share amounts) (1) Comprised of $0.7 million of the net favorable impact arising from our comprehensive annual actuarial review. (2) Comprised of an experience refund of $22.5 million related to a reinsurance agreement. (3) A non-GAAP measure. See pages 35 and 37 for a reconciliation to the corresponding GAAP measure. The table below summarizes the financial impact of significant items on our 2022 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. 2022 Significant Items
CNO Financial Group 35 (dollars in millions) * Management believes that an analysis of Net income applicable to common stock before: (i) net realized investment gains or losses from sales, impairments and the change in allowance for credit losses, net of taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities, net of taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) loss related to reinsurance transaction, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; and (viii) other non-operating items consisting primarily of earnings attributable to variable interest entities, net of taxes ("Net operating income," a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry. Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the company's underlying fundamentals. A reconciliation of Net operating income to Net income applicable to common stock is provided in the above table. Quarterly Earnings 4Q22 YTD 4Q22 1Q23 2Q23 3Q23 4Q23 YTD 4Q23 Insurance product margin Annuity 50.8$ 226.9$ 57.3$ 57.1$ 57.0$ 63.6$ 235.0$ Health 140.4 504.4 116.5 108.2 123.2 146.4 494.3 Life 43.3 205.2 47.4 57.9 59.8 64.6 229.7 Total insurance product margin 234.5 936.5 221.2 223.2 240.0 274.6 959.0 Allocated expenses (149.1) (596.6) (157.5) (149.5) (153.2) (138.8) (599.0) Income from insurance products 85.4 339.9 63.7 73.7 86.8 135.8 360.0 Fee income 9.2 23.7 15.5 0.6 (2.9) 17.8 31.0 Investment income not allocated to product lines 25.2 143.9 15.5 28.0 38.4 38.3 120.2 Expenses not allocated to product lines (12.8) (40.8) (18.3) (21.1) 7.5 (19.8) (51.7) Operating earnings before taxes 107.0 466.7 76.4 81.2 129.8 172.1 459.5 Income tax expense on operating income (24.1) (106.3) (17.8) (18.9) (28.5) (38.2) (103.4) Net operating income* 82.9 360.4 58.6 62.3 101.3 133.9 356.1 Net realized investment gains (losses) from sales, impairments and change in allowance for credit losses (27.2) (62.2) (12.7) (31.3) (20.1) 1.4 (62.7) Net change in market value of investments recognized in earnings (9.0) (73.2) (1.9) (4.0) (9.2) 8.8 (6.3) Changes in fair value of embedded derivative liabilities and market risk benefits (16.4) 440.2 (65.1) 50.4 109.4 (124.6) (29.9) Fair value changes related to agent deferred compensation plan 0.2 48.9 - - 6.8 (10.3) (3.5) Other (6.1) (3.9) 2.3 (0.2) (1.1) (1.3) (0.3) Non-operating income (loss) before taxes (58.5) 349.8 (77.4) 14.9 85.8 (126.0) (102.7) Income tax (expense) benefit on non-operating income (loss) 13.6 (79.6) 18.0 (3.5) (19.8) 28.4 23.1 Net non-operating income (loss) (44.9) 270.2 (59.4) 11.4 66.0 (97.6) (79.6) Net income (loss) 38.0$ 630.6$ (0.8)$ 73.7$ 167.3$ 36.3$ 276.5$
CNO Financial Group 36 Information Related to Certain Non-GAAP Financial Measures The following provides additional information regarding certain non-GAAP measures used in this presentation. A non-GAAP measure is a numerical measure of a company’s performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. While management believes these measures are useful to enhance understanding and comparability of our financial results, these non-GAAP measures should not be considered as substitutes for the most directly comparable GAAP measures. Additional information concerning non-GAAP measures is included in our periodic filings with the Securities and Exchange Commission that are available in the “Investors – SEC Filings” section of CNO’s website, www.CNOinc.com. Operating earnings measures Management believes that an analysis of net income applicable to common stock before net realized investment gains or losses from sales, impairments and change in allowance for credit losses, net change in market value of investments recognized in earnings, changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities, fair value changes related to the agent deferred compensation plan, loss on extinguishment of debt, changes in the valuation allowance for deferred tax assets and other tax items and other non-operating items consisting primarily of earnings attributable to variable interest entities (“net operating income,” a non- GAAP financial measure) is important to evaluate the financial performance of the Company and is a key measure commonly used in the life insurance industry. Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the Company’s underlying fundamentals.
CNO Financial Group 37 A reconciliation of net income applicable to common stock to net operating income (and related per-share amounts) is as follows: (dollars in millions, except per-share amounts) Information Related to Certain Non-GAAP Financial Measures 4Q22 YTD 4Q22 1Q23 2Q23 3Q23 4Q23 YTD 4Q23 Net income (loss) applicable to common stock 38.0$ 630.6$ (0.8)$ 73.7$ 167.3$ 36.3$ 276.5$ Non-operating items: Net realized investment (gains) losses from sales and impairments 27.2 62.2 12.7 31.3 20.1 (1.4) 62.7 Net change in market value of investments recognized in earnings 9.0 73.2 1.9 4.0 9.2 (8.8) 6.3 Changes in fair value of embedded derivative liabilities and market risk benefits 16.4 (440.2) 65.1 (50.4) (109.4) 124.6 29.9 Fair value changes related to the agent deferred compensation plan (0.2) (48.9) - - (6.8) 10.3 3.5 Other 6.1 3.9 (2.3) 0.2 1.1 1.3 0.3 Non-operating (income) loss before taxes 58.5 (349.8) 77.4 (14.9) (85.8) 126.0 102.7 Income tax expense (benefit) on non-operating income (13.6) 79.6 (18.0) 3.5 19.8 (28.4) (23.1) Net non-operating (income) loss 44.9 (270.2) 59.4 (11.4) (66.0) 97.6 79.6 Net operating income (a non-GAAP financial measure) 82.9$ 360.4$ 58.6$ 62.3$ 101.3$ 133.9$ 356.1$ Per diluted share: Net income (loss) 0.33$ 5.36$ (0.01)$ 0.64$ 1.46$ 0.32$ 2.40$ Net realized investment (gains) losses from sales and impairments (net of taxes) 0.18 0.41 0.09 0.21 0.14 (0.01) 0.42 Net change in market value of investments recognized in earnings (net of taxes) 0.06 0.48 0.01 0.02 0.06 (0.06) 0.04 Changes in fair value of embedded derivative liabilities and market risk benefits (net of taxes) 0.10 (2.89) 0.44 (0.33) (0.74) 0.85 0.20 Fair value changes related to the agent deferred compensation plan (net of taxes) - (0.32) - - (0.05) 0.07 0.03 Other 0.04 0.02 (0.02) - 0.01 0.01 - Net operating income (a non-GAAP financial measure) 0.71$ 3.06$ 0.51$ 0.54$ 0.88$ 1.18$ 3.09$
CNO Financial Group 38 A reconciliation of operating income and shares used to calculate basic and diluted operating earnings per share is as follows: (dollars in millions, except per-share amounts, and shares in thousands) Information Related to Certain Non-GAAP Financial Measures 4Q22 1Q23 2Q23 3Q23 4Q23 Operating income 82.9$ 58.6$ 62.3$ 101.3$ 133.9$ Weighted average shares outstanding for basic earnings per share 114,422 114,545 114,273 112,689 111,590 Effect of dilutive securities on weighted average shares: Stock options, restricted stock and performance units 2,231 - 1,377 1,773 2,067 Weighted average shares outstanding for diluted earnings per share 116,653 114,545 115,650 114,462 113,657 Net operating income per diluted share 0.71$ 0.51$ 0.54$ 0.88$ 1.18$ (a) (a) Equivalent common shares of 2,182.5 were not included in the diluted weighted average shares outstanding due to the net loss recognized in 1Q23.
CNO Financial Group 39 Book value per diluted share Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised, restricted stock and performance units were vested, and convertible securities were converted. The dilution from options, restricted shares and performance units is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period. In addition, the calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments. A reconciliation from book value per share to book value per diluted share, excluding accumulated other comprehensive income (loss) is as follows: (dollars in millions, except per-share amounts) Information Related to Certain Non-GAAP Financial Measures 4Q22 1Q23 2Q23 3Q23 4Q23 Total shareholders' equity 1,768.8$ 2,031.8$ 1,995.8$ 1,890.1$ 2,215.6$ Shares outstanding for the period 114,343,070 114,905,172 113,673,882 112,163,169 109,357,540 Book value per share 15.47$ 17.68$ 17.56$ 16.85$ 20.26$ Total shareholders' equity 1,768.8$ 2,031.8$ 1,995.8$ 1,890.1$ 2,215.6$ Accumulated other comprehensive loss (1,957.3) (1,664.4) (1,733.5) (1,956.7) (1,576.8) Adjusted shareholders' equity excluding AOCI 3,726.1$ 3,696.2$ 3,729.3$ 3,846.8$ 3,792.4$ Shares outstanding for the period 114,343,070 114,905,172 113,673,882 112,163,169 109,357,540 Dilutive common stock equivalents related to: Stock options, restricted stock and performance units 2,499,071 1,270,836 1,629,412 1,811,501 2,392,716 Diluted shares outstanding 116,842,141 116,176,008 115,303,294 113,974,670 111,750,256 Book value per diluted share (a non-GAAP measure) 31.89$ 31.82$ 32.34$ 33.75$ 33.94$
CNO Financial Group 40 Operating return measures Management believes that an analysis of net income applicable to common stock before net realized investment gains or losses from sales, impairments and change in allowance for credit losses, net change in market value of investments recognized in earnings, changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities, fair value changes related to the agent deferred compensation plan, changes in the valuation allowance for deferred tax assets and other tax items, loss on extinguishment of debt and other non-operating items consisting primarily of earnings attributable to variable interest entities (“net operating income,” a non-GAAP financial measure) is important to evaluate the financial performance of the Company and is a key measure commonly used in the life insurance industry. Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the Company’s underlying fundamentals. Management also believes that an operating return, excluding significant items, is important as the impact of these items enhances the understanding of our operating results. This non-GAAP financial measure also differs from return on equity because accumulated other comprehensive income (loss) has been excluded from the value of equity used to determine this ratio. Management believes this non-GAAP financial measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income (loss). Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. In addition, our equity includes the value of significant net operating loss carryforwards (included in income tax assets). In accordance with GAAP, these assets are not discounted, and accordingly will not provide a return to shareholders (until after it is realized as a reduction to taxes that would otherwise be paid). Management believes that excluding this value from the equity component of this measure enhances the understanding of the effect these non-discounted assets have on operating returns and the comparability of these measures from period-to-period. Operating return measures are used in measuring the performance of our business units and are used as a basis for incentive compensation. Information Related to Certain Non-GAAP Financial Measures
CNO Financial Group 41 The calculations of: (i) operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); (ii) operating return, excluding significant item, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); and (iii) return on equity are as follows: (dollars in millions) (Continued on next page) Information Related to Certain Non-GAAP Financial Measures 4Q22 1Q23 2Q23 3Q23 4Q23 Operating income 360.4$ 354.5$ 281.7$ 305.1$ 356.1$ Operating income, excluding significant items 342.5$ 336.6$ 281.2$ 287.7$ 312.8$ Net income 630.6$ 446.4$ 286.8$ 278.2$ 276.5$ Average common equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,323.3$ 3,434.8$ 3,519.3$ 3,582.8$ 3,631.5$ Average common shareholders' equity 2,384.1$ 2,046.3$ 1,931.5$ 1,918.3$ 1,977.5$ Operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 10.8% 10.3% 8.0% 8.5% 9.8% Operating return, excluding significant items, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 10.3% 9.8% 8.0% 8.0% 8.6% Return on equity 26.5% 21.8% 14.8% 14.5% 14.0% Twelve Months Ended
CNO Financial Group 42 The following summarizes: (i) operating earnings; (ii) significant items; (iii) operating earnings, excluding significant items; and (iv) net income (loss): (dollars in millions) (a) The significant items have been discussed in either the current or prior press releases. (Continued on next page) Information Related to Certain Non-GAAP Financial Measures Net operating income Significant items (a) Net operating income, excluding significant items Net operating income, excluding significant items - trailing four quarters Net income (loss) Net income - trailing four quarters 1Q22 64.5$ -$ 64.5$ 272.4$ 183.4$ 334.5$ 2Q22 135.1 (17.4) 117.7 292.6 233.3 520.1 3Q22 77.9 - 77.9 260.1 175.9 592.6 4Q22 82.9 (0.5) 82.4 342.5 38.0 630.6 1Q23 58.6 - 58.6 336.6 (0.8) 446.4 2Q23 62.3 - 62.3 281.2 73.7 286.8 3Q23 101.3 (16.9) 84.4 287.7 167.3 278.2 4Q23 133.9 (26.4) 107.5 312.8 36.3 276.5
CNO Financial Group 43 The calculations of: (i) operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); (ii) operating return, excluding significant item, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); and (iii) return on equity are as follows: (dollars in millions) (Continued on next page) Information Related to Certain Non-GAAP Financial Measures 4Q22 1Q23 2Q23 3Q23 4Q23 Pre-tax operating earnings (a non-GAAP financial measure) 466.7$ 458.6$ 365.6$ 394.4$ 459.5$ Income tax expense (106.3) (104.1) (83.9) (89.3) (103.4) Operating return 360.4 354.5 281.7 305.1 356.1 Non-operating items: Net realized investment losses from sales and impairments (62.2) (67.7) (71.9) (91.3) (62.7) Net change in market value of investments recognized in earnings (73.2) (49.6) (31.9) (24.1) (6.3) Changes in fair value of embedded derivative liabilities and market risk benefits 440.2 209.7 99.5 78.3 (29.9) Fair value changes and amendment related to the agent deferred compensation plan 48.9 26.2 12.2 7.0 (3.5) Other (3.9) (2.0) (2.0) (5.1) (0.3) Non-operating income (loss) before taxes 349.8 116.6 5.9 (35.2) (102.7) Income tax (expense) benefit on non-operating income (loss) (79.6) (24.7) (0.8) 8.3 23.1 Net non-operating income (loss) 270.2 91.9 5.1 (26.9) (79.6) Net income 630.6$ 446.4$ 286.8$ 278.2$ 276.5$ Twelve Months Ended
CNO Financial Group 44 A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders’ equity, is as follows: (dollars in millions) Information Related to Certain Non-GAAP Financial Measures 1Q21 2Q21 3Q21 4Q21 Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,003.2$ 2,989.0$ 2,993.3$ 3,067.3$ Net operating loss carryforwards 323.1 292.9 266.9 243.7 Accumulated other comprehensive income 73.1 306.7 337.5 373.7 Common shareholders' equity 3,399.4$ 3,588.6$ 3,597.7$ 3,684.7$ 1Q22 2Q22 3Q22 4Q22 Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,141.7$ 3,329.0$ 3,510.3$ 3,557.1$ Net operating loss carryforwards 238.2 214.7 190.9 169.0 Accumulated other comprehensive loss (561.5) (1,415.8) (1,837.8) (1,957.3) Common shareholders' equity 2,818.4$ 2,127.9$ 1,863.4$ 1,768.8$ 1Q23 2Q23 3Q23 4Q23 Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,543.8$ 3,603.0$ 3,744.2$ 3,712.8$ Net operating loss carryforwards 152.4 126.3 102.6 79.6 Accumulated other comprehensive loss (1,664.4) (1,733.5) (1,956.7) (1,576.8) Common shareholders' equity 2,031.8$ 1,995.8$ 1,890.1$ 2,215.6$
CNO Financial Group 45 A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders’ equity, is as follows: (dollars in millions) Information Related to Certain Non-GAAP Financial Measures 4Q22 1Q23 2Q23 3Q23 4Q23 Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,323.3$ 3,434.8$ 3,519.3$ 3,582.8$ 3,631.5$ Net operating loss carryforwards 212.5 192.5 170.7 148.6 126.4 Accumulated other comprehensive loss (1,151.7) (1,581.0) (1,758.5) (1,813.1) (1,780.4) Common shareholders' equity 2,384.1$ 2,046.3$ 1,931.5$ 1,918.3$ 1,977.5$ Trailing Four Quarter Average
CNO Financial Group 46 Debt to capital ratio, excluding accumulated other comprehensive income (loss) The debt to capital ratio, excluding accumulated other comprehensive income (loss), differs from the debt to capital ratio because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP financial measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income (loss). Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. A reconciliation of these ratios is as follows: (dollars in millions) Information Related to Certain Non-GAAP Financial Measures 2021 2022 2023 Corporate notes payable 1,137.3$ 1,138.8$ 1,140.5$ Total shareholders' equity 3,684.7 1,768.8 2,215.6 Total capital 4,822.0$ 2,907.6$ 3,356.1$ Corporate debt to capital 23.6% 39.2% 34.0% Corporate notes payable 1,137.3$ 1,138.8$ 1,140.5$ Total shareholders' equity 3,684.7 1,768.8 2,215.6 Less accumulated other comprehensive (income) loss (373.7) 1,957.3 1,576.8 Total capital 4,448.3$ 4,864.9$ 4,932.9$ Debt to total capital ratio, excluding AOCI (a non-GAAP financial measure) 25.6% 23.4% 23.1%
v3.24.0.1
Cover Page
|
Feb. 06, 2024 |
Document Information [Line Items] |
|
Document Type |
8-K
|
Document Period End Date |
Feb. 06, 2024
|
Entity Registrant Name |
CNO Financial Group, Inc.
|
Entity Incorporation, State or Country Code |
DE
|
Entity File Number |
001-31792
|
Entity Tax Identification Number |
75-3108137
|
Entity Address, Address Line One |
11825 North Pennsylvania Street
|
Entity Address, City or Town |
Carmel
|
Entity Address, State or Province |
IN
|
Entity Address, Postal Zip Code |
46032
|
City Area Code |
317
|
Local Phone Number |
817-6100
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
false
|
Entity Central Index Key |
0001224608
|
Amendment Flag |
false
|
Common Stock, par value $0.01 per share |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Common Stock, par value $0.01 per share
|
Trading Symbol |
CNO
|
Security Exchange Name |
NYSE
|
Rights to purchase Series E Junior Participating Preferred Stock |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Rights to purchase Series E Junior Participating Preferred Stock
|
No Trading Symbol Flag |
true
|
Security Exchange Name |
NYSE
|
5.125% Subordinated Debentures due 2060 |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
5.125% Subordinated Debentures due 2060
|
Trading Symbol |
CNOpA
|
Security Exchange Name |
NYSE
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a security having no trading symbol.
+ References
+ Details
Name: |
dei_NoTradingSymbolFlag |
Namespace Prefix: |
dei_ |
Data Type: |
dei:trueItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=cno_RightsToPurchaseSeriesEJuniorParticipatingPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=cno_A5125SubordinatedDebenturesDue2060Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
CNO Financial (NYSE:CNO)
Historical Stock Chart
From Sep 2024 to Oct 2024
CNO Financial (NYSE:CNO)
Historical Stock Chart
From Oct 2023 to Oct 2024